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 ABSTRACT 
Over 30 million people worldwide use aspirin and other non-aspirin non-steroidal anti-
inflammatory drugs (NSAID) on a daily basis. It is estimated that over 25% of patients treated 
for arthritis with NSAIDs have experienced gastrointestinal (GI) complications that required 
hospital admission and 60% of deaths from adverse drug reactions (ADRs) are attributable to 
NSAID use.  
Significant non-genetic risk factors for the development of NSAID-related gastrointestinal 
complications include gender, H. pylori infection, and concomitant medications. Three genes 
(UGT1A6, PAI-1 and EYA1) with biological plausibility for roles in NSAID-related ulcers were 
analysed. Our analysis of genetic risk factors for NSAID-related GI complications in 1197 
case-control subjects showed no association between a UGT1A6 polymorphism and NSAID-
induced GI toxicity (p=0.052). Furthermore, a meta-analysis of UGT1A6 studies confirmed 
that there was no association between NSAID-related GI complications and UGT1A6. The 
PAI-1 4G/5G polymorphism was also not associated with NSAID-related ulcers and bleeding 
(n=756), while the EYA1 rs12678747 single nucleotide polymorphism (SNP) was significantly 
(p<0.05, OR 1.52; 95% CI 1.21, 1.91) associated with binary ulcer status.  In healthy volunteers, 
EYA1 gene expression in gastric biopsies was not related to the carriage of this SNP; this 
contrasts with the difference observed in patients with ulceration suggesting that there may 
be a SNP-disease interaction, which needs further study. EYA1 was found to be expressed in 
atypical gastrin secreting (AGS) cells, but the relative expression was significantly (p<0.05) 
lower than in healthy human gastric epithelial cells and in renal cortical epithelial cells.  
Functional assays performed to explore the mechanism of NSAID-related gastric cell death 
and validate a plausible role for EYA1 in this process showed that there are multiple cell 
death pathways occurring concurrently in this cell model depending on the concentration of 
aspirin. At lower concentrations (10-20mM), PARP cleavage was observed suggestive of an 
apoptotic process, while at 50mM, necrotic cell death was the predominant mode of cell 
death. There was a significant (p<0.05) concentration-dependent decrease in the caspase 3 
and 7 activity in AGS cells despite a significant (p<0.05) fall in the viability of the cells 
compared to the controls, suggesting that there is a role for non-caspase dependent 
mechanisms in the cell death.  
In summary, the thesis has focused on the clinical, molecular and functional aspects of 
peptic ulceration caused by NSAIDs (including aspirin). A novel pathway involving EYA1 has 
been investigated; this needs further work to define the exact mechanisms by which EYA1 
leads to cell death and gastrointestinal injury in patients taking NSAIDs (including aspirin).
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1.1 Adverse drug reactions 
1.1.1 Definition of adverse drug reactions 
The World Health Organisation defines adverse drug reaction (ADR) as “noxious and 
unintended responses to drugs occurring at doses normally used in man for the prophylaxis, 
diagnosis or therapy of disease, or for modification of physiological function” (WHO, 1972). 
Due to the vague nature of this definition, because of the use of words like “noxious”, 
Laurence and Carpenter, in 1998 defined ADR as “A harmful or significantly unpleasant 
effect caused by a drug at doses intended for therapeutic effect (or prophylaxis or diagnosis) 
which warrants reduction of dose or withdrawal of the drug and/or foretells hazard from 
future administration” (Laurence & Carpenter, 1998). 
These two definitions did not include human errors, a common cause of ADR (Routledge, 
2012); effects of contaminants and supposedly inactive excipients as causes of adverse 
effects. In a bid to include these entities, Edwards and Aronson defined ADR “as an 
appreciably harmful or unpleasant reaction, resulting from an intervention related to the use 
of a medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product” (Edwards & Aronson, 2000). 
 
More recently, the European Parliament and Council of the European Union in 2010, 
proposed to amend the definition of ADR “to ensure that it covers noxious and unintended 
effects resulting not only from the authorised use of a medicinal product at normal doses, 
but also from medication errors and uses outside the terms of the marketing authorisation, 
including the misuse and abuse of the medicinal product” (EU, 2010). 
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Some authorities have tried to distinguish ADR from adverse drug events (ADE) which have 
been defined as harm associated with ADR as well as harmful effects from human error 
(Edwards & Aronson, 2000).  In general, the term ADR infers causality, while ADE can be 
applied to any event occurring in relation to the drug or intervention irrespective of 
causality. 
 
1.1.2 The public health burden of adverse drug reactions 
ADR are estimated to cause over 100 000 deaths annually in the United States (Lazarou et 
al., 1998).  However, the report was highly criticised since the death rate was extrapolated 
from admission rates in 1994, yet based on rates of ADR taken from studies done pre 1981. 
Moreover, it was felt that publication bias could have also contributed to what they 
regarded as inflated mortality data (Kvasz et al., 2000).  
A systematic review of hospital admissions in the United States, noted that between 5% and 
7% of all hospitalizations are due to an ADR with a further 10% to 20% of all hospitalized 
patients experiencing an ADR during the period of hospital admission (Alhawassi et al., 
2014). Between 3% and 6% of ADR are fatal or have serious complications, with an 
estimated 140,000 fatalities due to ADR occurring yearly in the USA (Lazarou et al., 1998; 
Moore et al., 1998; Wester et al., 2008). The estimated impact on hospital costs exceeds $30 
billion, or 5% of total hospital running costs per annum (Patel et al., 2007; White et al., 
1999). 
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An Italian study conducted over a 2-year period reported that of a total of 2,561,400 
Emergency Department (ED) visits made, 8,862 were ADR-related, with an overall 
prevalence rate of 3.5 per 1,000 ED visits. There were 4,111 serious ADR (46.4%), and among 
these 1,332 (15% of total ADR) led to hospitalization. The fatality rate for all ADR reported in 
the ED was 1.5%. This study stated further that the most commonly involved drugs were 
acetylsalicylic acid (34.5% being preventable), amoxicillin/clavulanic acid (32.1% 
preventable), and warfarin (48.6% preventable). The most frequent suspect drugs in serious 
ADRs and in inpatients that died within 30 days after discharge were aspirin with 437 deaths, 
(43.5%) preventable; warfarin with 420 deaths (55.7%) preventable and insulin and analogs 
with 312 deaths (67%) preventable (Perrone et al., 2014). This makes aspirin a leading cause 
of mortality from ADR, a significant percentage being preventable.  
In one of the largest prospective analysis of ADR in the National Health Service (NHS) 
Hospitals in the United Kingdom, it was reported that 6.5% of 18,820 admissions were 
related to ADRs and this figure generally correlates with data pooled from older studies and 
more recent reports (Davies et al., 2009; Pirmohamed et al., 2004).  Over a six-month period, 
a prospective analysis of 3695 patient-episodes assessed for ADR throughout their admission 
and each ADR analysed for causality, severity, avoidability and whether it impacted on the 
length of hospital stay, revealed that of the number assessed, 545 (14.7%) experienced ADR 
and 50% of these ADR were avoidable (Davies et al., 2009).  
A systematic review estimated that about 1.6 million bed days, which is equivalent to 13 to 
14 four hundred-bed hospital annually are attributable to in-patient ADR (Wiffen et al., 
2002), while another group reported that ADR related bed stay in the two NHS hospital 
where their study was conducted as 7659 and 9793 bed days respectively. The overall cost 
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for hospital bed day annually was estimated at £446M for both hospitals (Pirmohamed et al., 
2004). 
1.1.3 Classification of adverse drug reactions 
ADR has been classified as follows:  
Type A: Augmented pharmacologic effect, predictable and dose dependent. 
Type A reactions are the most common type of ADR and account for 80% of ADR 
(Pirmohamed & Park, 2001). They are usually a sequel to the known primary 
pharmacologic effects of the drug, and hence are often predictable. Examples of these 
include bleeding and thrombosis from use of warfarin (Srinivasan et al., 2004) and renal 
impairment from use of NSAID amongst others (Patrono & Dunn, 1987). Predictive animal 
models are often available for type A ADR.  
Their severity can vary, ranging from mild to severe and are associated with phase I-III 
drug metabolism pathways as well as pharmacodynamic variability (Edwards & Aronson, 
2000; Pirmohamed et al., 2004; Pirmohamed & Park, 2001). Various relevant factors that 
could increase the incidence and severity of type A ADR include age, drug-drug 
interactions, pharmacogenetic variations in pharmacokinetic/pharmacodynamics-related 
genes and gender (Ajayi et al., 2000; Meyer, 2000).  
 
Type B: These are unpredictable, idiosyncratic, and have no clear dose-response 
relationship or predictability from the known pharmacological effects of the drug. Type B 
reactions account for about 20% of ADR, and are usually discovered during phase IV drug 
development but occasionally in phase III.  They occur in susceptible individuals and are 
characterized by variability in onset of symptoms from a few minutes to sometimes 
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several months. There are no known widely acceptable animal models of type B ADR. The 
severity of the response is initially variable but increases when the subject is re-
challenged with the same drug (Pirmohamed, 2010; Pirmohamed & Park, 2001). As 
shown in table 1.1, the classification has further been extended to types C, D, E and F. 
Type C is dose and time dependent, while type D refers to delayed reactions. Type E and F 
ADR imply events that occur at the “end of use” and are “attributed to treatment failure”, 
respectively (Perrone et al., 2014). 
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Table 1.1: Classification of adverse drug reaction (modified from Edwards and Aronson, 
2000) 
Type of 
reaction 
Mnemonic Features Examples Management 
A: Dose 
related 
Augmented Common 
Related to the 
pharmacological 
action of the 
drug. Predictable, 
low mortality 
Digoxin toxicity, serotonin 
syndrome with SSRIs, 
Anticholinergic effects of 
tricyclic antidepressants 
Reduce dose or 
withhold  
Consider effects of 
concomitant 
therapy 
 
 
B: Non-dose-
related 
 
Bizarre  
 
Uncommon 
Not related to a 
known 
pharmacological 
action of the 
drug, 
Unpredictable 
High mortality 
 
Immunological  reactions: 
Penicillin hypersensitivity  
Idiosyncratic reactions: 
acute porphyria, 
malignant hyperthermia, 
Pseudo allergy (e.g., 
ampicillin rash) 
 
Withhold and 
avoid in future 
 
C: Dose and 
time-related 
 
Chronic 
 
Uncommon 
May be related to 
the cumulative 
dose 
 
Hypothalamic-pituitary-
adrenal axis suppression 
by corticosteroids 
 
Reduce dose or  
withhold; 
withdrawal may 
have to be 
prolonged 
   
D: Time-
related 
Delayed Uncommon  
Usually dose-
related  
Occurs or 
becomes 
apparent 
sometime after  
the use of the 
drug 
 
Teratogenesis (e.g., 
vaginal adenocarcinoma 
with diethylstilbestrol) 
Carcinogenesis 
Tardive dyskinesia with 
dopamine agonists 
Often intractable 
 
E: Withdrawal 
 
 
End of use Uncommon 
Occurs soon after 
withdrawal of the 
drug 
Opiate withdrawal 
syndrome 
Myocardial ischemia(β-
blocker withdrawal)  
 
Reintroduce and 
withdraw slowly 
 
 
F: Unexpected 
failure of 
therapy 
Failure Common 
Dose related 
Often caused by 
drug interactions 
Inadequate dosage of an 
oral contraceptive, 
particularly when used 
with specific enzyme 
inducers 
Increase dosage  
Consider effect of 
concomitant 
therapy 
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A more recent classification is based on the dosage of the drug, the time course of events, 
and the patients’ susceptibility (DoTS classification). It is thought that this new 
classification may improve drug development and management of drug adverse effects 
(Aronson & Ferner, 2003).  
 
1.1.4 Scales for assessment of severity and causality of adverse drug reaction 
ADR have been classified based on the severity and seriousness of the adverse reactions. 
This may be ranked as mild, moderate or severe. The Modified Hartwig Severity Scale 
(Table 1.2) ranks adverse effects using numbers 1 to 7. Scale 1 refers to an ADR that does 
not necessitate a change in treatment with the offending drug, while 7b, describes the 
most severe ADR, directly linked to a patient’s death (Davies et al., 2009). This grading, 
though, may be useful, but does not usually have international acceptance and may lack 
continuity in its logic. 
 
Table 1.2: The Modified Hartwig Severity Assessment Scale (Hartwig et al., 1992), adapted 
from (Davies et al., 2009).  
 
  Severity level Description 
1 An ADR occurred but no change in treatment with suspected drug 
required 
2 The ADR required that treatment with drug be held, discontinued 
or otherwise changed. No antidote or other treatment required. No 
increase in length of hospital stay 
3 ADR required that treatment with the suspected drug be held, 
discontinued, or otherwise changed and/or antidote or other 
treatment. No increase in length of stay. 
4 Level 3 ADR which caused an increase in hospital stay and by at 
least one day or is the cause of admission to hospital bed 
5 Any level 4 ADR that requires intensive medical care 
6 The ADR caused permanent harm to patient 
7a The ADR was indirectly linked to death of patient 
7b  The ADR was directly linked to death of patient 
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A widely used and easy to apply scale, developed to standardize assessment of causality for 
all ADR and for use in the controlled trials and registration of new medication is the Naranjo 
probability scale (Naranjo et al., 1981). The Naranjo probability scale essentially consists of 
10 questions that seek to establish the causality of a drug in ADR; these are presented in 
table 1.3. More specific ADR causality scales developed for the causality assessment of drug 
induced liver injury (DILI) is the Council for International Organisations of Medical Sciences 
or the Roussel Uclaf Causality Assessment Method (CIOMS/RUCAM) (Danan & Benichou, 
1993). This scale, though more complex to apply, had been reported to be superior to the 
Naranjo scale in terms of causality assessment of DILI (GarcÍA-CortÉS et al., 2008). 
Chapter 1 
 
12 
 
Table 1.3: The Naranjo adverse drug reaction causality scale  
Question Yes No 
Do Not 
Know 
Score 
1.  Are there previous conclusive reports on this reaction? +1 0 0 
 
2.  Did the adverse event appear after the suspected drug was administered? +2 -1 0 
 
3.  Did the adverse event improve when the drug was discontinued or a specific antagonist was administered? +1 0 0 
 
4.  Did the adverse event reappear when the drug was re-administered? +2 -1 0 
 
5.  Are there alternative causes that could on their own have caused the reaction? -1 +2 0 
 
6.  Did the reaction reappear when a placebo was given? -1 +1 0 
 
7.  Was the drug detected in blood or other fluids in concentrations known to be toxic? +1 0 0 
 
8.  Was the reaction more severe when the dose was increased or less severe when the dose was decreased? +1 0 0 
 
9.  Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 
 
10. Was the adverse event confirmed by any objective evidence? +1 0 0 
 
 
Total Score: 
Significant improvement in the inter-rater agreement in ADR causality when the Naranjo scale was applied compared to when conventional 
definitions of ADR were used. Definite causality=≥9; probable causality= 5-8; possible causality=1-4; unlikely causality=≤0 (Naranjo et al., 1981). 
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1.1.5 Risk factors for Adverse drug reactions 
 
The following factors have been identified and their role in the development of ADR 
explored: 
1.1.5.1 Metabolism and drug-drug interaction 
Pharmacokinetic drug-drug interaction is a leading factor associated with development of 
clinically significant ADR (Williams et al., 2004). This could occur via inhibition or induction of 
the hepatic monoxygenase enzyme system and has been studied extensively over time 
(Cadieux, 1989; Kamataki et al., 1996). The pharmacologic activity of a drug, in the point of 
view of efficacy or toxicity, is determined to a large extent, either directly or indirectly, by 
systemic exposure to the parent drug and/or its metabolites.  
Some drugs undergo first pass metabolism with the generation of metabolites which are 
several fold more potent than the parent compound. Examples include 
descarboethoxyloratadine, a metabolite of loratadine, a non-sedating selective H1-histamine 
antagonist which is 4 times more active than the parent compound (Friedman et al., 1999), 
and the 5- carboxylic acid derivative of Losartan, whose potency is about 40 times that of 
Losartan (Sica et al., 2005). Similarly, some observed toxicity arises as a result of the 
generation of chemically reactive intermediates, exemplified by chloramphenicol-associated 
aplastic anaemia as a result of the nitro-reduction of the parent compound.  
The concept of variability in metabolism is well known and this explains in part some of the 
unexpected toxicity and or poor efficacy observed following administration of a standard 
therapeutic dose of the drug. A good example of this is use of flecainide in the elderly, who 
by virtue of age-related decrease in hepatic metabolism and renal clearance, accumulate the 
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drug leading to severe ADR, particularly, life-threatening ventricular tachycardia associated 
with high serum concentrations of this drug (Meyer, 1992).  
Inhibition of the metabolism of some drugs can also lead to severe ADR. For instance, 
metabolism of terfenadine by the isoenzyme CYP450 3A4, is inhibited by commonly used 
drugs such as itraconazole, ketoconazole and clarithromycin. Concurrent administration of 
any these drugs with terfenadine leads to accumulation of terfenadine, with consequent QT 
prolongation and possible development of dangerous arrhythmias and death (Ajayi et al., 
2000; Arky et al., 1998). The co-administration of statins with fibrates is associated with the 
risk of severe myopathy. This interaction is due to metabolic perturbation by the fibrates 
especially gemfibrozil that interferes with the hepatic glucuronidation of statins (Santos, 
2014). 
 
1.1.5.2 Age and gender 
The risk of ADR are greatest at the extremes of life, being that at this points in life, organ 
development/and or function is compromised. In the neonatal period, most enzymes 
involved in drug metabolism are immature (Court, 2010); hence, drugs which are eliminated 
by these enzymes can accumulate and cause increased toxicity while a reduction in organ 
function as seen in the elderly population can cause reduced drug clearance.  
Either way, the chances of ADR occurring is significantly increased in these situations (Ajayi 
et al., 2000). Preliminary work that looked at the glucuronidation of phenolic substrates such 
as 1-naphthol and 4-nitrophenol by UDP-glucuronosyltransferase 1A (UGT1A) in human fetal 
liver showed very low to undetectable activities/levels of these isoforms (Rane et al., 1973).  
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A group examined a wider range of substances now known to be metabolised by UGT1A, 
using human fetal livers between 16-25 weeks gestation. The activities of these compounds 
metabolised by various UGT1 isoforms such as bilirubin, androsterone, testosterone, 1-
naphthol and 4-nitrophenol were very low, though detectable with the exception of 
serotonin which was present at activity levels similar to the liver of an adult (Leakey et al., 
1987).  
Women have been noted to have a higher chance of suffering ADR than men. Possible areas 
of difference between genders which hopefully could explain this difference are promptness 
in seeking medical care when complications arise, inappropriate use of drugs, and the insight 
and importance placed on ill health between genders, as well as gender-dependent 
differences in expression of some drug metabolising enzymes, for example CYP3A4 (Ajayi et 
al., 2000).  
 
1.1.5.3 Pharmacogenetics 
Polymorphisms in genes involved in drug metabolism are known to predispose to both 
idiosyncratic and pharmacological toxicity (tables 1.4 and 1.5). So far, most studies have 
concentrated on genes that code for enzymes involved in the biotransformation of drugs as 
risk factor for ADR. However, cell repair mechanisms, elaboration of cytokines and the role 
of immune response needs extensive work to explore genes that increases susceptibility to 
ADR (Pirmohamed et al., 1998). Success in these research areas will improve predictability of 
an individual’s susceptibility to an ADR. Aside from clinical and demographics factors, genetic 
factors are likely to play a key role in an individual’s predisposition to NSAID induced GI 
injury.  
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Table 1.4: Genetic variations affecting drug metabolism and associated therapeutic agents 
 
Genetic variation Therapeutic agent 
TPMT  mercaptopurine, thioguanine, azathioprine  
CYP2D6  modeine, tramadol, tricyclic antidepressants, 
aripiprazole, clomipramine 
CYP2C19  tricyclic antidepressants, clopidogrel, voriconazole  
VKORC1  warfarin  
CYP2C9  warfarin, phenytoin  
HLA-B  allopurinol, carbamazepine, abacavir, phenytoin  
CFTR  Ivacaftor  
DPYD  fluorouracil, capecitabine, tegafur  
G6PD  rasburicase, Nalidixic acid, Nitrofurantoin 
UGT1A1  irinotecan, atazanavir  
SLCO1B1  simvastatin  
IFNL3 (IL28B)  interferon  
CYP3A5  tacrolimus  
These genes are involved in the metabolism of these drugs and pharmacogenetic           
variations involving these genes could lead to pharmacokinetic variations requiring dose 
adjustments as appropriate. Some of these may require genetic testing to enable 
patient stratification and appropriate therapeutic goals (PharmGKB, 2015). 
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Table 1.5: Some clinically important genetic polymorphism of drug metabolism enzymes 
that influence drug response 
Enzyme Frequency of 
polymorphism 
Drug Alleles involved Drug effect 
CYP2C9 14-28% 
(heterozygotes) 
0.2-1% 
(homozygotes) 
Warfarin (Wypasek 
et al., 2015) 
Tolbutamide (Becker 
et al., 2008) 
Phenytoin (Caudle et 
al., 2014) 
Glipizide (Becker et 
al., 2013) 
Losartan (Dorado et 
al., 2014) 
CYP2C9*2/*3 
 
CYP2C9*3 
 
CYP2C9*3 
 
CYP2C9*3 
 
CYP2C9 IVS8-109T 
Hemorrhage  
 
Hypoglycemia 
 
Phenytoin toxicity 
 
Hypoglycemia 
 
Increased hydroxylation 
capacity 
 
CYP2D6 5-10% (poor 
metabolizers),  
1-10% (ultra-
rapid 
metabolizers) 
 
Antiarrhythmics 
 
Antidepressants 
(Hicks et al., 2013) 
 
Aripiprazole 
(Hendset et al., 
2007; Oosterhuis et 
al., 2007) 
 
Opiods (Crews et al., 
2012) 
 
Carvedilol (Baudhuin 
et al., 2010) 
*4, *5, *14, *21, *36  
 
*4/*4, *3/*4, *5/*5, 
5/*6 
 
4x *4/*4, *3-6/*3-6 
 
 
 
 
*4/*4, *4/*5, *5/*5, 
4/*6 
 
*3/*10,*4/4-*4/*6 
Proarrythmic and other 
toxic effects 
Toxicity in poor 
metabolizers, inefficacy in 
ultra-rapid metabolizers 
Tardive dyskinesia 
 
 
 
 
Inefficacy of codeine as 
analgesic, narcotic side 
effects, dependence 
 
Increased β-blockade 
CYP2C19 3-6% (whites) 
8-23% (Asians) 
 
 
Omeprazole (Furuta 
et al., 1998) 
  
Clopidogrel (Scott et 
al., 2013) 
CYP2C19∗2 
 
 
*2/*2, *2/*3, *3/*3 
Lower  cure rates at lower 
dosages 
 
Poor antiplatelet activity 
Dihydropyrimidine 
dehydrogenase 
 
0.1% Fluorouracil (Cai et 
al., 2014) 
IVS14+1G>A Neurotoxicity, 
myelotoxicity 
 
N-actyltransferase 40-70% Whites) 
8-23% (Asians) 
Hydralazine, (Sim et 
al., 2008) 
Isoniazid (Sim et al., 
2008) 
NAT2*5 
 
NAT2*5 
Hypersensitivity 
 
Drug-induced lupus 
erythematosus 
TPMT 0.3% Mercaptopurine, 
Thioguanine, 
azathioprine (Relling 
et al., 2011) 
*2, *3A, *3B, *3C, *4 Myelotoxicity 
UGT1A1 10-15% Irinotecan (Falvella 
et al., 2015) 
 
homozygous 
UGT1A1*28 
Diarrhea, myelosupression 
 
Frequencies are for the Caucasian population unless otherwise stated. CYP= Cytochrome P 
450 isozyme
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1.1.5.3.1 Pharmacogenetics of NSAID-induced gastric injury 
Several studies have investigated the role of genetics in NSAID-related GI complications and 
reports from these studies have highlighted important roles of genetic polymorphisms in 
enzymes involved in the oxidation and conjugation of drugs, genetic mutations of drug 
receptor and target sites, drug transport proteins and ion channels (see table 1.6). Promising 
results have been reported in the association of polymorphisms in metabolizing enzyme 
genes in the pathogenesis of gastroduodenal complications related to the use of NSAIDs and 
aspirin.  
On the contrary, there have been very few studies that have looked at the role of variations 
in genes that are involved in cellular repair mechanisms. Hence, Pirmohamed and Park’s 
recommendation for a widened search of candidate genes involving more pharmacodynamic 
targets, that focus on tissue injury underscores the need to explore plausible genetic roles of 
cell repair genes in NSAID-related GI complications (Pirmohamed et al., 1998; Pirmohamed & 
Park, 2001).   
Recently, an examination of the association of CYP2C19 genetic polymorphism with peptic 
ulcer disease in a Caucasian population (n=1239) with or without peptic ulcer disease, some 
of whom were NSAIDs users was carried out. It reported that a significant association 
between a gain of function polymorphism in CYP2C19* 17 and peptic ulcer disease (OR-1.47, 
95%CI-1.12-1.92; P= 0.005); an association that was independent of NSAID use. However, 
there were no associations between peptic ulcer disease and the other 7 CYP2C SNPs 
(CYP2C8*3{rs11572080 and rs10509681}, CYP2C8*4{rs1058930}, CYP2C9*2{rs1799853}, 
CYP2C9*3{rs1057910}, CYP2C19*2{rs4244285}, CYP2C19*3{rs4986893} (Musumba et al., 
2013).  Similarly, a lack of association between upper gastrointestinal symptoms and CYP2C9 
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(OR=0.80, 95%CI=0.41-1.56) or UGT1A6 polymorphisms (OR=0.85, 95%CI=0.44-1.67) in 160 
aspirin users in a coronary unit has been reported by an independent group (Van Oijen et al., 
2005b). A number of studies, though still very sparse, looking at the genetic predisposition 
to NSAID-related GI toxicity have been undertaken and a summary of them are presented in 
the table 1.6. 
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Table 1.6: Summary of research on genetic association of NSAID-related GI complications  
 Study  Design N   Outcome measures    Gene Report  
(Negovan et al., 2015)  Prospective   211   Endoscopic UGIB AGT  
 
AGT A-20C variant allele increases risk 
(Martínez et al., 2004)  Prospective    218   Endoscopic UGIB CYP2C9 CYP2C9 *2 alleles ↑ risk 
(Hayashi et al., 2012)  Case-control   548 PUD IL-17 IL-17 rs2275913 A allele increases risk 
 
(Pilotto et al., 2007)   Case-control   78   Endoscopic UGIB 
 
CYP2C9 CYP2C9*1/*3, CYP2C9*1/*2↑risk. Higher risk 
among CYP2C9*3 carriers 
 
(Van Oijen et al., 2005a)  Prospective    160   Symptomatology UGT1A6 
CYP2C9 
No association 
(Musumba et al., 2013)  Case-control 1239   Endoscopic UGIB CYP2C family CYP2C19*17 associated with PUD 
 
(Martin et al., 2001)  Retrospective     54 GU or GU scar CYP2C9 No association found 
 
(Arisawa et al., 2007)  Retrospective   480 PUD COX-1 1676T allele increases risk; c.-842A>G/c.50G>T 
no association seen  
  
(Van Oijen et al., 2005a)  Retrospective   194 PUD COX-1    c.-842A>G/c.50G>T showed inverse association 
 
(Halushka et al., 2003)     Prospective   38   Products of AA           
pathway ( PGFα2, TXA2) 
COX-1    c.-842A>G/c.50G>T haplotype had higher 
inhibition of PG formation by aspirin 
 
   (Piazuelo et al., 2008)     Case-control   354 UGIB eNOS gene The ‘a’ allele associated with lower risk 
 
(López-Rodríguez et al., 2008)     Prospective   69  Ibuprofen safety 
pharmacokinetics   
pharmacodynamics 
CYP2C9 
CYP2C* 
CYP2C9*3 linked to ↓ metabolism and 
clearance of R –ibuprofen, CYP2C8*3= 
↑clearance of R-ibuprofen, ↓iNOS expression, 
CYP2C8*3 and *4 linked to ↓ adverse effect 
N, number of subjects in study; UGIB, upper gastrointestinal bleeding; PUD, peptic ulcer disease; GU, gastric ulcer; CYP, cytochrome P450 
enzyme; AA, arachidonic acid ; TXA2, thromboxane A2; COX, cyclooxygenase; eNOS, endothelial nitric oxide synthetase; iNOS, inducible nitric 
oxide synthetase; PG, prostaglandin, modified from. 
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1.1.5.4 Physiological and pathophysiological states  
Comorbid conditions in an individual can influence the susceptibility to ADRs. There has 
been an exponential increase in the frequency of idiosyncratic ADR as a result of HIV disease. 
About 50% of HIV patients receiving high dose co-trimoxazole for Pneumocystis carinii 
(Pneumocystis jiroveci) pneumonia and 30% taking prophylactic doses presented with 
rashes, contrasting sharply with 3% in non-infected people (van der Ven et al., 1991).  This 
occurred particularly at a time before highly active antiretroviral therapy was introduced.   
Among renal failure patients on renal replacement therapies, there is an increased risk of 
gastrointestinal bleeding with the use of NSAIDs, with as much as 3 times increase among 
these patients compared to patients not on NSAID (Jankovic et al., 2009). The risk of 
gastrointestinal bleeding among patients with chronic renal failure has been noted to be 
increased while it is estimated that about 3-7% of all deaths among end stage renal disease 
patients is attributable to upper gastrointestinal bleeding (Wasse et al., 2003).  
Derangements in thrombocyte function and bleeding time, and chronic gastric mucosal 
inflammation is the norm in most uremic patients, and the synergistic effect of NSAIDs (as 
these are similar mechanisms of NSAID-induced gastrointestinal bleeding), in end stage renal 
disease patients makes them particularly prone to NSAID-related GI complication 
(Tschugguel et al., 1995). As in the general population, upper gastrointestinal bleeding is 
much more common than lower gastrointestinal bleeding in end stage renal disease, and 
NSAID use correlates positively with upper gastrointestinal bleeding due to gastric mucosal 
erosion or duodenal mucosal inflammation (Gheissari et al., 1990).  
More recently, an association between diabetes and increased risk of gastrointestinal 
bleeding in non-aspirin users and an inverse association among aspirin users has been 
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reported; however, the relevance and validity of these findings deserves further exploration 
(De Berardis et al., 2012).  
Disease states involving some key enzyme deficiencies are also know to predispose 
individuals with such deficiency to severe/life threatening ADR to ordinarily safe 
medications. A typical example is glucose-6-phosphate dehydrogenase (G6PD) deficiency, a 
sex-linked disorder prevalent among individuals of African, Mediterranean and Asian 
descent. It is associated with a deficiency of G6PD in red blood cells and generation of 
haemotoxic metabolites on exposure to some antimalarials such as mepacrine, primaquine 
and pamaquine; antibiotics such as nitrofurantoin and sulphonamides; fava beans; and anti-
mycobacterials such as dapsone, para-aminosalicylic acid and the sulfones. These individuals 
develop severe haemolytic anaemia and jaundice when offending drugs are administered 
(Frank, 2005; Manganelli et al., 2010). 
Identifying variability among patients in the point of view of age, gender, genetic                   
background, co-administered drugs, coexistence of other diseases and their concurrent 
effects on drug metabolism and excretion in drug development clinical trial is a major hurdle 
which when surmounted improves a drug ADR profile (Ajayi et al., 2000). 
 
1.2 Non-steroidal anti-inflammatory drugs  
1.2.1 Classification of non-steroidal anti-inflammatory drugs 
NSAIDs can be classified based on their chemical structure or their COX selectivity (see table 
1.7; modified from (Mourad & Bahna, 2014). 
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Table 1.7: Classification of non-steroidal anti-inflammatory drugs 
COX-selectivity Chemical classification 
Non selective COX-inhibitors 
 Aspirin 
 
 Aceclofenac, diclofenac, indomethacin, 
             ketorol,  sulindac, tolmetin 
 
 Dexketoprofen, dexibuprofen, 
fenoprofen,  flurbiprofen, ibuprofen, 
ketoprofen, loxoprofen, naproxen, 
oxaprozin 
 
 Flufemanic acid, meclofemanic acid, 
             mefenamic acid, Tolfenamic acid 
 
 Droxicam, isoxicam, lornoxicam, 
piroxicam, tenoxicam 
 
 Phenazone, phenylbutazone, 
propyphenazone 
 
 
COX 2 selective inhibitors 
 Celecoxib, etoricoxib, parecoxib, 
parvocoxib, rofecoxib 
 At low dose: etodolac, meloxicam, 
nabumetone, nimesulide 
 
Carboxylic acids 
 Salicylic Acids: Aspirin, diflunisal, 
salsalate, trisalicylate 
 
 Acetic Acids: Aceclofenac, 
indomethacin, ketorolac, sulindac, 
tolmetin 
 
 Propionic Acids:  Dexketoprofen, 
exibuprofen, fenoprofen, 
flurbiprofen, ibuprofen, ketoprofen,  
loxoprofen, naproxen, oxaprozin 
 
 Fenamic Acids: Flufemanic acid, 
eclofemanic acid, mefenamic acid, 
tolfenamic acid 
 
Enolic Acids 
 Oxicams: Droxicam, isoxicam, 
lornoxicam, piroxicam, tenoxicam 
 
 Pyrazolones: Phenazone, 
phenylbutazone, propyphenazone 
 
Sulfonilides 
 Nimesulide  
 
COX 2 selective inhibitors 
 Celecoxib, etoricoxib,  parecoxib, 
parvocoxib, rofecoxib 
Classification of NSAIDs based on chemical class and selectivity for cyclo-oxygenase (COX) 
enzyme. NSAIDs with similar chemical structure were grouped together based on their COX-
selectivity (left column).  
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1.2.2 Adverse reactions of non-steroidal anti-inflammatory drugs 
NSAIDs, though widely used, are known to have a wide range of ADRs affecting various 
organ systems of the body, including the skin, heart, respiratory system, blood, kidney and 
the gastrointestinal tract. They are thought to be responsible for a quarter of ADRs (Mourad 
& Bahna, 2014). The next sections will be highlighting some of these important ADRs.  
 
1.2.2.1 Hypersensitivity reactions to Non-steroidal anti-inflammatory drugs 
NSAIDs trigger a wide variety of hypersensitivity reactions in predisposed individuals, varying 
in the timing of onset, organ/system affected, the severity of the reaction and the underlying 
mechanistic processes, i.e. whether immunological or non-immunological (Kowalski et al., 
2013). A summary of the phenotypic characteristics of the different types of NSAID-related 
hypersensitivity reactions are presented in table 1.8 (modified from Kowalski et al, 2013 and 
(Ayuso et al., 2013). 
In 1902, Hirschberg was the first to describe an aspirin-induced hypersensitivity reaction, 
and subsequently several other NSAID-induced hypersensitivity reactions have been 
reported (Hirschberg, 1902). NSAIDs are the second most common cause of drug-induced 
hypersensitivity reactions, the first being antibiotics (Gomes & Demoly, 2005; Kowalski et al., 
2013). Two independent groups of researchers have reported the prevalence of aspirin-
induced hypersensitivity reaction in the general population to be 0.5%-1.9% (Gomes et al., 
2004; Isik et al., 2009; Settipane et al., 1980).  
Other workers have reported prevalence as high as 5.6%, although these figures vary 
depending on the population studied, method of assessment and the type of reaction (Doña 
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et al., 2012; Hedman et al., 1999). In asthmatics with nasal polyps, aspirin associated 
hypersensitivity is projected to reach 25.6%, while skin manifestations of NSAID 
hypersensitivity is about 0.3% in the general population, (Settipane et al., 1980). Among 
adult asthmatics assessed with questionnaires, the prevalence of NSAID hypersensitivity 
ranged from 4.3-11% and when data from a provocation test was added, it increased to 25% 
(Jenkins et al., 2004; Kasper et al., 2003). Regardless of the NSAID’s chemical structure or 
anti-inflammatory potency, hypersensitivity reactions have been reported for all known 
NSAID (Kowalski et al., 2011). 
 
1.2.2.2 Mechanistic processes driving NSAID-related hypersensitivity 
NSAID-related hypersensitivity reactions could be either immunologically (non-cross 
reactive) or non-immunologically (cross reactive) mediated. This has been variously classified 
by different workers; however, for the purpose of this work, we shall be sticking to the 
Kowalski et al classification (Kowalski et al., 2013) as presented in table 1.8. Some experts 
have suggested that NSAIDs fulfil the criteria of type B ADR (Mourad & Bahna, 2014). 
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Table 1.8: Phenotypic characteristics of different types of NSAID-related hypersensitivity reactions (Ayuso et al., 2013; Kowalski et al., 2013). 
Types of 
reaction 
Clinical features Timing of 
reaction 
Type of reaction Underlying disease Putative mechanism 
NERD 
 
Rhinitis/asthma Immediate Multiple NSAIDs 
hypersensitivity 
Asthma/rhinosinusitis COX-1 inhibition 
 
 
NECD Wheals/angioedema Immediate Multiple NSAIDs 
hypersensitivity 
 
Chronic urticaria COX-1 inhibition 
NIUA Wheals/angioedema Immediate Multiple NSAIDs 
hypersensitivity 
 
None Unknown, possibly 
COX-1 inhibition 
SNIUAA Wheals/angioedema/anaphylaxis Immediate Single NSAID 
hypersensitivity 
 
Atopy, food and drug 
allergy 
IgE-mediated 
 
SNIDR Various symptoms and organs involved 
(e.g. fixed drug eruptions, nephritis, 
pneumonitis, SJS/TEN, contact and 
photo-contact dermatitis, bullous skin 
reactions, aseptic meningitis 
Delayed onset 
(usually more 
than 24hrs) 
Single NSAID 
hypersensitivity 
None T-cell mediated, 
cytotoxic T cells, NK 
cells 
 
NERD: NSAID-exacerbated respiratory disease; NECD: NSAID-exacerbated cutaneous disease; NIUA: NSAID-induced urticaria/angioedema; 
SNIUAA: Single-NSAID-induced urticarial/angioedema or anaphylaxis; SNIDR: Single-NSAID-induced delayed reactions. 
Chapter 1 
 
27 
 
1.2.3 Renal toxicity of Non-steroidal anti-inflammatory drugs 
NSAIDs, a widely used class of pain and inflammation control medications, due to their 
perceived efficacy and safety, are the commonest cause of drug-induced renal injury. It has 
been reported that the world wide incidence of renal side effects of NSAIDs is 1-5 % (Anders, 
1980). Table 1.9 shows a list of renal complications associated with NSAIDs. 
 
Table 1.9: Renal complications arising from use of NSAIDs. 
NSAID-related renal complications Mechanism 
 Acute tubular necrosis 
 Acute kidney injury  
 Pre-renal azotaemia 
 Acute papillary necrosis 
 Hypertension 
 Chronic tubule-interstitial nephritis 
 Acute interstitial nephritis 
 Membranous nephropathy 
 Hyponatremia 
 Minimal change disease 
 Hyperkalaemia and minimal change  disease 
 
The mechanism of NSAID-induced 
renal complications/ acute kidney 
injury occurs via inhibition of 
prostaglandin. PGs are essential for 
the maintenance of normal 
physiological functions of the 
kidney. They are known to improve 
renal perfusion by causing 
vasodilation of renal glomerular 
capillaries thereby enhancing 
hemofiltration and normal milieu 
of body fluids. Hence, in the 
presence of NSAIDs, this 
homeostasis is impaired and renal 
hemodynamics altered (Pazhayattil 
& Shirali, 2014). 
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1.2.4: Cardiovascular adverse effects of non-steroidal anti-inflammatory drugs 
NSAIDs can also cause cardiovascular adverse effects; the mechanisms by which these effects 
occur are listed in table 1.10. 
NSAID-related cardiovascular complications occurring via various mechanisms such as 
modulation of the RAS, fluid and electrolyte retention, inhibition of PGI2 and subsequent 
increased thrombotic event and plaque destabilization, COX-2 inhibition. NSAIDs also cause 
endothelial dysfunction by depletion of available nitric oxide. 
NSAID-related cardiovascular 
complication 
Mechanism 
Fluid and electrolyte retention Interference with the renin-angiotensin system (RAS) via 
PG inhibition (Camin et al., 2015). 
Hypertension NSAIDs cause fluid and electrolyte retention, and, long 
term cause an increase in blood pressure (Plouin, 2006).  
Increased risk of cardiovascular 
events 
A number of non-clinical studies have reported that 
inhibition of prostacyclin (PGI2) cause artherogenesis via 
plaque destabilization and thrombosis which could be 
either a platelet dependent or independent mechanism 
(Egan et al., 2005; Rudic et al., 2005). 
Worse prognosis for ischemic 
reperfusion injury 
In ischemic reperfusion injury that could occur following 
heart attack, COX-2 has been shown to be 
cardioprotective and is a major source of PGI2 (Bolli et al., 
2002). 
Increased thrombotic events Reduction in the level of antithrombotic PGI2, an 
enhanced synthesis of leukotrienes and generation of 
reactive oxygen species and consumption of 
antithrombotic nitric oxide (Antman et al., 2005) 
Aggravation of doxorubicin 
cardiotoxicity 
An animal study reported that diclofenac sodium, a non-
selective COX- inhibiting NSAIDs aggravated the 
cardiotoxicity of doxorubicin, suggesting that in the 
presence of diclofenac sodium, the risk of cardiovascular 
events due to oxidative stress is increased (Kumar Singh 
et al., 2010; Singh et al., 2014). 
Degradation of aortic elastin protein Blockage of cross linkage formation (Oitate et al., 2007a; 
Oitate et al., 2007b) 
Endothelial dysfunction Reduction in available nitric oxide due to COX-2 inhibition 
(Virdis et al., 2005). 
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1.2.5 The non-targeted adverse drug reactions of non-steroidal anti-inflammatory drugs 
The adverse effects of NSAIDs on the central nervous system and the hepatobiliary system 
are mainly non-targeted as they do not involve specific enzyme or receptor targets. These 
could be related to any moiety of a drug molecule, and can be limited to a single molecule in 
a class of drugs. Most off-target ADRs are picked up during post marketing surveillance if 
missed during drug development and this has led to the withdrawal of NSAIDs like 
bromfenac, ibufenac and benoxaprofen (Goldkind & Laine, 2006; Goldkind & Simon, 2006). 
 
1.2.5.1 Hepatic toxicity of non-steroidal anti-inflammatory drugs 
The majority of this class of drugs are eliminated through hepatic metabolism involving the 
oxidation and/or conjugation of these drugs. The process of oxidation and conjugation 
during the phase I and phase II reactions respectively, leads to an increase in the solubility of 
these intermediate metabolites with consequent biliary and or renal excretion. Also, phase I 
reactions produce highly reactive intermediaries which may form adducts and thereby cause 
damage to cellular components. This is established for paracetamol at doses greater than 
4g/day and most likely may be applicable for all metabolized NSAIDs (Wehling, 2014), but of 
course, the liver injury with paracetamol has a clear dose-response relationship, while liver 
injury with NSAIDs is better categorised as a type B reaction. 
 An increase in transaminases, a marker for hepatocellular injury, of up to 3.5% has been 
reported for most NSAIDs including diclofenac (Rostom et al., 2005); (Bessone, 2010).  Some 
NSAIDs like ibufenac, bromfenac and benoxaprofen have either been withdrawn or failed to 
reach the market due to their high rates of hepatotoxicity (Goldkind & Laine, 2006). 
However, the hepatotoxicity of most NSAIDs has been reported to be low, ranging from 
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0.29-3.1/100000 exposed individuals in a population based study. Similarly, a large US drug 
induced liver injury (DILI) registry reported that only 4 of 133 cases caused by single agents 
were linked to bromfenac while other NSAIDs caused one or two cases at most (Reuben et 
al., 2010).  
In chronic NSAIDs users, it is recommended that transaminase and bilirubin levels are 
monitored but the utility of this approach is unclear.  Nevertheless, a threefold increase in 
transaminase levels is an absolute indication for stopping the offending NSAID (Wehling, 
2014). A rise in serum bilirubin levels should necessitate instant discontinuation of the NSAID 
regardless of the transaminase level, according to Hy’s law (Temple, 2006). 
 
1.3 Gastrointestinal complications of aspirin and other NSAIDs 
Low dose aspirin and other NSAIDs are known to commonly cause gastrointestinal adverse 
drug reactions, and these may range from mild symptoms like dyspepsia to severe 
complications like peptic ulceration and in the extreme cases, upper gastrointestinal 
bleeding and perforation which may be associated with significant morbidity and mortality 
(Lanas et al., 2011).                     
 
1.3.1 Peptic ulcer in aspirin and NSAID-users 
Low dose aspirin, generally, defined as between the range of 75mg and 325mg daily (Baigent 
et al., 2009), is commonly prescribed for the primary and secondary prevention of ischemic 
heart diseases, cerebrovascular diseases and currently being advocated for the primary 
prevention of colon cancers and other non-colonic cancers (Baron & Sandler, 2000). An audit 
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of primary care prescription revealed that in England, in 2007 alone, over 30 million 
aminosalicylic acid (ASA) prescriptions were issued, while in the US; it is thought that over 
one-third of the adult population, and over 80% of those diagnosed with a cardiovascular 
disease use aspirin (Ajani et al., 2006); National Health Service information centre, 2007).  
Less severe aspirin-related upper gastrointestinal ADR reported by low dose ASA users 
include gastroesophageal reflux and/or heart burn, bloating, belching, epigastric discomfort, 
early satiety, and postprandial nausea and these can be found in about 15-20% of low dose 
ASA users (Cayla et al., 2008; Yeomans et al., 2008).  
As with other medications, compliance with low dose aspirin is affected by the frequency of 
ADR. The UGLA survey reports that about 15.4% of patients having ASA have upper GI 
symptoms, mainly gastroesophageal reflux and 12% of these patients did not comply with 
treatment. Presence of prior dyspepsia was predictive of patients who would have low dose 
aspirin related GI symptoms (Cayla et al., 2010). Other studies have reported discontinuation 
rates of about 50% in patients who had been on long term low dose aspirin, despite the 
overwhelming evidence in support of the cardiovascular protective effects of aspirin. This 
non-compliance rate is quite alarming as various studies have reported increased incidence 
of cardiovascular and cerebrovascular events following discontinuation of aspirin (Collet & 
Montalescot, 2004; Collet et al., 2004).  
The GI complications associated with the use of low dose aspirin can affect the entire GI 
tract including the colon, but most commonly, the gastric antrum, especially the pre-pyloric 
area, which is the most commonly affected. Damage may initially be in the form of petechial 
lesions, ecchymosis, erosions, and ultimately ulcers. The extent of injury may vary depending 
on the dose of aspirin used, the concomitant use of other medications, and patient specific 
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risk profiles (Yeomans, 2011). The mucosal injury associated with low dose aspirin occurs 
gradually, rather than being an instantaneous event, with loss of superficial cells of the 
mucosa with each dose of aspirin used.  
Similarly, typical NSAIDs (non COX-selective NSAIDs) cause GI toxicity by way of peptic 
ulceration and as such it has been suggested that typical ulcers in the elderly usually implies 
NSAID use, and is stronger evidence than history of use volunteered by the patient (Wehling, 
2014). Just like aspirin, use of typical NSAIDs causes abdominal discomfort, bloating, acidic 
reflux, pain and loss of appetite and these may be present without any obvious endoscopic 
evidence of disruption of mucosal architecture or may herald more serious mucosal damage 
and bleeding (Bjarnason, 2013).  
 
1.3.2 Lower gastrointestinal injury in low dose aspirin users 
It was previously thought that low dose aspirin does not cause any injury to the lower 
gastrointestinal tract. In support of this thinking is the fact that ASA is almost completely 
absorbed before reaching the small intestine and as such the topical effect is limited. 
Emerging evidence now indicates that ASA can cause mucosa damage below the ligament of 
Trietz (Sostres & Gargallo, 2012).  
Protein loss and bleeding in the small bowel in chronic ASA users significant enough to cause 
hypoalbuminemia and iron deficiency anemia have been described (Fortun & Hawkey, 
2005). In an attempt to evaluate the effect of enteric coated low dose ASA on the small 
bowel, it was shown that half of twenty healthy volunteers who underwent vidoecapsule 
endoscopy following ingestion of 100mg of enteric coated aspirin showed some level of 
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mucosal injury and erosions; median baseline permeability was increased following use of 
ASA while one patient developed two ulcer lesions (Smecuol et al., 2009). The clinical 
significance of these data is uncertain and further studies are required to validate them. 
 
1.3.3 Upper gastrointestinal bleeding in aspirin and NSAID users 
Aspirin/NSAIDs are some of the most commonly prescribed medications, with an estimated 
annual production of over 45,000 tons and average yearly consumption of 80 tablets per 
person worldwide (Vane & Booting, 1998). Over 111million NSAID prescriptions were 
written in the United States in 2004 (Shaheen et al., 2006). 
NSAID-related GI ulceration is the most important adverse drug reaction from a public health 
perspective. The majority of ulcers are asymptomatic and usually heal naturally; however, 
occasionally, there could be an erosion into a vessel or perforation of the gut wall, both of 
which, though less common, are life threatening complications (Sostres & Gargallo, 2012). 
Several factors increase the risk of GI complications in low dose aspirin users and these are 
discussed in more detail in subsequent chapters.  
Most importantly, concomitant use of NSAIDs and other antiplatelet agents amongst others 
could significantly increase the risk of GI bleeding in low dose aspirin users. In a meta-
analysis of 61 randomized controlled trials, it was estimated that there is an increased risk of 
major GI bleeding with low dose aspirin (OR,1.55; 95% CI, 1.27-1.90). This risk is even further 
aggravated when low dose aspirin is taken concomitantly with the antiplatelet, clopidogrel 
or other anticoagulants (OR, 1.86; 95% CI, 1.49-2.31 and OR, 1.93; 95% CI, 1.42-2.61 
respectively) (Lanas et al, 2011). In a cohort of 903 patients taking aspirin followed up for 45 
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months, 41 (4.5%) had significant bleeding requiring admission. In terms of site of bleed, 12 
(29%) had a bleeding gastric lesion, 10 (24%) a bleeding duodenal ulcer and 19 patients 
(46%) had gastroduodenal mucosal lesions. This implies that the rate of major GI bleed is 
4.54% and an incidence of 1.2/100 patient-years (Serrano et al., 2002). 
1.3.4 Epidemiology and burden of nonsteroidal anti-inflammatory drug complications 
Endospically confirmed ulcer lesions are estimated to be present in 15-35% of patients 
within 3 months of commencement of NSAIDs treatment (Bjarnason, 2013). NSAIDs have 
been estimated to cause 3500 hospital admissions and 400 deaths from ulcer bleeding per 
annum in the UK in those aged over 60 years (Langman, 2001). In the United States, NSAIDs 
led to over 100, 000 hospitalisations and 17,000 deaths per annum (Wolfe et al., 1999). In 
another study conducted on deaths from adverse drug reactions involving 1225 patients in 
the United Kingdom, over 60% of these were attributable to NSAIDs (Pirmohamed et al., 
2004), making NSAIDs ADR a major cause of mortality directly linked to drug use.  
In Germany, GI ADRs from NSAIDs use is perceived to be more dangerous than the risk of 
driving a car, as 1 out of 1220 (in UK, 1 out of 2000 patients) NSAID users will die of GI ADR 
each year (Bolten, 2001; Cryer, 2005). An independent estimate reported that in 2009, the 
cost of managing NSAID-related complicated gastrointestinal ulcers in the UK was $6825 per 
patient (Belsey, 2010). 
1.3.5 Risk factors for NSAID-induced upper GI complications 
Various risk factors have been implicated in the development of NSAID-related GI 
complications. As discussed in section 1.1.4, most of the factors noted above also play a role 
in NSAID-related gastric complications. Particularly, concomitant use of other anti-platelets, 
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different NSAIDs, steroids and anticoagulants are associated with increased risk (Valkhoff et 
al., 2012) while comorbid conditions like diabetes, cardiovascular, hepatic and renal disease 
(Deighton et al., 2009) have been associated with increased bleeding risk with use of NSAIDs. 
The risk of gastrointestinal bleeding is increased by 2.1% among users of low dose aspirin 
with previous history of PUD, and in the same cohort, 13.5% of cases with UGIB reported a 
previous history of UGIB in contrast to only 2.3% without an UGIB (Lanas et al., 2000). Table 
1.11 presents the various risk factors for NSAID-related ulcers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
36 
 
Table 1.11: Risk factors for NSAID-related gastrointestinal complications, modified from 
(Valkhoff et al., 2012) 
Risk factors Identified as risk factors due to aspirin 
(definite/probable/controversial/No) 
Identified as 
risk factors 
due to 
NSAIDs 
(Yes/No)* 
Patient-specific risk factors   
History of PUD or GI bleeding Definite (Lanas et al., 2000) Yes 
Older age Controversial (García Rodríguez et al., 2001) Yes 
Concomitant use of 
NSAIDs+coxibs 
Definite (Lanas et al., 2006) Yes, + LDA 
 
Concomitant use of 
anticoagulants  
including anti-platelets 
Probable (Gulløv et al., 1999) Yes 
 
Presence of comorbidities Controversial except patients with hypertension 
and diabetes and chronic debilitating disorders 
(Deighton et al., 2009; Sirois et al., 2014) 
Yes, 
especially 
cardiovascul
ar disease 
Male gender No (Ng et al., 2006; Okada et al., 2009) No 
Excessive alcohol use Probable (Okada et al., 2009; Serrano et al., 2002) No 
 
Current Smoking  
 
No (Soriano & García Rodríguez, 2010) No 
 
High Body Mass Index 
 
Probable (Ng et al., 2006) No 
 
Concurrent corticosteroids 
 
Controversial (de Abajo & García Rodríguez, 
2001; Lanas et al., 2002) 
 
Yes 
No 
Concurrent calcium Channel 
blockers  
 
Probable (Lanas et al., 2002) 
 
No 
Concurrent use of SSRI Definite (Anglin et al., 2014) No  
History of dyspepsia Probable (Soriano & García Rodríguez, 2010) No  
H. pylori infection 
 
Definite (Lanas et al., 2002) Yes  
Aspirin related factors 
High dose aspirin 
 
Probable (Derry & Loke, 2000; Lanas et al., 2006; 
Serebruany et al., 2005) 
 
Yes, high 
dose 
 
Short aspirin duration Definite (Lanas et al., 2000; Lanas et al., 2006) No  
Plain aspirin preparation No (de Abajo & García Rodríguez, 2001; Kelly et 
al., 1996) 
No 
Regular aspirin duration Probable (Kelly et al., 1996) No 
*according to American College of Gastroenterology guidelines (Lanza et al., 2009); SSRI: selective 
serotonin reuptake inhibitors; LDA: low dose aspirin. 
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1.4 Mechanistic hypothesis of NSAID-induced upper GI injury 
 
Aspirin and NSAIDs cause GI mucosal injury via both topical and systemic effects. However, 
the systemic effect is believed to be more dominant in the pathogenesis of NSAID-related 
ulcers. Strong evidence in support of this is the failure of parenteral or rectal administration 
of NSAIDs to fully prevent the development of ulcers (Sostres et al., 2010). The systemic 
effects of NSAIDs are mediated mainly by the inhibition of COX I and II enzymes with the 
attendant blockage of the synthesis of prostaglandins. However, it is worthy of note here 
that strong evidence points to the existence of several other prostaglandin-independent 
mechanisms important in ulcerogenesis.   
 
1.4.1 Direct gastric epithelial injury 
Aspirin and most other NSAIDs are weak organic acids with a pKa of 3-5 and this acidic 
nature of NSAIDs initiates and perpetuates the initial GI mucosal injury by disrupting the 
epithelial cell barrier of the gastric mucosa. Their ability to remain in the non-ionised form in 
the highly acidic gastric environment (pH2.5) enhances their lipophilicity, and this as well, 
favours their cell membrane permeability (Schoen & Vender, 1989). There is a correlation 
between the ability of NSAIDs to cause transient topical damage and their pKa and lipid 
solubility. The carboxylic acid group of NSAIDs enhances significantly their water solubility 
and this improves their interaction with cell membrane phospholipids, thereby enhancing 
their rate of entry into the gastric epithelial cells (Bjarnason et al., 2007).  
While in the intracellular location with a pH of about 7, NSAIDs being weak acids, easily 
dissociate into the ionised form, thereby causing intracellular ion trapping. Various 
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functional studies have shown that when NSAIDs accumulate in gastric epithelial cells via the 
mechanism described above, there is an uncoupling of mitochondrial oxidative 
phosphorylation and inhibition of the respiratory chain, also known as the electron transport 
chain (figure 1.1). This leads to a significant consumption of intracellular ATP, increased 
intracellular calcium and attendant toxicity; and increased generation of reactive oxygen 
species (ROS) (Musumba et al., 2009).  
Besides the direct effect of ROS on oxidation of cellular components like proteins, lipids, and 
nucleic acids, NSAIDs cause genotoxic injury to cells leading to the initiation of apoptosis 
and/or necrosis. When oxidative phosphorylation is uncoupled, mitochondrial membrane 
potential is dissipated with subsequent release of cytochrome c and initiation of apoptosis 
(Nagano et al., 2005). As stated earlier, the properties of NSAIDs confers on them the ability 
to attenuate the hydrophobic surface barrier of the gastric mucosa by way of its interaction 
with the phospholipid bilayer present on the surface of the mucous gel in the GI, thereby, 
disrupting the hydrophobic barrier properties of this layer.  
NSAIDs can also alter GI cell membrane permeability by initiating changes in membrane pore 
formation, fluidity, thickness, bending stiffness and hydrophobicity. These events cause acid 
‘back diffusion’ and initiate cell death via apoptosis and necrosis with formation of the GI 
ulcer lesion (Darling et al., 2004; Lichtenberger et al., 2006).  
The propensity of aspirin and other NSAIDs to cause injury through the topical effect is 
highlighted by experiments in laboratory animals which have reported gastric mucosa 
lesions following oral administration of indomethacin in rats (Esume C et al., unpublished 
data 2016), while other NSAIDs cause GI injury irrespective of route of administration 
(Mashita et al., 2006). The role of oxidative stress in the pathogenesis of indomethacin-
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related ulcers has been reported and it was suggested that  irreversible inactivation of 
gastric peroxidase occurs with indomethacin treatment in rats (Chattopadhyay et al., 2006). 
Figure 1.2 illustrates the various mechanistic processes of NSAID-induced gastrointestinal 
injury. 
 
 
Figure 1.1: A schematic illustration of the topical effect of aspirin leading to gastric cell death 
via “ion trapping and acid back diffusion” as described by Nagano et al., 2005 and Musumba 
et al., 2009.  Aspirin and other NSAID accumulates in the gastric epithelial cells and this 
causes uncoupling of the mitochondrial respiration and depletion of ATP, leading to 
increased intracellular Ca2+, release of cytochrome C and generation of reactive oxygen 
species culminating in cell death.  
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Figure 1.2: Schematic representation of cellular and molecular pathogenesis of NSAID-
induced ulcers (adapted from Musumba et al, 2009). PLs: Phospholipids; CSE: Cystathione-y-
lyase; ECE-1: endothelin-converting enzyme-1; ATL: Aspirin triggered lipase; cNOS: 
constitutive nitric oxide; ODC: ornithine decarboxylase; GMBF: gastric mucosal blood flow; 
CGRP: calcitonin gene related peptide; MT: Melatonin; SPs: stress proteins; TFFs: trefoil 
factors; ROS: reactive oxygen species. 
 
 
1.4.2 Inhibition of cyclo-oxygenase 1 and 2 enzymes 
There is a strong correlation between NSAID-induced ulcerogenesis and their ability to 
supress gastric synthesis of prostaglandin and their selective inhibition of COX 1 in 
preference to COX 2. The COX enzymes are crucial for the conversion of arachidonic acid to 
prostaglandin endoperoxides and prostanoids, and gastric mucosa integrity is maintained by 
the continuous generation of prostacyclin (PGI2) and prostaglandin E2 (PG E2). While COX 1 is 
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constitutively secreted and is in abundance in the gastric epithelium, the expression of COX 2 
is inducible, the inhibition of COX 1, following gastric epithelial injury or an ongoing gastric 
lesion being  major inducers of COX 2 expression (Tanaka et al., 2002).  So following a 
perturbation of gastric epithelial cell membrane integrity by various noxious agents, an 
increase in the expression of the COX enzymes occur leading to an elevated level of gastric 
cytoprotective prostaglandins.  
Aside from the pivotal role that PGI2 and PGE2 play in all aspects of gastric cytoprotection 
and healing, they are both potent vasodilators causing increased mucosal blood flow thereby 
protecting the mucosa from acid injury. There is a compensatory mechanism that is 
triggered following acid disruption of the mucosal barrier and this mechanism acts to reduce 
intracellular hydrogen ions by increasing mucosa blood flow. Failure of these mechanisms 
cause cell death and ulcer formation (Araki et al., 2000; Takeuchi et al., 2001).  
1.4.3 COX and Prostaglandin signalling in NSAID-related ulcers 
Four G-protein coupled receptors, EP1 to EP4 mediate the various functions of PGE2 while 
PGI2 acts via prostacyclin receptors. Activation of EP1, EP2and EP4 receptors by PGE2 triggers 
an increase in intracellular Ca2+ or cyclic adenosine monophosphate activation (cAMP) 
whereas, coupling of EP3 causes a decrease in cAMP (Dey et al., 2006).   
COX 1 or COX 2 deficient mice do not develop spontaneous gastric lesions and neither does 
exposure to selective COX inhibitors, even though both conditions attenuate prostaglandin 
synthesis. It appears that inhibition of both COX enzymes is a prerequisite to the 
development of  NSAID-related ulcers, as mice in which both enzymes were inhibited, or 
exposed to non-selective COX inhibitors developed severe gastric lesions (Gretzer et al., 
2001; Tanaka et al., 2002; Wallace et al., 2000).  
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The effect of NSAIDs in depleting platelet thromboxane levels following inhibition of platelet 
COX1 is a driving factor in their tendency to cause GI bleeding. Two groups independently 
reported up-regulation of COX 1 and 2 at gastric ulcer margins in humans, while in rats; only 
COX 2 was upregulated (Nguyen et al., 2007; Perini et al., 2003). COX2-dependent 
prostaglandins are known to play crucial role in ulcer healing and act by promoting growth 
factor mediated epithelial cell proliferation and angiogenesis, while COX 1 becomes relevant 
in a COX 2 deficient state (Schmassmann et al., 2006).  
Moreover, a delay in onset of repair and restitution was observed in COX 1 knock-out mice 
with superficial gastric mucosa injury. This could be suggestive of a plausible role of COX 1-
derived PGE2 as a mediator of gastric cytoprotection against the initial and early processes 
that drive the progression of gastric epithelial damage (Starodub et al., 2008).  
Meanwhile, inhibition of both COX 1 and COX 2 in knock out mice, greatly attenuated 
healing ulcer lesions more than selective inhibition of COX 2, with no effect noted with 
inhibition of COX 1 (Schmassmann et al., 2006). Among most NSAIDs, naproxen has been 
shown to delay healing of NSAIDs related ulcers to a greater measure than celecoxib, or 
aspirin and this corroborates reports from whole animal experiments (Dikman et al., 2009).  
COX inhibition also leads to gastric hypermotility, which is mediated by COX 1. It is thought 
that the increased amplitude of smooth muscle contraction results in reduced mucosal 
perfusion leading to microvascular injury as a result of hypoxia, neutrophil endothelial 
interaction, and a decrease in the resistance of gastric mucous membrane. A summary of the 
role of prostaglandins and their mediators of gastric cytoprotection are presented in the 
table 1.11. 
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Table 1.12: The role of Prostaglandins and their mediators in gastric mucosal defence, adapted from (Musumba et al., 2009)   
Gastroprotective Effect Receptors (Species) COX-
isoform 
References 
Inhibit acid secretion EP3 (Mouse, rat)  
IP (mouse) 
COX 1 (Kato et al., 2005; Nishio et al., 2007) 
Stimulate acid secretion EP4 (rat)  (Kato et al., 2005) 
Stimulate mucous secretion in stomach EP4 (rat)  (Araki et al., 2000) 
Stimulate HCO3 secretion in stomach EP1 (rat, mouse) COX 1 (Baumgartner et al., 2004; Takeuchi et al., 2006) 
Stimulate HCO3 in duodenum EP4 (rat, human)  (Aoi et al., 2004; Larsen et al., 2005) 
Maintain mucosal hydrophobicity ? (mouse) COX 1 (Darling et al., 2004) 
Increased GMBF EP2/EP3/EP4 (rat) 
EP1(mouse) 
COX 1 (Araki et al., 2000; Komoike et al., 2003) 
Facilitate CGRP-mediated hyperemic response EP2, EP4 (mouse)  (Takeuchi et al., 2003) 
Supress ↑TNFα suppression EP2, EP4 (mouse) COX 2 (Taira et al., 2009) 
Inhibit neutrophil adherence and activation EP2, EP4 COX 2 (Taira et al., 2009) 
Inhibit epithelial cell apoptosis EP2, EP4 (guinea pig)  (Hoshino et al., 2003) 
↓ gastric hypermotility EP1 (rat) COX 1 (Araki et al., 2000; Tanaka et al., 2005) 
↓epithelial paracellular permeability ? (rat) COX 1 (Takezono et al., 2004) 
Adaptive gastric cytoprotection EP1 (rat, mouse)  (Takeuchi et al., 2001) 
Accelerate restitution ? (rat, mouse) COX 1/2 (Starodub et al., 2008; Terano et al., 2001) 
Accelerate ulcer healing EP4 (mouse) COX 2 (Hatazawa et al., 2007) 
Resist ischemia and reperfusion induced injury IP COX 2 (Kotani et al., 2006) 
GMBF: gastric mucosal blood flow; CGRP: calcitonin gene related peptide; COX: cyclooxygenase; EP: Prostaglandin E2 receptor; IP:   
prostacyclin receptor; ↑: increase; ↓: decrease. Adapted from (Musumba et al., 2009).  
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1.4.4 Inhibition of ulcer-healing cytokines 
 
1.4.4.1 Concept of adaptive cytoprotection 
As stated earlier, secretion of PGs is stimulated by perturbation of the cell membrane of the 
GI, which can occur following cell trauma from exposure to acid or alkali, in addition to 
various irritants including hypertonic saline (Nishiyama et al., 1992), thermal injury and 
ethanol (Katori et al., 1990; Robert et al., 1983). Injury to the GI tract is prevented or at least 
ameliorated following a challenge with these injurious substances which would ordinarily 
damage the stomach, a phenomenon known as “adaptive cytoprotection” (Schoen & 
Vender, 1989).  
  
1.4.4.2 Acid back-diffusion enhances calcitonin gene-related peptide (CGRP) secretion from 
sensory nerve endings 
It is believed that endogenously secreted PGs are mediators of the adaptive cytoprotection 
and this is thought to be exerted via calcitonin gene-related peptide (CGRP) and substance P-
releasing extrinsic sensory primary afferent nerves (Robert et al., 1983). The local protective 
function of spinal afferent neurons has been reported to occur in virtually all anatomic 
regions of the GI tract but those involving the gastro-duodenal region have been most 
extensively studied (Holzer, 1998). There is significant evidence demonstrating that these 
afferent neurons originating from the dorsal root ganglia have other important roles in GI 
circulation, secretion, motility, mucosal homeostasis and repair (Holzer, 2007). Acid back-
diffusion from the lumen to the mucosal cells disrupts the mucosal barrier and this surge in 
the intracellular acidity triggers the spinal afferents to release CGRP and nitric oxide (NO), 
both of which cause immediate hyperaemia of the GI mucosa, and also call into action other 
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gastric mucosa defence mechanism via secretion of bicarbonate and attenuation of gastric 
acid secretion (Holzer, 2007; Musumba et al., 2009).   
There is an inherent ability of PGs to protect the GI from damage and this occurs even at 
concentrations that would not interfere with gastric acid secretion. It has been established 
that there is an early and very crucial role of microvascular damage in NSAID-related 
ulcerogenesis, which gives credence to the fact that the response from the mucosal 
vasculature is invariably the most crucial aspect of mucosal defence against injury 
(Musumba et al., 2009).  
Kim and his colleagues assessed gastric blood flow using a laser Doppler flowmeter and 
reported a significant reduction of blood flow in the gastric antrum of 20 healthy volunteers 
following administration of ibuprofen (Kim et al., 2007).  
1.4.4.3 Biologic effects of CGRP 
The release of the CGRP and NO messenger system acts to stimulate the synthesis and 
release of mucin from the gastric mucosa, and attenuates the myoelectrical activity of the 
gastric smooth muscles. Interestingly, CGRP itself, by stimulating the release of PGI2 and 
inhibiting the release of tumour necrosis factor-α (TNF-α) and accumulation of neutrophils in 
tissues, initiates an anti-inflammatory response (Okajima & Harada, 2006).  
On the other hand, following NSAIDs and aspirin use, pro-inflammatory mediators such as 
TNFα, interleukin-1β (IL-1β), interleukin-8 (IL-8) and platelet activating factor (PAF) are now 
known to be upregulated and mediate the subsequent event of gastric injury and healing 
(Watanabe et al., 2004). These mediators (except IL-1β), enhance the ensuing inflammatory 
response and tissue destruction via mobilization of monocytes and neutrophils  to site of 
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injury, by enhanced expression of adhesion molecules (ICAM-1) on the vascular endothelial 
walls and CD11b/CD18 from neutrophils (Souza et al., 2004; Watanabe et al., 2004). Physical 
injury occurs following occlusion of micro vessels by activated neutrophils and the 
subsequent ischemia causes tissue-destroying ROS and proteases to be released (Musumba 
et al., 2009). Unlike the other cytokines, IL-1β acts to ameliorate the damaging effects of 
NSAIDs on the GI by inhibiting PAF and leucocyte adhesion and enhancing elaboration of PG 
and NO via increased expression of both mediators (Martin & Wallace, 2006). Moreover, a 
synergistic action of CGRP and COX-derived PGI2 is purported to improve ulcer healing via 
the an enhanced expression of vascular endothelial growth factor (Ohno et al., 2008).  
There is a gender difference in the expression of CGRP in the dorsal root ganglia cells, the 
reason for this difference being explained by the fact that estrogen enhances the expression 
and availability of releasable CGRP in the dorsal root ganglion. Hence, induced oestrogen-
deficient states attenuate CGRP expression making the mucosa more liable to damage 
(Shimozawa et al., 2007; Shimozawa et al., 2006).  
This could possibly explain the higher frequencies of ulcer in human males than females. A 
decline in the amount of CGRP elaborated, as reported in ageing rats with reduced number 
of mucosal CGRP-releasing nerve fibre, has been associated with impaired mucosal mucin 
synthesis (Holzer, 2007). In humans, there is a perceived association between chronic 
gastritis and increased expression of gastric CGRP, as well as an association between 
enhancement of CGRP and substance P expression in the antral mucosal and dyspeptic 
symptoms in H. pylori-infected patients (Dömötör et al., 2007; Mönnikes et al., 2005).  
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1.4.5 NSAIDs attenuates the gastroprotective effects of nitric oxide and hydrogen sulphide 
Two endogenously generated gaseous mediators, nitric oxide and hydrogen sulphide, are 
important in the maintenance of gastrointestinal mucosal homeostasis and integrity by 
mimicking most of the biological effects of PGs (Oh et al., 2006). Both enhance the induction 
of the expression of heme oxygenase 1 (HO-1), a potent antioxidant, anti-inflammatory and 
anti-apoptotic proteins, and also exert a direct antinecrotic and anti-apoptotic effect on the 
gastric mucosa (Berndt et al., 2005; Li et al., 2007). The ability of nitric oxide to upregulate 
the expression of COX 2, with attendant increased elaboration of PGE2 in rat fibroblasts has 
been demonstrated (Berg et al., 2005). This leads to increased manifestation of the 
gastroprotective and other downstream effects of PGE2 on the GI.  
Nitric oxide is generated via the action of nitric oxide synthase on the amino acid L-arginine 
(Palmer et al., 1988), and this important enzyme occurs in three isoforms, two of which 
(endothelial NOS and neuronal NOS) are constitutive enzymes, and the third an inducible 
isoform (iNOS). While the latter is calcium independent, the endothelial and neuronal 
isotypes are calcium/calmodulin dependent enzymes and synthesize low amounts of NO 
that perform very essential gastroprotective roles such as promotion of angiogenesis and 
increased mucosal blood flow thereby leading to improved ulcer healing and repair 
(Calatayud et al., 2001).  
However, the effects of iNOS could be beneficial or detrimental depending on the type of 
tissue, the duration and level of expression of iNOS, and possibly the oxidation-reduction 
status of the tissue. Depending on the above factors, iNOS could increase mucosal blood 
flow leading to enhanced ulcer healing or rejuvenate pro-apoptotic mechanisms and 
ultimately induce tissue injury and mucosal ulceration (Calatayud et al., 2001).  
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Non-enzymatic mechanisms of generating NO exists and this includes the use of NO donors 
and these have been fused to COX inhibitors, to form a compound known as COX-inhibitor 
nitric oxide donor (CINODs), with the prospect of improving the GI safety of existing COX-
inhibitors (Fiorucci S, 2007). The first CINOD to successfully complete phase III trials is 
naproxcinod (HCT3012) but was declined the United States food and drug agency (FDA) 
approval for lack of long term data on gastrointestinal and cardiovascular safety and GI 
benefits over COX inhibitors (Fiorucci & Santucci, 2011) .  
There are several pathways through which hydrogen sulphide (H2S) can be generated, the 
most crucial being that involving two pyridoxal-5’ phosphate-dependent enzymes, that can 
convert L-cysteine, cysteine and homocystiene to H2S. These two enzymes, cystathione-β-
synthetase (CBS) and cystathione-Ү-lyase (CSE), involved in the synthesis of H2S are 
expressed in the gastric mucosal cells. H2S elaborated from the mucosa acts in part, by the 
activation of ATP-sensitive K+ channels and also stimulates angiogenesis in a manner 
independent of VEGF (Wang, 2002).  
The effects promote epithelial cell proliferation and increased mucosal blood flow, both of 
which are essential for ulcer healing and repair (Fiorucci et al., 2007). Furthermore, H2S has 
been demonstrated to possess anti-inflammatory properties following the observation that 
H2S-donors suppressed leukocyte adherence to the endothelium of blood vessel and caused 
a reduction in leucocyte migration and extravasation to inflammatory sites and edema 
formation while inhibition of endogenous H2S caused an opposing effect from the above 
(Zanardo et al., 2006). These have been exploited in the search for novel derivatives of 
mesalamine, used for the management of inflammatory bowel disease (Fiorucci et al., 2007).  
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Of relevance, there is attenuation of the synthesis of endogenous H2S after the use of NSAID, 
demonstrated to be mediated by the suppression of the expression of a key enzyme, 
cystathione-y-lyase necessary for the conversion of L-cysteine to H2S (Fiorucci et al., 2007). 
Hence, the reduction of mucosal H2S may well be another mechanism of NSAID-related GI 
injury, aside the well-known COX inhibition (Fiorucci et al., 2007). Still at an attempt to 
ameliorate the GI complications of currently used NSAIDs, H2S-elaborating NSAIDs (ATB-346) 
with gastroprotective effects similar to that of CINODs have been synthesised (Fiorucci & 
Santucci, 2011; Li et al., 2007; Wallace et al., 2007). 
 
1.4.6 Inhibition of growth factor production and role of various proteins 
Growth factors exert their gastroprotective actions by enhancing mucosa re-epithelisation, 
granulation tissue formation and stimulation of angiogenesis and are found to be 
upregulated at ulcer margins following stimulation by cytokines, gastrin and PGE2 (Koike et 
al., 2007; Szabo & Vincze, 2000). The above effects are mediated essentially by various 
mechanisms including elaboration of COX-derived PGE2, enhanced expression of NOS and 
prevention of apoptosis through the modulation of pro-and anti-apoptotic proteins (Kosone 
et al., 2006; Netzer et al., 2003).  
Growth factors such as epidermal growth factors, vascular endothelial growth factor, 
hepatocyte growth factor, transforming growth factor and trefoil factors are important in 
the process of restitution while platelet-derived growth factor, fibroblast growth factor-α, 
insulin-like growth factor-1 and vascular endothelial growth factor facilitate connective 
tissue restoration and integrity of the vasculature (Hoffmann et al., 2005; Hoffmann et al., 
2004). Aside the role of trefoil factors in the promotion of restitution, the peptides acts to 
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stabilize the mucous gels and exerts some pro-angiogenic and anti-apoptotic effects which 
are essential for ulcer healing and repair. By suppressing PGE2-mediated growth factor 
production, NSAID may cause a delay in the repair of GI injury.  
The polyamines and other polycations such as spermine, putrescine, and spermidine, 
adequately expressed in most eukaryotic cells, are important for cell growth and 
proliferation and are also essential for the various restitutive processes following GI injury 
from NSAIDs and other mucosal irritants. Because the intracellular levels of polyamines are 
crucial for determining what effects they exert, with high level promoting rapid cell 
proliferation and low level inducing apoptosis, their levels are neatly controlled by the 
biosynthetic enzyme ornithine decarboxylase (ODC) and the catabolic enzyme 
spermine/spermidine N1-acetyltransferase (SSAT).  
A group demonstrated increased cell death, in-vitro in cancer cells, following decrease in the 
intracellular levels of polyamines caused by the inhibitory effect of NSAIDs on ODC 
(Saunders, 2008). Available evidences indicate that there could be a role for polyamine 
depletion in NSAID-induced ulcerogenesis by mechanisms mentioned above. This is 
consistent with the finding that in rats treated with the NSAID indomethacin, there was 
elevated gastric acid secretion but significantly reduced gastric ulcer index and elevated 
mucin content, with attenuation of neutrophil infiltration in those rats administered 
exogenous spermine (Motawi et al., 2007).  
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases found in most 
peripheral blood cells and gastric epithelial cells, whose secretion is highly regulated at 
various levels such as inhibition by tissue metalloproteinases (TIMPs), gene expression, and 
spatial localisation (Egeblad & Werb, 2002). The constitutively expressed MMP-2 plays a role 
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in the physiological turnover of gastric extracellular matrix, while MMP-9 which appears to 
be inducible through the action of cytokines, growth factors and hormones has been 
implicated to play a crucial role during the initial events in development of ulcers.  
Indomethacin causes an increase in the activity of MMP-9 while decreasing the activity of 
MMP-2 in gastric ulcer tissue, and the increase in the MMP-9/MMP-2 ratio correlates with 
the ulcer severity index (Swarnakar et al., 2005). The generation of ROS regulates MMP 
expression in a manner that could enhance the transcription of MMP-9 or suppress MMP-2 
transcription and this pathways could be PG-dependent or independent (Pan & Hung, 2002). 
 
1.4 Aim of the thesis 
A genome-wide association study (GWAS) of NSAID-induced gastrointestinal complications 
has previously been undertaken at the University of Liverpool, the cohort and recruitment of 
which was described elsewhere (Musumba et al., 2013). This identified a number of 
associations between NSAID-related gastrointestinal complications and biologically plausible 
genes. The “top hit” gene in this study has been identified to be in the EYA1 gene locus on 
chromosome 8 (p<10-6).  
EYA1 is an important transcription factor, and also plays critical role in the apoptosis or 
repair decision-making of cells following genotoxic injury (Cook et al., 2009; Tadjuidje et al., 
2012). The ability of a cell to achieve DNA repair would be dependent on whether the EYA1 
gene is functional or not. As noted earlier, previous studies on the pharmacogenetics or 
pharmacogenomics of NSAID-induced gastrointestinal complications have concentrated 
mainly on the polymorphisms of drug metabolising enzymes, genetic mutations in drug 
transport proteins and ion channels (Pirmohamed, 2011). However, there are currently no 
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studies which have looked at polymorphisms in genes involved in cell repair in relation to 
NSAID-induced gastrointestinal injury and particularly, no studies have previously examined 
the role of EYA1 in NSAID-related gastrointestinal injuries.  
The aim of this study was to elucidate the biological plausibility and functional effects of 
EYA1 genetic mutation in the pathogenesis of NSAID-related gastrointestinal injury; we will 
be looking at it from the molecular and functional points of view using various techniques. 
We will also examine the role of previously reported polymorphism in UGT1A6 gene 
(Shiotani et al., 2009; Van Oijen et al., 2009a; Van Oijen et al., 2009b), and a plausible role 
for PAI-1 (Kenny et al., 2013b) polymorphism in the pathogenesis of NSAID and aspirin-
related gastrointestinal complications. 
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Chapter 2 
Relationship between a loss-of-function polymorphism of 
UGT1A6 and low-dose aspirin related upper gastrointestinal       
complications in a Caucasian population. 
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2.1 Introduction 
2.1.1 Aspirin and upper gastrointestinal bleeding 
Aspirin/NSAIDs are amongst the most commonly prescribed medications, with an estimated 
annual production of over 45,000 tons and average yearly consumption of 80 tablets per 
person per year (Vane & Booting, 1998). World-wide, over 30 million people use aspirin and 
other non-aspirin NSAID on a daily basis, and a retrospective study in the United States 
reported that approximately 25% of a group of medicaid recipients treated for arthritis with 
NSAIDs experienced NSAID-related gastrointestinal complications that required further care 
(Bloom, 1988; Singh & Triadafilopoulos, 1999). In the United States, one-third of the adult 
population and over 80% of those diagnosed with a cardiovascular disease use aspirin (Ajani 
et al., 2006). 1n 2007, primary care prescriptions of aspirin were estimated to be over 30 
million in England alone (National Health Service information centre, 2007).  
NSAIDs are prescribed commonly for their anti-inflammatory, analgesic and antipyretic 
effects while aspirin is useful for the secondary prevention of ischemic vascular diseases. It is 
currently being recommended for the primary prevention of cancer of the colon (McGreavey 
et al., 2005).  NSAIDs have been estimated to cause 3500 hospital admissions and 400 deaths 
from ulcer bleeding per annum in the UK in those aged over 60 years (Langman, 2001). 
These figures are consistent with a more recent study of adverse drug reaction-related 
hospital admissions which identified NSAIDs as the most important reason for admission 
(Pirmohamed et al., 2004). In the United States, NSAIDs led to over 100,000 hospitalisations 
and 17,000 deaths per annum (Wolfe et al., 1999). In a study conducted on deaths from 
ADRs involving 1225 patients in the United Kingdom, over 60% of these were attributable to 
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NSAID (Pirmohamed et al., 2004). Therefore, NSAID-related GI ulceration is the most 
important ADR from a public health perspective.    
The aim of this work was to determine whether UGT1A6 genetic variability is a risk factor for 
aspirin/NSAID-related upper gastrointestinal complications. We would also ascertain the 
allelic and genotype frequencies of UGT1A6 SNP rs1105879, the prevalence of PUD and 
upper GI bleeding in a Caucasian population exposed to aspirin and other NSAIDs. 
 
2.1.2 Role of UGT1A6 in aspirin metabolism 
Two enzymes are involved in the biotransformation of acetylsalicylic acid via hydroxylation 
and glucuronidation and both pathways are very important in acetylsalicylic acid 
metabolism. These enzymes, cytochrome P450 2C9 (CYP2C9) and UDP-
glucuronosyltransferase 1A6 (UGT1A6) are highly polymorphic hence, their activity differs in 
different individuals (Van Oijen et al., 2005a). 
Following the absorption of aspirin, the drug is rapidly transformed to salicylic acid via 
deacetylation. Only about 68% of administered dose reaches the general circulation as 
nonspecific esterases, mainly in the liver and to a lesser extent in the stomach, hydrolyse the 
drug (Needs & Brooks, 1985). About 10% of the dose is eliminated unchanged in the urine. 
Salicyuric acid, a glycine conjugate of salicylic acid is the major metabolite (see figure 2.1), 
and accounts for about 63% of recovery from the urine, with a large interindividual 
variability (20-75%). This conjugation with glycine is catalysed by the xenobiotics/medium 
chain fatty acid:CoA ligase (ACSM2B) (Hutt et al., 1986; Lares-Asseff et al., 2004). However, 
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variability in ACSM2B gene is extremely low compared to CYP2C9 and UGT1A6 (Agundez et 
al., 2009).  
 
Figure 2.1: Schematic drawing of the pathway for aspirin metabolism, modified from Carr, 
2016 (personal communication). The first step is the hydrolysis of aspirin by non-specific 
esterases in the liver and GI tract to salicylic acid, with only 68% of a dose reaching the 
systemic circulation. The proportion of each metabolite recovered in urine at therapeutic 
dose is shown as percentage (%). 
 
Salicylic acid is also glucuronidated to form the acyl and phenolic glucuronides. Although, 
UGT1A1, 1A3, 1A7-10, 2B4 and 2B7 also catalyse the conjugation of salicylic acid, UGT1A6 is 
the major enzyme involved in the conjugation of this metabolite in vivo (Kuehl et al., 2006). 
CYP2C9 is also known to oxidize salicylic acid to a minor metabolite, Gentisic acid (2, 5-
dihydroxybenzoic acid) (Bigler et al., 2001; Ciotti et al., 1997; Kuehl et al., 2006). UGT family 
of enzymes are vital in the biotransformation of aspirin/NSAID, morphine, steroids, retinoids 
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and bile acids to more active and occasionally to more toxic substances (Abbot & Palmour, 
1988; Vore et al., 1983; Vore & Slikker, 1985).  
 
2.1.3 Aspirin glucuronidation and UGT1A6 polymorphism 
3-UDP-glucoronosyltransferases (UGTs), a family of enzymes, are involved in the 
glucuronidation of endogenous compounds like bilirubin, drugs and other xenobiotics.  
Glucuronidation through two UGT families (UGT1A’s and UGT2B’s) is important for aspirin 
clearance (Kuehl et al., 2006; Lampe et al., 1999). In aspirin glucuronidation, the most 
important contributors are UGT1A1, UGT1A6, UGT1A7 and UGT1A9 (Agundez et al., 2009).  
UGT1A6 is the founding member of the rat and human UGT1 family. It is expressed in liver 
and extrahepatic tissues such as intestine, kidney, testis, and brain and it conjugates planar 
phenols and arylamines (Bock & Kohle, 2005). UGT1A6, like other members of the UGT1A 
family is located on chromosome 2 and encodes a complex gene consisting of 16 exons, 
whereby alternative splicing of exon 1 to the four common exons (2-5), generates a number 
of isoforms. About two-thirds of the lumenal domain is encoded by the first exon, while 
exons 2-5 encodes the remaining one-third of the lumenal domain, as well as the 
transmembrane domain and the cytosolic tail (Radominska-Pandya et al., 1999).  
Two studies have looked at the relationship between loss of function polymorphisms in 
UGT1A6 in aspirin users and development of GI complications. None of these studies have 
confirmed an association between UGT1A6 polymorphism as a risk factor in the 
development of ulcer in aspirin and NSAID users (Shiotani et al., 2009; Van Oijen et al., 
2009b). 
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2.1.4 Structure of UGT1A6 enzymes 
The UGTs are type 1 transmembrane-based proteins which reside, along with the active site, 
in the luminal side of the endoplasmic reticulum (ER) (Bock & Kohle, 2005). This is evidenced 
by the fact that there is a latency period during which UGT activity can be activated following 
the addition of detergents or pore forming agents such as alamethacin, creating an 
unrestricted entry of the cofactor UDP-glucuronic acid to the enzyme’s active site 
(Radominska-Pandya et al., 1999). However, lipophilic aglycones, found in high 
concentrations in the ER plasma membranes, have been reported to have unrestricted 
access to the active site (Bock & Lilienblum, 1994). There is increasing evidence to suggest 
that the substrate specificity of the UGTs is affected by their dimeric actions (Ishii et al., 
2001).  
The UGT1A family of enzymes are encoded by a single large gene spanning about 200kb on 
chromosome 2q37; being composed of different but homologous first exons. Each is 
preceded by its own promoter that encodes the N-terminal of the enzyme and a shared set 
of 5 exons 2-5 that together encode the C-terminal half of the proteins. The N-terminal 
domain, usually about 260 amino acids long (though variable), is thought to contain the 
binding site for the aglycones substrate while the 246 amino acid C-terminal domain which is 
common to all UGT1A is thought to provide the binding site for the common glucuronic acid 
donor, UDP-glucoronic acid (UDPGA) (Ghemtio et al., 2014).  
There is close sequence homology between human UGT1A6 and other mammalian UGT’s for 
instance, sequence analysis work has determined that the human UGT1A6 and the 
cynomolgus monkey UGT1A6 copy deoxyribonucleic acid (cDNA) have an open reading 
frame of 1599 bp, with a 96% identity at both nucleotide and amino acid levels (Hanioka et 
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al., 2006). However, the mammalian UGT1A6 differs from plant and bacterial UGTs in that 
the C-terminal region is hydrophobic, folding into a single trans-membrane α helix that 
traverses the membrane, with a short C-terminal end exposed to the aqueous medium on 
the other side of the membrane. In plants, the hydrophobic domain is not required for UGT 
function (Ghemtio et al., 2014). The interaction of compounds with UGT1A6 can be tested by 
an indirect method, in vitro, by measuring the rate of glucuronidation or directly by  
detecting its effect on the glucuronidation of a probe substrate such as 1-napthtol (Ghemtio 
et al., 2014). 
 
2.1.5 UGT1A6 alleles 
Several variant alleles have been described for UGT1A6, resulting from changes in amino 
acids resulting in homozygous and heterozygous variant forms; this homo-and heterozygous 
occurrence of UGT1A6 markedly affects enzyme activity. The most important of these alleles 
are two which are defined by changes in the amino acids at p.T181A and p.R184S. The single 
nucleotide polymorphisms (SNP) under investigation rs1105879, is associated with the 
amino acid substitution of threonine for alanine at position 181, arginine for serine at 
position 184 and nucleotide substitution of adenine for cytosine at position 552 (see table 
2.1). Carriage of these amino acid substitutions have been shown, in vitro, to confer a 30%-
50% decrease in enzyme activity compared to the wild type (Ciotti et al., 1997).  
UGT1A6*1 and *2 are the most common allozymes accounting for 90% of allozymes of 
UGT1A6  (Carlini et al., 2005). Several other UGT1A6 allozymes with various combinations of 
amino acid variants have been described. These variants include UGT1A6*1, UGT1A6*2, 
UGT1A6*3, UGT1A6*4, UGT1A6*5, UGT1A6*6, UGT1A6*7, UGT1A6*8 and UGT1A6*9. A 
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detailed presentation of polymorphisms affecting the UGT1A6 gene locus is presented in 
table 2.1. Some of the NSAID-related pharmacogenomic targets for UGT1A6 gene seem to 
be SNP rs1105879 and rs2070959, while the functional effect of the SNP rs6759892 is yet to 
be fully elucidated (Agundez et al., 2009). 
Allelic variations in the coding region of the human UGT1A6 has been observed to cause 
over 25- and 85-fold differences in enzyme activity and immunoreactive protein respectively 
(Nagar et al., 2004). Polymorphisms of the cis-acting response elements and the trans-acting 
transcription factors are thought to be responsible for the variability in enzyme levels (Bock 
& Kohle, 2005). Interplay of the above factors culminates in a high interindividual variability 
in the activity and expression level of UGT1A6. 
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Table 2.1: Major single nucleotide polymorphism affecting the open reading frame for UGT1A6, modified from:         
http://www.pharmacogenomics.pha.ulaval.ca/files/content/sites/pharmacogenomics/files/Nomenclature/UGT1A/UGT1A6.htm 
Allele naming Protein Nucleotide change Amino acid change References 
£UGT1A6 *1a UGT1A6.1    
UGT1A6*1b UGT1A6.1 -1535(G>A)/ -427(G>C)  
Krishnaswamy et al., 
2005 
UGT1A6*1c UGT1A6.1 -427(G>C)  
Krishnaswamy et al., 
2005 
UGT1A6*1d UGT1A6.1 -1535(G>A)/ -1377(G>A)/ -427(G>C)  
Krishnaswamy et al., 
2005 
∆UGT1A6 *1e 
 
UGT1A6.1 105(C>T) D35D Saeki M, 2005 
¥UGT1A6 *1f UGT1A6.1 IVS1+120(A>G)  Saeki et al., 2005 
αUGT1A6 *1g UGT1A6.1 IVS1+142(C>T)  Saeki et al., 2005 
±UGT1A6*2a UGT1A6.2 19(T>G)/315(A>G)/541(A>G)/552(A>C)/ 
IVS1+130(G>T) 
S7A/L105L/T181A/R184S Saeki et al., 2005 
UGT1A6*2c UGT1A6.2 19(T>G)/315(A>G)/541(A>G)/552(A>C)/ 
IVS1+109(C>T)/IVS1+130(G>T) 
S7A/L105L/T181A/R184S Saeki et al., 2005 
UGT1A6*2d UGT1A6.2 19(T>G)/279(A>G)/315(A>G)/541(A>G)/ 
552(A>C)/IVS1+130(G>T) 
S7A/S93S/L105L/T181A/R184S Saeki et al., 2005 
UGT1A6*2e UGT1A6.2 -1710(C>G)/ -1377(G>A)/ -1310 (del 
AGGAG)/-652(G>A)/19(T>G)/ 
315(A>G)/541(A>G)/552(A>C) 
S7A/L105L/T181A/R184S Krishnaswamy et al., 
2005 
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Allele naming Protein Nucleotide change Amino acid change References 
UGT1A6*3a UGT1A6.3 -1710(C>G)/ -1377(G>A)/ -1310 (del 
AGGAG)/-652(G>A)/ 19(T>G) 
S7A Krishnaswamy et al., 
2005 
UGT1A6*3b UGT1A6.3 -1710(C>G)/ -1377(G>A)/ -1310 (del 
AGGAG)/-652(G>A)/ 19(T>G)/315(A>G) 
S7A/L105L Krishnaswamy et al., 
2005 
UGT1A6 *4a UGT1A6.4 19(T>G)/315(A>G)/552(A>C) S7A/L105L/R184S Nagar et al., 2004 
UGT1A6 *4b UGT1A6.4 19(T>G)/315(A>G)/552(A>C)/627(G>T) S7A/L105L/R184S/V209V Saeki et al., 2005 
UGT1A6 *4c UGT1A6.4 -1710(C>G)/ -1377(G>A)/-1310 (del AGGAG)/-
652(G>A)/ 19(T>G)/ 315(A>G)/ 552(A>C) 
S7A/L105L/R184S Krishnaswamy et al., 
2005 
UGT1A6*5 UGT1A6.5 541(A>G) T181A Krishnaswamy et al., 
2005 
€UGT1A6*6 UGT1A6.6 19(T>G)/308(C>A)/315(A>G)/541(A>G)/552(A
>C)/IVS1+130(G>T) 
S7A/S103X/L105L/T181A/R184S Saeki et al., 2005 
UGT1A6*7 UGT1A6.7 19(T>G)/269(G>A)/315(A>G)/541(A>G)/552(A
>C)/IVS1+130(G>T) 
S7A/R90H/L105L/T181A/R184S Saeki et al., 2005 
βUGT1A6*8 UGT1A6.8 541(A>G)/552(A>C) T181A/R184S Ciotti et al., 1997 
UGT1A6*9 UGT1A6.9 552(A>C) R184S Ciotti et al., 1997 
±High enzyme activity in vitro (Krishnaswamy et al., 2005b; Nagar et al., 2004); βlow enzyme activity in vitro (Ciotti et al., 1997), high activity 
(Krishnaswamy et al., 2005d); £wild type, with normal in vivo and in vitro enzyme activity; ∆silent effect and renamed from UGT1A6*1b; 
¥renamed from UGT1A6*1c; αRenamed from UGT1A6*1d; €renamed from UGT1A6*5. 
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2.1.6 Regulation of UGT1A6 expression 
Two modes of expression have been proposed; a high constitutive/lower inducible 
expression and with a low constitutive/high inducible expression. This postulate was based 
on the finding of high constitutive expression in rat kidney and low basal expression in rat 
liver with high inducibility by Ah-type inducers (Munzel et al., 1994). 
Factors involved in the regulation of the expression of UGT1A6 include environmental, 
genetic and tissue-specific factors. HNF1 and HNF4 are thought to regulate tissue specific 
high constitutive expression of UGT1A6 (Mackenzie et al., 2003). The effect of gender is 
controversial; one group reported that there is a 50% reduction in hepatic UGT1A6 
expression in females (Court et al., 2001), while another group observed no gender 
difference in the level of UGT activity (Nagar et al., 2004).  
Environmental factors controlling UGT expression include drugs, hormones and other 
xenobiotics that act as ligands for multiple sensors such as constitutive androstane receptor 
(CAR), the aryl hydrocarbon (Ah) receptor, pregnane X receptor (PXR), and transcription 
factor mediating stress responses, Nrf2 (Bock & Kohle, 2005). 
 
2.2 Methods 
2.2.1 Study subjects 
This study was a multi-centre observational study involving 15 hospitals in the United 
Kingdom (figure 2.2). Endoscopy databases of participating hospitals were used to identify 
patients who had undergone endoscopy between July 2005 and June 2011. Following 
identification of the patients, they were invited to participate in the study either via 
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telephone calls, letter or were recruited prospectively in hospital as in-patients or day-cases 
during their attendance at endoscopy from January 2008.  Ethical approval was given by the 
Liverpool Research Ethics Committee.  
The patients were assigned to 3 different groups as follows: 1) patients who have 
endoscopic diagnosis of peptic ulcer disease (PUD) within 2 weeks of use of NSAID and /or 
aspirin; 2) endoscopic confirmation of PUD without history of use of NSAIDs and/or aspirin 
within 3 months of diagnosis; and 3) subjects without endoscopic evidence of PUD, whose 
use or non-use of NSAID was established before endoscopy was performed. Study 
participants in groups 1 and 2 were recruited pro- and retrospectively, while group 3 were 
recruited prospectively by a random selection of outpatient attendees scheduled for upper 
gastrointestinal (UGI) endoscopy at the Royal Liverpool University Hospital.  
Eligibility criteria were age over 18 years at the time of recruitment, capacity to give 
informed consent and clinical indication for undergoing UGI endoscopy.   Patients who were 
unable or refused to give consent, subjects who could not be contacted, patients with 
malignant peptic ulcer, previous gastrointestinal surgery or Zollinger Ellison syndrome and 
those with blood borne transmissible diseases were excluded from the study (Musumba et 
al., 2013).  
 . .          ’   m g                          m                  
 All patients participating in this study were interviewed using a structured questionnaire 
with emphasis on medical and drug history, demographic data, co-morbidities, alcohol 
intake, smoking habits, and previous H. pylori eradication. Pre-endoscopy interview forms 
and endoscopy reports were carefully checked for details of patients’ clinical presentation, 
ulcer characteristics and use of ulcerogenic drugs like NSAIDs. Further information was 
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sourced from case notes or when necessary, the patients’ general practitioner was 
contacted. From the drug history, those that had used NSAID as  part of a treatment for a 
continuous period of 1 week or more, for the 2 weeks preceding endoscopy were defined as 
NSAID users, while non-users were defined as those who had  not used any NSAID in the 3-
months prior to endoscopy. 
2.2.3 Endoscopy and H. pylori infection 
PUD was defined as a breach in mucous membrane ≥ 3mm or from the endoscopist’s 
description. Upper gastrointestinal bleeding (UGIB) was defined, according to the Forrest 
criteria as hematemesis, melena or anaemia and/or endoscopic stigmata of a recent bleed 
(Forrest et al., 1974). According to the standard of practice in the centres, most patients had 
gastric biopsy done for the rapid urease test (Pronto Dry, Medical Instruments Corporation, 
Solothurn, Switzerland or CLO test) and/or histology to test for H. pylori infection.  
A positive histology or urease test was taken as an indication for presence of H. pylori 
infection and when negative or not done, a positive serology test was taken as evidence of 
past or current infection, while a negative serology test was taken to indicate absence of 
infection. Once a patient was enrolled, about 20mls of venous blood was collected in 2 
specimen bottles and sample (whole blood) was stored frozen at -80⁰c.  
2.2.4 Genomic deoxyribonucleic acid extraction 
Genomic DNA was extracted from 5ml whole blood using the Chemagen DNA extraction kit 
on the Chemagic Magnetic separation Module 1, according to the manufacturer’s protocol 
(AutoQ Biosciences, Germany).  
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Figure 2.2: Map of England showing the 15 sites from which the patient cohorts where recruited, tagged A-O. 11 of the centres are 
located in the North West of England, while 2 are in the North East and the other 2 are in the South of England. To the right of the map 
is the key showing the details of the study centres (adapted from Musumba, unpublished work, 2016). 
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2.2.5 Allelic discrimination for UGT1A6 SNP rs1105879 
Genotyping of UGT1A6 SNP rs1105879 A/C (encoding a p.R184S amino acid substitution) 
was performed with TaqMan® SNP Genotyping assays (Applied Biosystems, USA) using DNA 
samples from study participants following the manufacturer’s instructions. This PCR based 
assay utilises the 5’ nuclease activity of Taq®DNA polymerase to distinguish between alleles.  
This custom Taqman assay contains a VIC and a FAM labelled probe, which detects one of 
the SNP-specific alleles by emitting an allele-specific fluorescent signal after degradation of 
the probe. Fluorescence and allelic discrimination were determined using the SDS software 
(version 2.2; Applied Biosystems, USA). The primer (VIC/FAM) sequence of this assay is: 
GTTCCCTGGAGCATACATTCAGCAG [A/C] AGCCCAGACCCTGTGTCCTACATTC.  
20ng of DNA was placed in a sterile 384-well Polymerase chain reaction (PCR) plate, skipping 
alternate rows to avoid sample contamination. The plate was quickly placed in a Vortexer to 
dry for 5 minutes. The 5µl reaction mix consisted of x1 Taqman Genotyping Mastermix, x20 
drug Metabolism Genotyping Assay (both assays supplied by Applied Biosystems) and 
Nuclease free water (from miliQ machine).  For quality assurance, 10% of the test samples 
were duplicated and 2 negative controls included in each 384-well plate.  
Thermal cycling was performed at the following conditions: 10 minutes at 95o C followed by 
45 cycles of the denaturing step at 95oC for 15 seconds and an annealing step for 1 minute at 
60oC. Amplification and signal detection was then undertaken using the AB 7900 HT Real 
time PCR system as per manufacturers’ instructions (Applied Biosystems).  Genotypes were 
determined using automatic calling on VIC/FAM signal cluster plots, an example of which is 
shown in Figure 2.3.  
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Figure 2.3: Allelic discrimination by TaqMan real-time PCR as displayed by the SDS software. 
Each cluster represents a genotype call as per whether they are homozygous wild type (AA), 
homozygous variant (CC) or heterozygous variant (AC). A good calling of SNPs genotype as 
shown in the graph should have clustering of genotypes into 3 clearly distinguished points 
from each other and from the normal template control (NTC). The ‘A’ allele is called closer to 
the X (horizontal) axis, while the ‘C’ allele is called towards the Y (vertical) axis in this plot. 
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AA 
NTC 
Chapter 2 
 
71 
 
2.2.6 Statistical Analysis 
Non-Caucasian patients, patients who withdraw from the study and those with missing 
genotype data were excluded from the analysis. This reduced the sample size to 1197 
patients, 800 cases and 397 controls. Genotype frequencies were tested for Hardy-Weinberg 
equilibrium (HWE) in the control group only and in the sample as a whole, with a p value 
<0.01 assumed to indicate deviation from HWE. Univariate analysis of non-genetic covariates 
was undertaken, and those showing significance (p<0.1) such as aspirin use, PPI use and 
gender were included in the multivariate analysis.  
In order to test for association between rs1105879 and PUD (ulcer vs. no ulcer), two logistic 
regression models were fitted. The first (the ‘baseline model’) included covariates to 
represent aspirin use, PPI use and gender. The second (the ‘genetic model’) was the same 
model, but with the addition of a covariate to represent rs1105879. An additive mode of 
inheritance was assumed, with wild-type homozygotes coded 0, mutant heterozygotes 
coded 1 and mutant homozygotes coded 2. The two models were compared using a 
likelihood ratio test to determine the association between rs1105879 and ulcer status. An 
odds ratio with 95% confidence intervals was computed for rs1105879. Further analyses 
were carried out using just gastric ulcer and just duodenal ulcer cases.  
The logistic regression analysis was repeated for the additional outcome measure of 
gastrointestinal bleeding. Tests were conducted to assess the association between 
rs1105879 and upper gastrointestinal bleeding (UGIB vs. no UGIB), and between rs1105879 
and bleeding ulcers (bleeding ulcer vs. non-bleeding ulcer). For all analyses, sensitivity 
analyses were conducted including only cases without any evidence of H. pylori infection.  
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2.2.7 Meta-analysis 
A meta-analysis (see figure 2.4) of closely related studies was done by identifying these 
publications from the following  online sources: Scopus, Pubmed, Medline, Web of Science, 
EBSCohost, Proquest and Scifinder  using  “polymorphism”, “UGT1A6”, “Aspirin”, “NSAIDs”, 
“peptic ulcer” and “gastrointestinal bleeding” as search terms.  
The inclusion criteria are that the studies were reported in English Language, rs1105879 was 
genotyped, the study was case-controlled, and have comparable clinical phenotypes and 
demographic characteristics. However, due to limited number of studies, all ethnicities were 
included in the meta-analysis. The Forrest plot was constructed using Review Manager 
Software, version 5.3.  
 
2.3 Results 
2.3.1 Patients, demographics and data analysis 
A total of 1197 patients (46.5% females, n=557) completed the study, of which 800 (66.8%) 
were cases. In the case group, 466 patients who had an endoscopic diagnosis of ulcer had a 
history of NSAID use [135 (29%) non-aspirin; 260 (56%) aspirin and 71 (15%) both non- 
aspirin NSAIDs and aspirin] within 2 weeks prior to presentation with symptoms. 334 
patients had ulcer but were not exposed to NSAIDs, while 275 patients neither had ulcer nor 
were exposed to NSAIDs. 23% (n=107) of PUD patients with history of use of NSAIDs had 
upper GI bleeding, while 13.8% (n=48) of non-NSAIDs users with evidence of PUD had upper 
GI bleeding. About 30% of the cases were current smokers while over 37% were previous 
smokers. Significant alcohol use was also noted in over 15% of both cases and control 
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groups. Complete detail of patients’ distribution and demographics is presented in figure 2.4 
and tables 2.2 and 2.3.  
Univariate analysis of non-genetic covariates reported a significant association (p<0.05) 
between gender, H. pylori infection, use of PPI, steroid, low aspirin dose, and NSAID and 
binary ulcer status. A detailed report of the analysis is presented in table 2.3.  
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Figure 2.4: Schematic presentation of patients’ demographics, cohorts and recruitment process. Of the targeted 1500 patients, 1300 patient 
were recruited, excluding patients of non-Caucasian background. The case cohort included patients with peptic ulcer disease (PUD) 
with/without NSAID use while the control cohort is patients without history of PUD with/without history of NSAID use. The case cohort is 
further stratified based on presence or absence of upper gastrointestinal bleeding among the NSAID users and non-users
Patients recruited into study n=1300 
Excluded, n=103(7.9%) Equivocal 
NSAIDs use 25; non-white ethnicity 
31, ulcer status unknown 6; 
withdrawn 41 
Caucasian patients (n=1197) 
Patients without PUD, n=397(33.2%) 
NSAIDs users 
n=122(30.7%) 
NSAIDs non-users 
n=275(69.3%) 
Patients with PUD n=800(66.8%) 
NSAIDs users 
n=466(58.3%) 
NSAIDs non-user 
n=334(41.7%) 
UGIB n=107(23%) No UGIB n=359(77%) UGIB n=48(14.4%) No UGIB n=286(85.6%) 
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Table 2.2: Patient demographics, treatment group and ulcer distribution 
Clinical Variable n (%) 
Gender: Male  
Ulcer cases 
NSAID  
640 (53.5) 
 
Non-aspirin  135 (28.9) 
Aspirin  260 (57.8) 
Both aspirin and Non-aspirin NSAIDs 
Total 
                                                
71 (15.2) 
466 (57.3) 
NSAID negative 
Total  
 
Ulcer site 
Gastric ulcer   
Duodenal ulcer   
Both 
Pyloric 
Unknown 
Total  
334 (42.7) 
800 
 
 
407 (50.9) 
313 (39.1) 
62 (7.8) 
16 (2.0) 
2 (0.003) 
800 
 
Non-ulcer controls  
Non-aspirin NSAIDs  27 (22.1) 
Aspirin NSAIDs  85 (69.7) 
Both aspirin and non-aspirin NSAIDs  
No ulcer+ exposure to NSAIDs 
10 (8.2) 
122 (30.7) 
No ulcer, no exposure to NSAIDs 275 (69.3) 
Total  397 
Total  number of participants  1197 
 
 
2.3.2 Genotype and allele frequencies in study patients 
The genotype frequencies for rs1105879 for all study subjects were as follows: AA=46%; AC= 
43% and 11% for the CC (table 2.4). These frequencies correlate with reports from several 
other studies (Agundez et al., 2009; Krishnaswamy et al., 2005a; Krishnaswamy et al., 2005d; 
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Saeki et al., 2005). The genotype frequencies did not deviate from Hardy-Weinberg 
equilibrium (p>0.05). 
2.3.3 Association between SNP and PUD/UGIB 
The data on the logistic regression analysis is summarised in Table 2.5.  An analysis between 
SNP rs1105879 and binary ulcer and bleeding status was done to determine the association 
between the SNP and NSAID-related ulcers, assuming an additive mode of inheritance with 
covariates included to represent NSAIDs use, PPI use and gender.  
Association was tested by logistic regression using likelihood ratio test (LRT) comparing 
models with and without a covariate representing the rs1105879 SNP. The analysis 
suggested a trend towards an association between the SNP and ulcer status, and use of 
NSAIDs (p=0.052, odds ratio 1.21, 95% CI 1.00, 1.47). A sensitivity analysis was undertaken 
which included only cases without any evidence of H.pylori infection in the case cohort 
(n=365), which gave a high p value (0.664). This association could be as a result of the 
confounding effects of H. Pylori infection. Further analysis that excluded non-aspirin NSAIDs 
with covariates to represent use of aspirin, PPI and gender using a LRT as above revealed a 
lack of association between SNP and aspirin-related ulcers (p=0.106, odds ratio 1.17; 95% CI 
0.97, 1.41).  
An analysis to determine the association between the SNP and UGIB status was modelled 
first to include all NSAIDs with case (n=155) and control (n=1042) outcome status, there was 
no association between NSAIDs use (p=0.725) or aspirin use (p=0.492) and UGIB. A sensitivity 
analysis excluding cases with H. pylori infection in both NSAIDs and aspirin-only users did not 
change the outcome measure. The above result agrees with previous reports on UTG1A6 
polymorphisms and NSAIDs use; with no association reported in all studies that looked at 
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this area (Agundez et al., 2009; Oijen et al., 2005; Valkhoff et al., 2012; Van Oijen et al., 
2009b).  
2.3.4 Influence of PPI use and gender 
To further explore the trend towards association between SNP and NSAID-related ulcer, an 
analysis was modelled to investigate if this trend was due to the interaction between SNP 
and PPI use and gender. In the entire cohort, 546 PPIs were used by 527 patients with some 
using more than one PPI. The distribution of PPI use was as follows: omeprazole (242); 
lansoprazole (211); esomeprazole (53); pantoprazole (32) and rabeprazole (8). Concomitant 
use of NSAIDs and PPIs was noted in about 250 patients (47.4%).  
Introducing PPI use or gender as covariates in the previously fitted genetic model, a LRT was 
used to compare the new model and the genetic model. In the PUD cohort, 299 (37.5%) 
patients used PPI while 228 (57.4%) patients in the control used PPI. The analysis revealed 
no association (p=0.484) between an interaction of PPI status and genotype, and 
development of ulcers.  
In terms of gender, 475 (58.4%) men had ulcer (see table 2.3), revealing a higher incidence 
of PUD in male patients than females (41.6%). An analysis refitted as above, including an 
interaction term between SNP and gender did not show any evidence of association 
(p=0.948) between gender and genotype at SNP rs1105879 and developing an ulcer. This 
higher incidence of PUD in males supports current available evidence (Wu et al., 2008). 
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2.3.5 Influence of the location of ulcer 
The data on distribution of ulcer based on location is presented in table 2.2. Analysis of the 
association with SNP was repeated as above but first including only GU (n=407) in the model 
with those without any ulcers as controls (n=397). Those with both ulcers (62) were excluded 
from this analysis. There was a statistically significant association (p=0.002) between 
duodenal ulcers and genotype at SNP rs1105879. However, sensitivity analysis including only 
cases without evidence of H. pylori did not show any association (p=0.302). A similar analysis 
as above reported no association (p=0.383) between gastric ulcers and SNP rs1105879.  
Table 2.3: Clinical and demographic characteristics of study participants 
 Patients 
with PUD 
(n=800) 
Patients 
without 
PUD 
(n=397) 
Univariate analysis using Chi 
square  
Pearson 
chi-square 
*LRT p 
Age, mean (SD) 65.2 (13.6) 57.6 (14.7) 0.159 0.162 0.15 
Male sex, n (%) 470 (58.8%) 170 (42.8%) 26.3 26.3 0.001 
BMI, mean (SD) 26.9 (7.7) 27.3 (7.8)   0.998 
H. pylori Infection 435 (54.4%) 59 (14.9%) 96.8 99.9 0.001 
Endoscopy indication, n %)                                                           95%CI                LRT 
Hematemesis/melena  317 (39.6%) 24 (6.0%) 4.396-9.670 6.491  
Dyspepsia/abdominal pain 228 (28.5%) 189 (46.9%) 0.510-0.691 0.593  
Anaemia 109 (13.6%) 68 (16.9%) 0.598-0.691 0.788  
Reflux symptoms 20 (2.5%) 8 (2.0%) 0.559-2.713 1.229  
Other 146 (17.8%) 114 (28.3%) 0.509-0.780 0.629  
NSAID used 
Low dose aspirin 
 
318 (38.1%) 
 
94 (23.3%) 
 
42.6 
 
43.8 
 
0.0001 
High dose aspirin 18 (2.2%) 1 (0.2%) 42.6 43.8 0.0001 
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Diclofenac 104 (12.5%) 18 (4.5%) 26.9 30.9 0.0001 
Ibuprofen 77 (9.2%) 15 (3.7%) 15.4 17.3 0.0001 
Ketoprofen 4 (0.5%) 1 (0.2%) 7.4 8.4 0.007 
Naproxen 30 (3.6%) 6 (1.5%) 7.4 8.4 0.004 
Oxicams 15 (1.8%) 0 (0%) 15.4 17.3 0.0001 
Coxibs 13 (1.6%) 2 (0.5%) 7.4 8.4 0.007 
Ketoprofen 4 (0.5%) 1 (0.2%) 7.4 8.4 0.007 
Indomethacin 3 (0.4%) 0 (0%) 26.9 30.8 0.001 
Concomitant medications, n (%) 
Proton pump inhibitors 299 (37.5%) 228 (57.4%) 44.6 44.8 0.001 
Antisecretory medications 32 (4.0%) 13 (3.3%) 0.493 0.505 0.524 
Antiplatelets 44 (5.5%) 19 (4.8%) 0.188 0.190 0.786 
Anticoagulants 51 (6.4%) 20 (5.0%) 1.05 1.08 0.365 
Steroids 32 (4.0%) 14 (3.5%) 7.8 9.4 0.001 
SSRIs 54 (6.8%) 52 (13.1%) 13.2 12.5 0.001 
Smoking*, n (%)  
Never 
Current 
Former 
 
276 (34.5%) 
247 (30.9%) 
311 (38.9%) 
 
185 (46.6%) 
106 (26.7%) 
113 (28.5%) 
95%CI 
0.627-0.835 
0.932-1.374 
1.118-1.60 
LRT 
0.723 
1.129 
1.333 
 
 
Alcohol intake*, n (%) 
Audit score <8 
Audit score 8-15 
Audit score >15 
 
672 (84%) 
126 (15.8%) 
37 (4.6%) 
 
327 (82.4%) 
57 (14.5%) 
20 (5.0%) 
95%CI 
0.940-1.056 
0.803-1.430 
0.531-1.516 
LRT 
0.994 
1.070 
0.531 
 
Univariate analysis performed by Chi-square shows significant association between NSAIDs 
use, PPI use, gender, H. pylori infection and binary ulcer status, hence these covariates were 
added to the list of variables used in the logistic regression analysis. *Likelihood ratio test 
performed using 2 x k table on StatsDirect.
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               Table 2.4: UGT1A6 Genotype and allelic frequencies for single nucleotide polymorphism for NSAID users and non-users 
                                                                     
                                                                           Genotype frequency 
 
 
Allele frequency 
 
Status 
 
n      NSAIDs Users (n=588)        Non-users (n=609)   NSAIDs users  
         (n=588) 
    Non-users  
     (n=609) 
  AA 
 
AC CC AA AC CC       A C A C 
Ulcer 
 
800 0.48  0.41  0.10  0.41  0.46  0.14  0.69 0.31 0.64 0.36 
No ulcer 397 0.52  0.39  0.08    0.46  0.45  0.09  0.73 0.27 0.68 0.32 
*UGIB 
 
155 0.50  0.36  0.13  0.46  0.40  0.15  0.69 0.31 0.66 0.34 
*No UGIB 1042 0.49  0.42  0.09  0.43  0.45  0.11  0.70 0.30 0.66 0.43 
Ulcer with UGIB 155 0.50  0.36  0.13  0.46  0.40  0.15  0.69 0.31 0.66 0.34 
Ulcer without UGIB 645 0.48  0.42  0.09  0.40  0.46  0.13  0.69 0.31 0.63 0.37 
 
 
      Aspirin Users (n=426)        Non-users (n=771)      Aspirin Users  
             (n=426) 
     Non-users  
      (n=771) 
  AA 
 
AC CC AA AC CC       A C A C 
Ulcer 
 
800 0.47 0.42 0.11 0.44 0.44 0.12 0.68 0.32 0.66 0.34 
No ulcer 397 0.51 0.42 0.07 0.47 0.43 0.09 0.72 0.28 0.69 0.31 
*UGIB 
 
155 0.49 0.37 0.14 0.49 0.38 0.13 0.67 0.33 0.68 0.32 
*No UGIB 1042 0.48 0.43 0.09 0.45 0.44 0.11 0.69 0.31 0.67 0.33 
Ulcer with UGIB 155 0.49 0.37 0.14 0.49 0.38 0.13 067 0.33 0.68 0.32 
Ulcer without UGIB  645 0.47 0.43 0.10 0.43 0.45 0.12 0.69 0.31 0.65 0.35 
The genotype and allelic frequencies correlates with reported frequencies for the European population and there was no significant       
difference (p˃0.05) between these frequencies in the case and control groups. UGIB= upper gastrointestinal bleeding; AA=homozygote 
wild type; AC= heterozygote variant; CC= homozygote variant; *the UGIB status of 2 patients was missing. 
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Table 2.5: NSAID covariates tested against SNP rs1105879 
Covariates tested 
against UGT1A6 SNP n Test of association 
 Cases Control p Odds ratio Association 
$`Binary ulcer status 800 397 0.052 1.21 (95% CI 1.00, 1.47) Indicative 
 
^Binary ulcer status 800 397 0.106 1.17 (95% CI 0.97, 1.41) No 
$Upper GI bleed status 155 1042 0.492  No 
 
$Ulcer and GI bleed 
status* 
155 645 0.131  No 
 
                                  GU                   
$Ulcer location            
                                  DU             
                                          
407 397 0.383  No 
 
313 397 0.022  Yes 
Gender                   female  
 
                                male 
333 
 
470 
224 
 
170 
 
0.948 
        
No 
Use of NSAIDs 588 609 0.05 1.63 95% CI 1.24, 2.13 Yes 
 
Use of PPI 515 670 0.484  No 
^excluding non-aspirin NSAIDs, $`including non-aspirin NSAIDs; GU= gastric ulcers; DU= 
duodenal ulcers; PPI= proton pump inhibitors; *the upper GI bleeding status of 2 patients 
were missing. 
 
2.3.6 Meta-analysis 
The following databases: Scopus, Pubmed, Medline, Web of Science, EBSCohost, Proquest 
and Scifinder were assessed on the 20th of June, 2012 using the search terms 
“polymorphism”, “UGT1A6”, “Aspirin”, “NSAID”, “peptic ulcer” and “gastrointestinal 
bleeding” identified 4 similar studies that sought to answer the same research question, 
used case-control study design and similar patient demographics and clinical phenotypes.  
Two studies (van Oijen et. al., 2005; and Shiotani et. al., 2008) were excluded. The first was 
excluded because it was not a case-control study, while the second paper published in 2008 
by the Japanese group was also excluded because the patient’s phenotype and 
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characteristics were the same as the 2009 paper. Hence, a total of 3 studies were used for 
the meta-analysis and all studies included were free of biases due to inclusion and exclusion 
criteria.  
The result of meta-analysis indicates that there was no association between polymorphisms 
of UGT1A6 and aspirin-induced upper GI complications. From the meta-analysis (Figure 2.5), 
our study has the largest Mantel-Haenszel weight, accounting for over 70%, while Shiotani et 
al and van Oijen et al weighted 7.1 and 22.3% respectively. There was very minimal 
heterogeneity (I2 = 0) between the studies analysed, suggesting that the patient 
characteristics and study designs were very similar. However, when all 3 studies were pooled 
together, there was no association (P=0.31, OR= 1.11, 0.91, 0.36) between the UGT1A6 
polymorphism and GI complications in aspirin/NSAID users.  
 
 
Figure 2.5: Meta-analysis of available studies on the UGT1A6 polymorphism and NSAID-
induced GI complications. Overall effect size was improved on adding the individual studies 
but did not change the lack of association between UGT1A6 polymorphism and aspirin-
related gastrointestinal bleeding reported in the individual studies. 
Chapter 2 
 
83 
 
2.4 Discussion 
The frequency for the variant allele for rs1105879 was 0.31 in the case cohorts that used 
NSAIDs. There was no statistically significant (p˃0.05) difference between this and the allelic 
frequencies in the non-ulcer group. The allelic frequencies for all groups were not different 
from those reported for the general population among patients of European descent. 
Previous reports of the allelic frequency of the variant allele of this SNP in other ethnic 
groups were 43.5 and 32.5% for Japanese and African populations, respectively (Agundez et 
al., 2009). This suggests that there is no significant interethnic difference in the allelic 
frequency of variant UGT1A6 between African and European populations, while that of 
patients of Japanese descent was slightly higher (see table 2.4).     
The above also holds true for the aspirin-only users, as their allelic frequencies did not vary 
from that of the general NSAIDs group. Our data reports that the genotype frequencies of 
the variant alleles are commoner than the wild type; 54 and 46% respectively as represented 
in figure 2.2.  
Similar to previous reports, there was no association between rs1105879 C-allele and binary 
ulcer status (p>0.05; OR, 1.2; 95% CI, 1.00-1.47); SNP and binary ulcer and bleeding status 
(p>0.05) for both NSAIDs and the aspirin-only group (Shiotani et al., 2009; Van Oijen et al., 
2005b; Van Oijen et al., 2009b).  Due to the small sample sizes of the two previous studies, 
the results could be adjudged inconclusive, but going by the result of our study, with a 
sample size that is 4-7 fold larger, further weight is added to the argument that, there may 
be no association between polymorphisms of UGT1A6 enzymes and UGI complications in 
patients exposed to NSAIDs and/or aspirin.  
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The UGT family of enzymes are involved in the phase II detoxification of a variety of 
endogenous and exogenous compounds and toxins including tamoxifen, estrogen and 
bilirubin making them less toxic (Mackenzie et al., 1996; Tukey & Strassburg, 2000). UGT1A6 
is involved in the glucuronidation of aspirin and other NSAIDs and is the major enzyme 
involved in the conjugation of salicylic acid in vivo, though other closely-related enzymes 
such as UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A9, UGT1A10 UGT2B4 and UGT2B7 play 
some role in the formation of conjugates of salicylic acid (Bigler et al., 2001; Kuehl et al., 
2006).  
Glucuronidation of salicylic acid by UGT1A6 leads to the formation of the phenolic and acyl 
glucuronide and each of these accounts for about 7% of the recovery from urine, though it 
varies widely from 1-40%. Furthermore, a minor metabolite, gentisic acid arises from the 
hydroxylation of salicylic acid by CYP2C9 (see figure 2.1) and accounts for about 4% (1-4%). 
Gentisic acid, though an aspirin metabolite, is only detectable at very high doses in man 
(Bigler et al., 2001; Lares-Asseff et al., 2004; MacDonald et al., 2004). Overall, UGTIA6 
accounts for about 25-30% of salicylic acid metabolism and it’s worth noting that there is 
significant interindividual, interethnic and gender-related variability in the metabolism of 
aspirin.  
The interethnic differences in aspirin metabolism suggest that genetics play a role in this 
variability of aspirin metabolism (Carlini et al., 2005; García-Martín, 2008); however, this 
variability does not seem to play significant role in the pathogenesis of aspirin-related ulcers, 
as revealed by our reports. UGT1A6 polymorphisms that involves amino acid changes at 
position 181 and 184 (rs2070959 and rs1105879 respectively) is associated with a 30-50% 
reduction in enzyme activity compared to the wild type (Lampe et al., 1999). 
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From a functional point of view, these two SNPs are thought to be the most relevant targets 
for the UGT1A6 gene (Agundez et al., 2009). With the established loss-of-function associated 
with the polymorphism of SNP rs1105879, it is expected that the level of salicylic acid, the 
aspirin metabolite degraded by UGT1A6 would be relatively higher in individuals who carry 
this variant allele due to lower clearance rates and higher drug plasma concentration, and 
may lead to an increase in the GI complications and other ADRs associated with aspirin.  
The lack of significant association between this loss-of-function polymorphism and NSAID 
ulcers as reported in our study could be as a result of  compensation by the alternative 
pathways involved in the metabolism of salicylic acid- via the salicyluric acid and the gentisic 
acid pathways catalysed by ACSM2B and CYP2C9 enzymes respectively (Agundez et al., 
2009).  
This increased elimination of salicylic acid via the gentisic acid and salicyluric acid pathways 
could compensate for the slow glucuronidation of salicylic acid in carriers of the variant 
allele, leading to a lack of effect of UGT1A6 polymorphisms in aspirin-related GI 
complications. Secondly, the intermediate products salicyluric acid, and gentisic acid are 
both inhibitors of PG synthesis (Hinz et al., 2000). Attenuation of PG synthesis further drives 
gastric mucosal injury through loss of mucosa protective-mucin secretion and other gastro-
protective effects of PG. Furthermore, carriers of the variant CYP2C9*3 alleles, as expected, 
would have a decreased formation of gentisic acid with attendant reduction in the inhibitory 
effect of this metabolite on PG synthesis and better mucosa protection.  
Some, if not most of the ulcerogenic effects of aspirin are known to occur due to the 
direct/topical effect which occur independent of COX-1 inhibition and prostaglandin 
depletion or changes in activity of phase I and II drug metabolising enzymes. Aspirin and 
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other NSAIDs are concentrated in gastric epithelial cells via “ion trapping” and it is through 
this mechanism that the topical effects of NSAID occur (Bjarnason et al., 2007; Schoen & 
Vender, 1989). Other NSAIDs that are weak organic acids such as indomethacin (pKa 5.2), 
phenylbutazone (pKa 4.8) are also concentrated in gastric mucosal cells via a similar process 
as aspirin (Bjarnason et al., 2007). These events activate the uncoupling of the mitochondrial 
oxidative phosphorylation and inhibition of the electron transport chain resulting in 
intracellular ATP depletion and cellular calcium ion toxicity and generation of reactive 
oxygen species (ROS), as shown in figure 1.1. In contrast to other NSAID that cause GI injury 
irrespective of the route of administration, aspirin has been shown to cause GI toxicity in 
mice only when given orally (Mashita et al., 2006).  
The direct/topical effects of aspirin are independent of aspirin metabolism by UGT1A6 in the 
liver and as such may attenuate any likely effect due to polymorphism of drug metabolism 
enzymes. It is highly possible that the cases of ulcers seen in these patients are as a result of 
the topical effect of NSAIDs.  
There is a gender difference in the expression of UGT1A6 in the liver, with 50% lower level 
reported in females. This is in accordance with the lower rate of metabolism of paracetamol 
in females (Bock & Lilienblum, 1994; Court et al., 2001). This lower expression of UGT1A6 
would be expected to be associated with a higher tendency for the females to develop 
ulcers, due to drug and active metabolite accumulation. However, contrary to that 
expectation, we observed there were a lower proportion of women with ulcers than men. 
This trend of higher prevalence of PUD in men (58.8%) than women (41.2%) observed in our 
study has been reported elsewhere (Wu et al., 2008).  
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However, there are other mechanisms known to protect the female population from 
developing ulcers, such as the role of CGRP, where expression in the dorsal root ganglia, is 
gender dependent and the stimulatory role for estrogen enhancing its expression has also 
been described (Shimozawa et al., 2007; Shimozawa et al., 2006).   
Interestingly, alcohol consumption is an established factor that induces UGT1A6 expression, 
via the CAR receptor (Bock et al., 1987), reflected by significantly higher mRNA, protein and 
glucuronidation activities of UGT1A6 in the livers of donors with history of more than 14 
drinks per week compared with those donors with lower or no history of alcohol 
consumption (Krishnaswamy et al., 2005c). 
Over 25% of the cases and controls in our study were smokers while another significant 
proportion were former smokers. Alcohol consumption is also noted to be prevalent among 
participants of the study, with about 20% of both cases and controls having an alcohol audit 
score greater than 15, implying high alcohol consumption. It is expected that the use of 
substances which could induce the expression of UGT1A6 would increase the activity of 
UGT1A6 even in individuals with the variant allele to higher than expected levels, leading to 
aspirin metabolite levels similar to that seen in individuals with the wild type allele. Whether 
this augmented activity of UGT1A6 from the use of alcohol and cigarette smoking blunted 
the trend towards association between UGT1A6 SNP and NSAID-related GI complications in 
our study needs to be further explored.   
There are a few studies conducted to determine the association between UGT1A6 SNP and 
GI complications in NSAID users, and none of these studies have reported an association 
(Shiotani et al., 2009; Van Oijen et al., 2005a; Van Oijen et al., 2009b). Of the 4 studies 
identified (association between UGT1A6 SNP and aspirin/NSAID-related GI complications), 
Chapter 2 
 
88 
 
only 2 met our inclusion criteria and were included in the meta-analysis. Furthermore, the 3 
studies used in this meta-analysis had many similarities such as answering the same research 
question, use of case-control study design and similar patient demographics. This is reflected 
in the heterogeneity score of zero recorded from our meta-analysis. The pooling of the data 
in the 3 studies to increase the effect size did not yield any significant association between 
the SNP and GI complications in aspirin and NSAIDs users (P=0.31, OR= 1.11, 0.91, 0.36). This 
validates the report of the individual study and one can report a lack of association between 
UGT1A6 SNP and GI complications related to NSAID.  
The limitations of this meta-analysis include the sample size of the other two studies, very 
few published data on the study and also inclusion of a genetically different population 
(Japanese) whose allelic frequency for the variant SNP under study is significantly different 
than that of the Caucasian population we examined (Shiotani et al., 2009). These limitations 
probably diminished the power of association in this meta-analysis.    
Our study to date is the largest (1200 participants) and hence had the best chance to 
elucidate the relationship between NSAID use and a loss-of-function polymorphism in the 
UGT1A6 gene locus. Prior studies included 192 and 114 patients as reported by Shiotani et al 
and van Oijen et al, respectively (Shiotani et al., 2009; Van Oijen et al., 2009b). Secondly, in 
recruiting our study patients, endoscopy, which is the gold standard for the diagnosis of 
peptic ulcer disease, was performed to ascertain the presence or absence of ulcers; hence 
we did not rely on subjective evidence like patients’ self-reporting (which could be very 
deceptive) but on more objective evidence. Our study also took into account the role of H. 
pylori in the pathogenesis of peptic ulcer disease, making it possible to perform a sensitivity 
analysis, including only cases without any evidence of H. pylori infection as cases, which gave 
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a high p value (p=0.106) suggesting that the trend towards some association earlier seen 
when H. pylori positive patients were included in the analysis could be as a result of the 
confounding effect of H. pylori infection. The limitations of our study are that we had an 
incomplete data on smoking, and as such we, were unable to stratify patients based on the 
number of pack-years. This limited our ability to analyse any effect cigarette smoking would 
have on the role of UGT1A6 gene in NSAID-related ulcer. Secondly, we did not genotype 
other UGT1A6 SNP which are in close LD with rs1105879, particularly, rs2070959 and 
rs6759892 which are thought to be the most relevant as far as UGT1A6 polymorphism and 
aspirin bio-disposition are concerned (Agundez et al., 2009).  
In conclusion, we have reported a lack of association between a loss-of-function 
polymorphism of UGT1A6 and GI complications associated with the use of NSAID and 
aspirin. Furthermore, we conducted a meta-analysis of all available publications on this topic 
with a view to increasing the effect size and improve the chance of finding an association, 
but the meta-analysis also revealed a lack of association between the UGT1A6 
polymorphism and aspirin/NSAID-related GI complications.  
It is important to investigate the role of other mechanisms such as the role of other SNP, the 
role of pro-apoptotic and anti-apoptotic molecules. Other relevant pharmacogenomic 
targets as regards aspirin intolerance are ACSM2B, CYP2C9, COX-1 and COX-2 (Agundez et 
al., 2009).  There is increasing evidence of both caspase dependent and caspase independent 
mechanisms in the pathogenesis of NSAID-induced ulcer (Jana, 2008). Polymorphisms in 
these pro-and anti-apoptotic genes may explain the inter-individual variability in the 
development of PUD and this requires further investigation.                                    
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Chapter 3 
Association of a functional promoter polymorphism 
(rs1799889) in the Plasminogen activator inhibitor gene 
(PAI-1) and NSAID-related upper gastrointestinal toxicity 
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3.1 Introduction 
3.1.1 The role of Plasminogen activator inhibitor (PAI-1) in gastric mucosal protection 
PAI-1 is a member of the serine protease inhibitor superfamily that plays crucial role as a 
primary regulator of plasminogen activator and hence important in the control of the 
thrombotic and the fibrinolytic systems (Bayramoglu et al., 2014).  
PAI-1 has a role in the protection of the gastric mucosa, a concept that was developed 
following earlier observations of increased expression of plasminogen activator and 
increased fibrinolytic activity at the edge of gastric ulcers. Specifically, there was a high level 
of expression and activity of tissue type plasminogen activator (tPA) from biopsy specimens 
of ulcer lesions. However, the amount and activity of tPA in biopsy samples from non-ulcer 
lesions of active ulcers or from both ulcer lesions and non-ulcer lesions of inactive ulcers 
showed no significant difference (Kurose et al., 1990). This group also reported significantly 
elevated PAI-1 levels in the plasma of gastric ulcer patients with active ulcers compared to 
patients with inactive ulcers (Kurose et al., 1990). This suggests that there is a role for tPA in 
the pathogenesis of gastric ulcers as the increased fibrinolytic activity would cause increased 
local fibrinolysis which may be crucial for ulcer formation. 
It has also been reported that there is increased urokinase plasminogen activator (uPA) and 
PAI-1 activity at the edge of gastric and duodenal ulcers, accompanied by a remarkable 
reduction in the tissue plasminogen activity in gastric and duodenal ulcer lesions (Kurose et 
al., 1990). They also observed that there was a partial reversal of tPA towards the normal 
pattern in healed duodenal ulcers but uPA activity remained persistently high. This led them 
to speculate that the fibrinolytic system may have a role in the reoccurrence of ulcers at or 
near previous scars (Wodzinski et al., 1993). Impaired fibrinolysis at ulcer lesions would 
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compromise the microcirculation in the gastroduodenal mucosal via thrombosis leading to 
ischemic injuries to the affected mucosa, and further exposure to other noxious factors 
would then lead to formation of peptic ulcers. Repair of ulcers requires uPA for tissue 
remodelling (Wodzinski et al., 1993). While early activation of tPA and uPA inhibits 
haemostasis via fibrin degradation, their later activation is associated with enhanced tissue 
remodelling with their activity being inhibited by several inhibitors, the most important 
being PAI-1 (Dupont et al., 2009).  
More recently, it was reported that following exposure to aspirin and NSAIDs in humans and 
mice, there was a 2-6 fold increase in the PAI-1 mRNA expression compared to control, a 
response which was not observed in PAI-1 null mice. Furthermore, unlike PAI-1-H/K mice 
(mouse in which PAI-1 is over-expressed in the gastric parietal cells), PAI-1 null mice are 
susceptible to ethanol and indomethacin-induced gastric lesions, and because of the above 
findings it is highly likely that these effects are pathways related to PAI-1 (Kenny et al., 
2013b). In the presence of H. pylori infection, PAI-1 expression, uPA and its receptor uPAR 
expression are increased and this is associated with inhibition of gastric epithelial 
proliferation through the suppression of the uPA-mediated release of heparin-binding 
epithelial growth factor, and inhibition of epithelial cell migration (Kenny et al., 2008).  
In the light of the above, it appears that PAI-1 acts to halt fibrinolysis in an autoregulatory 
manner activated by mucosal injury and a strategy to selectively modulate PAI-1 might be 
therapeutically useful in preventing ulcerogenesis in selected patients (Kenny et al., 2013b). 
The biology of PAI-1 is however very complex and there is evidence for actions that are 
independent of tPA or uPA (Lijnen, 2005).  
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Fibrin degradation (fibrinolysis) is an important physiological process occurring in the 
circulatory system but over-activation of the fibrinolytic system may overwhelm the 
mechanisms which inhibit fibrinolysis, particularly the plasminogen activator inhibitor and 
the α2-plasmin inhibitor (α2-PI). When this occurs, bleeding and inflammation may be 
produced by the active enzyme plasmin followed by the activation of the complement 
system (Dellas & Loskutoff, 2005; Kurose et al., 1990).  
Using various models, it has been demonstrated that plasminogen activators increase at the 
site of mucosal injury and because of this finding it was thought that the increased 
fibrinolytic activity in the areas of injury might be important for mucosal bleeding (Kenny et 
al., 2013b; Wodzinski et al., 1993). The mucosal haemorrhagic changes which occurred in an 
experimental rat model had been attributed to the microvascular endothelium derived t-PA 
which is speculated to play a crucial role in this event (Kurose et al., 1988).  
An examination of the disturbances in the fibrinolytic system in gastric ulcer patients showed 
that plasma PAI-1 levels in both active and inactive ulcers was significantly increased 
compared with the control group while the tPA levels did not differ between cases and 
controls.  
Furthermore, other coagulation factors such as the activated partial thromboplastin time, 
fibrinogen, prothrombin time, fibrinogen degradation products, plasminogen, antithrombin-
111, and α2-PI showed no significant difference among the controls and patient with active 
and inactive ulcers (Kurose et al., 1990). A tight control of the fibrinolytic system is crucial for 
the much desired homeostasis in the coagulation pathway, as an imbalance in the system 
could lead to a thromboembolic state while excessive activation of the system would also 
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trigger increased fibrinolysis and consequently a bleeding disorder (Gils & Declerck, 2004a; 
Gils & Declerck, 2004b).  
PAI-1 plays an important regulatory role in the fibrinolytic system by reducing the generation 
of plasmin from plasminogen, and it has been observed that a deficiency of PAI-1 by way of a 
functionally abnormal protein or a lack of plasma PAI-1 antigen results in a hyperfibrinolytic 
state (Dieval et al., 1991; Schleef et al., 1989). 
 
3.1.2 The biology of plasminogen activator inhibitor (PAI-1) 
PAI-1 was first isolated from culture media of human endothelial cells and then later 
identified in plasma, platelets, placenta and media of fibrosarcoma cells and hepatocytes 
(Kruithof, 1988a). Other tissues from which PAI-1 has been isolated include vascular smooth 
muscle cells, mesangial cells, fibroblasts, monocytes/macrophages and stromal cells of 
adipose tissues (Lijnen, 2005).  
Except in platelets where PAI-1 can be stored in an inactive form, in other tissues, it is rapidly 
and constitutively secreted after synthesis. Its secretion is known to exhibit circadian 
variation, attaining the highest plasma concentration in the morning and lowest in the 
evening, while the exact opposite circadian variation has been described with tPA (Wiman & 
Hamsten, 1990). The synthesis and secretion of PAI-1 is modulated by various agonists such 
as cytokines, growth factors, endotoxin, hormones, with some evidence of transcriptional 
regulation of PAI-1 synthesis (Dawson et al., 1991; Lijnen & Collen, 1995b).  
PAI-1 is a member of the serpine family whose reactive site peptide bond is located at 
Arg345-Met346 and is composed of a single chain glycoprotein of about 45kDa with 379 
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amino acids, but can be up to 381 amino acids due to NH2 terminal heterogeneity 
(Stefansson et al., 2003). The PAI-1 gene is located on chromosome 7, bands q21.3-q22, 
spanning approximately 12.2kb and consists of nine exons (Lijnen, 2005). The enzyme is 
stabilized by binding to a PAI-1 binding protein, vitronectin at residues 12-30 of the 
somatomedin B domain of vitronectin and the active inhibitory form of this protein rapidly 
transforms to a latent conformation that can be partially reactivated by denaturing agents 
(Declerck et al., 1988; Deng et al., 1996).  
PAI-1 is known to react very rapidly with the single chain and the two-chain tPA and with the 
two-chain u-PA, but not with the single-chain uPA (Kruithof, 1988b). Plasminogen activators 
are serine proteases that convert the proenzyme plasminogen in blood into the 
fibrinolytically and thrombolytically active protease, plasmin. There are several functionally 
and immunologically active distinct forms of plasminogen activators; however, tPA is 
thought to be the most important in the initiation of fibrinolysis and thrombolysis (Lijnen, 
2005). 
  
3.1.3 Genetic variation of PAI-1 
The PAI-1 rs1799889 (accession no. P05121) genetic polymorphism encoded on 
chromosome 7 (Bayramoglu et al., 2014; Cosan et al., 2009) is associated with variation in 
PAI-1 plasma levels, with the 4G homozygous individuals having high PAI-1 levels, 
intermediate levels in heterozygous participants and low PAI-1 levels in 5G homozygous 
subjects (De Lange et al., 2013).   
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The 4G/5G polymorphism is perceived as a “response polymorphism” in that the difference 
between the PAI-1 levels in carriers of 4G and 5G alleles becomes more pronounced in the 
presence of disease and environmental factors which enhance PAI-1 expression (Hoekstra et 
al., 2004). This is thought to play an essential role in the regulation of PAI-1 gene expression, 
with the 4G allele which occurs at frequency of 0.56 in Caucasians, being associated with 
higher plasma PAI-1 levels (Dawson et al., 1991). The frequency of the 5G allele of the 4G/5G 
polymorphism in Black subjects has been reported to be 0.85 (De Lange et al., 2013). Other 
PAI-1 genetic polymorphisms which are in close linkage disequilibrium to the 4G/5G 
polymorphism have been described (Lijnen, 2005).  
The role of PAI-1 in various diseases has been demonstrated. For instance, there are reports 
of increased PAI-1 expression in gastric cancer, a state that is associated with poor disease 
outcome; and in radiation damage, in experimental colitis, and in Crohn’s disease (Lijnen, 
2005).  
In insulin resistance, high PAI-1 levels were observed with a significant association with body 
mass index (BMI), triglycerides levels, insulin levels and systolic blood pressure (De Lange et 
al., 2013; Juhan-Vague et al., 1991). There is also an association between the 4G/5G PAI-1 
polymorphism and waist circumference, triglyceride concentrations and cardiovascular 
disease risk (De Lange et al., 2013). Altered PAI-1 expression may also predispose to asthma 
in human subjects, as evidenced by the observation of massive infiltration of PAI-1-
producing mast cells in the airways of these individuals and a higher 4G allele frequency in 
asthmatic patients than in controls (Cho et al., 2004). 
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3.1.4 The role of Plasminogen activator inhibitor (PAI-1) in the fibrinolytic system 
Following trauma and surgery, patients with deficiency of PAI-1 as a result of a homozygous 
frameshift developed abnormal bleeding (Fay et al., 1997). A study involving patients who 
were undergoing coronary angiography reported higher plasma PAI-1 levels and lower 
fibrinolytic activity in patients with severe atheromatosis (Fernandes et al., 2015). 
Furthermore, an analysis of the gene expression profile of aspirated coronary thrombi in 
acute myocardial infarction showed that long ischaemic time is associated with a relative 
increase in the expression of tPA, uPA, and PAI-1 (Helseth et al., 2015).  
Increased fibrinolytic activity has been reported in patients with bleeding peptic ulcers and 
this is decreased by acid suppression and at least in part, by increased plasma PAI-1 levels 
(Vreeburg et al., 2001). A meta-analysis reported an association between PAI-1 4G/5G 
polymorphism and recurrent pregnancy loss as a result of microthrombosis in Caucasians (Li 
et al., 2015).   
The aim of the work within this chapter was to assess whether the functional polymorphism, 
PAI-1 rs1799889 (4G/5G), increases the risk of development of peptic ulcer and its tendency 
to bleed among NSAID users in a Caucasian population.  
 
3.2 Methods 
3.2.1 Patients recruitment, demographics and sample collection 
Patient cohort, recruitment and sample collection are as described in section 2.2.1 and 2.2.2. 
 
3.2.2 Genomic Deoxyribonucleic acid extraction  
This is as described in section 2.2.4. 
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3.2.3 Allelic discrimination of PAI-1 SNP rs1799889 
Following genomic DNA extraction, genotyping of PAI-1 SNP rs1799889 was performed using 
TaqMan® SNP Genotyping assays according to manufacturer’s instructions. Fluorescence and 
allelic discrimination were determined using the SDS software (version 2.2; Applied 
Biosystems, USA). The forward primer sequence of this assay was 
5’AGACAAGGTTGTTGACAAGAGA3’, while the reverse primer sequence was 
5’GGCCGCCTCCGATGATAC3’. Details of the thermocycling conditions are as described in 
section 2.2.5. 
 
3.2.4 Statistical analysis  
The statistical analysis was modelled as described in section 2.2.5, but in addition to this, we 
performed a logistic regression model to determine the association of H.pylori, gender and 
age and NSAID-ulcer status irrespective of PAI-1 genotype.  
 
3.3 Results 
 
3.3.1 Patients, demographics and data analysis 
Figure 3.1 is a flow diagram of the demographic characteristics and patient distribution of 
the case and control cohorts. Of the 1300 recruited patients, 544 participants were excluded 
for various reasons as follows (figure 3.1): unknown NSAID status (n=25), non-white ethnicity 
(n=31), unknown ulcer status (n=6), withdrawal (n=41) and lack of DNA samples to complete 
SNP genotyping (n=441). Peptic ulcer disease was confirmed by endoscopy in 68% (514) of 
patients recruited (case cohort) while the remaining 32% did not have any ulcers on 
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endoscopy. Among the case cohort, the incidence of UGIB was 22.4% and 14.1% among 
NSAID users and non-users, respectively.  
Table 3.1 presents further details on the socio-demographic characteristics of this study 
population. The result of the univariate analysis of the non-genetic covariates relevant to 
this population is presented in table 3.2. 
 
Table 3.1: Patient demographics, treatment group and ulcer distribution 
 
 
Clinical Variable n (%) 
Gender: Male  
Ulcer Cases 
NSAID 
425 (56.2) 
 
Non-aspirin NSAIDs 80 (30.8) 
Aspirin NSAIDs  148 (57.1) 
Both aspirin and Non-aspirin NSAIDs 
Number of cases NSAID positive 
                                                
31 (11.9) 
259 (50.4) 
Number of cases NSAID negative 
Total number of cases 
 
Ulcer site 
Gastric ulcer   
Duodenal ulcer   
Both 
Pyloric   
Missing    
Total  
                                                                                                                                     
255 (49.6) 
514 
 
 
237 (46.1) 
228 (44.4) 
35 (6.8) 
12 (2.3) 
2 (0.4) 
514 
Non-ulcer controls  
Non-aspirin NSAID exposed 11 (15.7) 
Aspirin-NSAID exposed 59 (84.3) 
Both aspirin and non-aspirin NSAID exposed 
No ulcer, with exposure to NSAID 
0 (0) 
70 (28.9) 
No ulcer, and no exposure to NSAID 172 (71.1) 
Total number of controls 242  
Total  number of participants  756 
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Figure 3.1: Schematic presentation of patients’ demographics, cohorts and recruitment process. 1300 patient were recruited, excluding 
patients of non-Caucasian background. The case cohort included patients with peptic ulcer disease (PUD) with/without NSAID use while the 
control cohort is patients without history of PUD with/without history of NSAID use. The case cohort is further stratified based on the presence 
or absence of upper gastrointestinal bleeding among the NSAID users and non-users. 
Patients recruited into study =1300 
Excluded, n=103(7.9%) Equivocal 
NSAIDs use 25; non-white ethnicity 
31, ulcer status unknown 6; 
withdrawn 41; n=441-no DNA 
samples Caucasian patients (n=756) 
Patients without PUD, n=242 (32.0%) 
NSAIDs users n=70 
(28.9%) 
NSAIDs non-users 
n=172 (71.1%) 
Patients with PUD, n=514 (68.0%) 
NSAIDs users 
n=259 (50.4%) 
NSAIDs non-user 
n=255 (49.6%) 
UGIB n=58 (22.4%) No UGIB n=201 (77.6%) UGIB n=36 (14.1%) No UGIB n=219 (85.9%) 
Chapter 3 
 
103 
 
Table 3.2: Clinical and demographic characteristics of study participants 
Covariates Patients with 
PUD (n=514) 
Patients 
without PUD 
(n=242) 
Univariate analysis using Chi 
square  
Pearson chi-
square 
*LRT p 
Age, mean (SD) 65.2 (13.6) 57.6 (14.7) 29.8 30.3 <0.05 
Male sex, n (%) 312 (60.7%) 113(46.7%) 13.1 13.1 <0.05 
BMI, mean (SD) 26.8 (7.7) 27.1 (7.8)   >0.05 
H. pylori Infection 121 (23.5%) 41 (16.9%) 100.3 108.0 <0.05 
Endoscopy indication, n (%)                                                                    95%CI                 LRT 
Hematemesis/melena  217 (42.2%) 24 (10.0%) 3.496-6.570 4.429  
 Dyspepsia/abdominal pain 198 (38.5%) 189 (78.1%) 0.325-0.489 0.487  
 Anaemia 92 (17.9%) 58 (23.9%) 0.398-0.441 0.358  
 Reflux symptoms 20 (3.89%) 8 (3.3%) 0.359-1.913 0.929  
Other 76 (14.8%) 34 (14.0%) 0.205-0.605 0.429  
NSAID used 
Low dose aspirin 
 
179 (34.8%) 
 
59 (24.4%) 
 
23.7 
 
24.8 
 
<0.05 
Non-aspirin NSAID 111 (21.6%) 11 (4.5%) 19.8 20.4 <0.05 
Concomitant medications      
Antiplatelets 22 (4.2%) 11 (4.5%) 25.7 26.5 <0.05 
Anticoagulants 23 (4.5%) 14 (5.7%) 0.372 0.459 >0.05 
Steroids 20 (3.8%) 9 (3.7%) 11.2 12.4 >0.05 
SSRI 25 (4.9%) 36 (14.9%) 0.590 0.720 >0.05 
Proton pump inhibitors 22 (4.3%) 11 (4.5%) 44.6 44.8 <0.05 
Antisecretory medications 32 (6.2%) 13 (5.4%) 0.493 0.505 >0.05 
Univariate analysis performed by Chi-square shows significant association between NSAID 
use, PPI use, gender, age, H. pylori infection and binary ulcer status, hence these covariates 
were added to the list of variables used in the logistic regression analysis. *Likelihood ratio 
test performed using 2 x k table on StatsDirect. 
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3.3.2 Genotype and allele frequency of study patients 
The genotype frequencies for the PAI-1 4G/5G polymorphism in the case cohort were 0.22 
for 5G/5G; 0.52 for 4G/5G and 0.26 for the 4G/4G SNP. These frequencies are similar to the 
reports of the genotype frequency of this SNP in a Caucasian population (Emonts et al., 
2007). We also observed a statistically significant (p<0.05) higher frequency of the 4G allele 
(0.54) compared to the 5G (0.46) in our study population; a finding that is similar to previous 
reports on the allele frequencies of this SNP in Caucasians (Dawson et al., 1991). The PAI-1 
SNP 4G/5G SNP was in Hardy-Weinberg equilibrium (p > 0.05). 
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                       Table 3.3: Genotype and allele frequencies for PAI-1 4G/5G SNP in NSAIDs users and non-users 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
The genotype and allelic frequencies correlate with reported frequencies for the European population and there was no significant difference (p˃0.05) 
between these frequencies in the case and control groups. However, we observed a significant (p<0.05) difference in the 4G and 5G allelic frequencies. 
UGIB= upper gastrointestinal bleeding; 5G/5G=homozygote wild type; 4G/5G= heterozygote variant; 4G/4G= homozygote variant.
                                                                  Genotype frequency                                                                                                          Allele frequency 
 
Status 
 
n   NSAIDs Users (n=332)  Non-users (n=424) NSAIDs Users (n=332) Non-users (n=424) 
  5G/5G 4G/5G 4G/4G 5G/5G 4G/5G 4G/4G 5G 4G 5G 4G 
Ulcer 514 0.22 0.52 0.26 0.24 0.46 0.30 0.48 0.52 0.49 0.51 
No ulcer 242 0.25 0.55 0.20 0.21 0.57 0.22 0.46 0.54 0.48 0.52 
UGIB 94 0.18 0.50 0.32 0.17 0.51 0.32 0.45 0.55 0.47 0.53 
No UGIB 662 0.24 0.49 0.28 0.20 0.44 0.36 0.49 0.51 0.49 0.51 
Ulcer with UGIB 
 
94 0.18 0.50 0.32 0.17 0.51 0.32 0.47 0.53 0.48 0.52 
Ulcer  no UGIB   
    
420 0.24 0.52 0.24 0.25 0.52 0.23 0.48 0.52 0.46 0.54 
Status 
 
n   Aspirin Users (n=238)  Non-aspirin users (n=518) Aspirin-users (n=238) Non users (n=518) 
  5G/5G  4G/5G 4G/4G 5G/5G 4G/5G 4G/4G 5G 4G 5G 4G 
Ulcer 514 0.21 0.52 0.27 0.24 0.47 0.29 0.47 0.53 0.48 0.52 
No ulcer 242 0.27 0.42 0.31 0.21 0.51 0.28 0.45 0.55 0.47 0.53 
UGI bleed 94 0.18 0.50 0.32 0.20 0.50 0.30 0.44 0.56 0.48 0.52 
No UGIB 662 0.24 0.48 0.28 0.23 0.49 0.28 0.48 0.52 0.48 0.52 
Ulcer with UGIB 
 
94 0.17 0.49 0.34 0.20 0.50 0.30 0.47 0.53 0.48 0.52 
Ulcer without UGIB 420 0.22 0.50 0.28 0.22 0.51 0.27 0.48 0.52 0.49 0.51 
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3.3.3 Influence of PPI use and gender 
In terms of gender, 312 (60.7%) men had ulcers (see table 3.2), revealing a higher incidence 
of PUD in male patients than in females (39.3%). An analysis refitted, including an interaction 
term between SNP and gender did not show any evidence of association (p=0.710) between 
gender and genotype at SNP rs1799889 and developing an ulcer.  
However, a further analysis of the association between gender and binary ulcer status 
showed a significant association (p=0.001, OR 1.76; 95% CI 1.27, 2.44) between gender and 
ulcer status (figures 3.4 and 3.5). The higher incidence of PUD in males supports current 
available evidence (Wu et al., 2008). Similarly, PPI use was significantly associated (p=0.001) 
with binary ulcer status. 
3.3.4 Influence of location of ulcer 
In terms of the location of the ulcers, the distribution in this cohort is shown in table 3.1. 
Test of association between SNP and site of ulcer was performed including only gastric ulcers 
as cases in the first analysis and then repeating the analysis with only duodenal ulcers as 
cases and in both cases, no ulcers as control (n=242). Those with both gastric and duodenal 
ulcers were excluded from the analysis. There was no association between PAI-1 SNP and 
gastric or duodenal ulcers (p=0.144 and p=0.170, respectively). Furthermore, gastric and 
duodenal ulcer sensitivity analysis which included only cases without any evidence of H. 
pyIori infection as cases (n=211 for gastric ulcers and n=123 for duodenal ulcers) reported 
p>0.05 for both (table 3.5.) 
3.3.5 Association between SNP PAI-1 SNP rs1799889 and PUD/UGIB 
We tested the PAI-1 SNP rs1799889 for association with case-control outcome status. This 
was done using logistic regression with covariates representing NSAID use (whether none; 
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non-aspirin NSAIDs; aspirin or both aspirin and non-aspirin NSAIDs), PPI use and gender. An 
analysis including only patients who used NSAIDs and developed ulcer as cases (n=259), and 
those that had an endoscopic diagnosis of PUD without NSAIDs use as control (n=255) was 
done; association was tested by logistic regression using likelihood ratio test (LRT) to 
compare models with and without covariate representing PAI-1. The test of association was 
not statistically significant for both models with covariates and without covariates (p=0.516, 
odds ratio 0.871; 95% CI 0.575, 1.321; without covariates and p=0.124 with covariates; odds 
ratio 1.371; 95% CI 0.917, 2.00). The Nagelkerke R2 for model without covariates was 12.0%. 
These are summarised in table 3.4.  
Furthermore, assuming an additive model, a repeat analysis in which the cases (n=514) were 
expanded to include ulcer patients with and without NSAID use, reported no association 
between PAI-1 SNP and gastrointestinal complications of NSAID use (p=0.742, odds ratio 
0.925; 95% CI 0.582 to 1.47). The Nagelkerke R2 for model including NSAIDs use, H. pylori 
status, PPI use, gender, and PAI-1 was 26%. A sensitivity analysis was done, including only 
cases without any evidence of H. pylori as cases (n=398); there was no association between 
SNP and binary ulcer status (p=0.124). However, an analysis including only H. pylori positive 
ulcer patients as cases (n=121), revealed a significant association between SNP and binary 
ulcer status (p=0.0001, OR 1.69; 95% CI 0.11, 0.247).  
Further tests of association were undertaken for PAI-1 SNP and upper GI bleeding status 
with patients who have upper GI bleeding as cases (n=94) and no upper GI bleeding as 
controls (n=662). Applying the genetic model described above, there was no association 
between PAI-1 and upper GI bleeding status (p=0.198). Still assuming an additive mode of 
inheritance and applying the genetic model described above, association of SNP and ulcer 
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and bleeding status was tested by logistic regression with patients who had ulcer and GI 
bleed as cases (n=94) and ulcer with no bleed as control (n=420); the test of association did 
not show statistical significance (p=0.644). Table 3.4 presents the logistic regression of the 
non-genetic covariates while table 3.5 presents a summary of covariates tested against PAI-1 
and the association/outcome measures. 
Table 3.4: Logistic regression for non-genetic covariates 
Non-genetic covariates             n  
 Cases Control p Odds ratio 
No NSAID exposure 255 172 0.267 0.06; 95% CI 0.001-9.0 
NSAID exposure 259 70 0.171 3.63; 95% CI 0.573-23.0  
Aspirin exposure 179 59 0.158 1.57; 95% CI 0.84-2.94 
Non-aspirin NSAID  80 11 0.346 2.27; 95% CI 0.41-12 
PPI exposure 311 355 0.001 5.08 95% CI 2.73-9.47 
Gender 514 242 0.001 1.76 95% CI 1.27-2.44 
H. pylori 121 41 0.0001 1.69 95% CI 0.11, 0.25 
 
Table 3.5: Association of NSAID and ulceration status with PAI-1 SNP   
Covariates tested against PAI-1 SNP 
rs1799889 
             n   
Cases Control        p OR 
$Binary ulcer status 259 255 0.516 0.871; 95% CI 0.56, 1.32 
$Upper GI bleed status 94 662 0.198 0.631; 95% CI 0.39, 1.13 
$Ulcer and GI bleed status* 94 420 0.644 0.831; 95% CI 0.42, 1.85 
Ulcer status, expanded cohort 514 242 0.742 0.930; 95% CI 0.58, 1.47 
                                                                                                                                                      
$Ulcer location:                                             
                                                                GU                                                
                                                                                                                                                                                   
                                                                DU 
 
237
 
242
 
0.144 
 
0.980; 95% CI 0.48, 1.60  
228 242 0.170 
 
0.857; 95% CI 0.54, 1.58 
Gender 514 242 0.0001 1.790, 95% CI 1.30, 2.45 
PPI use 311 355 0.001 3.560; 95% CI 1.95, 6.53 
*Ulcer and bleed=case, ulcer no bleed=control; GU=gastric ulcer; DU=duodenal ulcer. $covariates 
include NSAIDs use, PPI use and gender. 
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3.4 Discussion 
 
This work has examined the association of the PAI-1 4G/5G polymorphism (rs1799889) with 
the risk of NSAID-related gastrointestinal complications. Our study did not find any 
association between the PAI-1 polymorphism and binary ulcer status (p=0.516).   
The genotype frequencies of the 4G/5G polymorphism in our study population were 0.22 for 
5G/5G; 0.52 for 4G/5G and 0.26 for the 4G/4G SNP. Also, the allelic frequencies of this SNP 
showed a statistically significantly (p=0.025) higher frequency of the 4G allele than the 5G 
allele; 0.54 and 0.46 respectively. Furthermore, there was no statistically significant (p>0.05) 
difference in the genotype and allele frequencies of the 4G/5G polymorphism between the 
case and control cohorts.   
These results do not differ from previous data on the genotype and allele frequencies of this 
SNP in Caucasians (Dawson et al., 1991; Emonts et al., 2007). Similarly, among Asian 
populations, the genotype frequencies of the 4G/4G is also higher than that of the 5G/5G 
which has been reported to be 0.32 and 0.14 respectively (Kim et al., 2014). By contrast, in 
Black Africans, significantly higher genotype frequencies of the wild type allele (5G/5G=0.73) 
compared to the 4G/4G (0.0261) allele has been demonstrated (De Lange et al., 2013). This 
suggests a difference between our data and previous studies in other ethnicities on allele 
frequencies of PAI-1 genotype.  
The genetic variation at the PAI-1 gene polymorphic locus is associated with differences in 
the levels of PAI-1 in the plasma of study subjects, with a single guanosine insertion deletion 
(4G/5G) polymorphism in the PAI-1 promoter region playing an important role in the 
regulation of PAI-1 gene expression (Dawson et al., 1991). The variant allele which occurred 
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at a higher frequency in our study population is associated with higher plasma PAI-1 levels, 
but various other factors such as hormones, growth factors, endotoxins, cytokines, and 
phorbol esters are known to modulate PAI-1 synthesis and secretion (Festa et al., 2003; 
Lijnen & Collen, 1995a).   
This study did not show any association between PAI-1 5G/4G polymorphism and NSAID-
related GI complication. Theoretically, an inactive PAI-1 protein would lead to failure in 
mucosal protection by PAI-1, and high PAI-1 level resulting from 5G/4G polymorphism  
would cause enhanced inhibition of tPA and uPA, which would consequently lead to the 
development of multiple thrombus (Fernandes et al., 2015; Sun et al., 2010) in the gastric 
microvasculature resulting in ischemia and a predisposition to ulcers from gastric mucosal 
necrosis (Wodzinski et al., 1993).  
However, several factors could explain our finding. Firstly, the variant form of PAI-1 
rs1799889 SNP, 4G/4G, is associated with higher PAI-1 plasma levels in carriers of this 
variant genotype, a phenomenon that could compensate for the defect in the actions of the 
4G/4G PAI-1 protein if these exist. In a mouse model, PAI-1 knockout mice were shown to 
develop increased haemorrhagic lesions in response to NSAIDs, absolute ethanol and 50% 
ethanol compared to control mice in which there was targeted overexpression of PAI-1 to 
gastric parietal epithelial cells (Kenny et al., 2013b). This would imply that the 4G/4G 
polymorphic variant is not associated with a loss of function of the PAI-1 protein. Secondly, 
studies have shown that despite the increased plasma PAI-1 level in carriers of the 4G/4G 
genotypes compared to carriers of the 5G/5G and the 4G/5G genotypes, the polymorphic 
variation did not affect the activity of the PAI-1 (De Lange et al., 2013). Thirdly, medications 
such as NSAIDs and PPI increase PAI-1 expression in humans. Aspirin and NSAID use is 
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associated with a 2-5 fold increase in the gastric PAI-1 mRNA relative abundance in the 
gastric biopsy samples of patients receiving these medications (Kenny et al., 2013b). 
Similarly, PPI may stimulate PAI-1 expression via the gastrin pathway (Nørsett et al., 2011), 
and both of these medications were used by most of our patients in the case and control 
cohorts. It is likely that use of NSAIDs and PPI in our study cohorts may have confounding 
effects in the interaction between the PAI-1 polymorphism and binary ulcer status. This is 
supported by the observation that introducing the non-use of NSAIDs as an interaction term 
in our analysis, showed some trend toward association between PAI-1 polymorphism and 
ulcer status, although not statistically significant (p=0.099).  
Available evidence suggests a possible interaction of H. pylori with PAI-1 activity, an 
interaction that may interfere with the role of PAI-1 in mucosal protection. There is 
increased expression of uPA, uPAR and PAI-1 in the human gastric corpus in the presence of 
H. pylori infection. Also, in H. pylori infection there was an increase in the activity of cell-
bound and the soluble uPA, and this increase was enhanced by PAI-1 knockdown. Moreover, 
in the presence of H. pylori infection, there was increased epithelial cell proliferation 
mediated by uPA and enhanced by PAI-1 knockdown (Kenny et al., 2008).  
From the foregoing, it is likely that H. pylori infection modulates the function of the uPA and 
the PAI-1 system to drive gastric cancer development; however, the exact role of this 
interaction in the pathogenesis of NSAID ulcers is yet to be determined functionally. 
However, taken in conjunction with our results, it seems safe to conclude that H. pylori 
infection which was detected in our study subjects (cases=121 and control=41), could have 
interacted with 4G/5G polymorphism in several of the mechanisms highlighted above to 
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attenuate any significant association we would have found between binary ulcer status and 
this SNP.  
Our study was the first to evaluate the relationship between PAI-1 polymorphism and 
NSAID-induced gastrointestinal complications. Several studies have been investigating the 
association in the PAI-1 4G/5G polymorphism and other disease conditions such as recurrent 
pregnancy loss, outcome of sepsis, risk of otitis media, cardiovascular disease risk, 
abnormality of the fibrinolytic system and prognosis of gastric cancer (Cho et al., 2004; De 
Lange et al., 2013; Emonts et al., 2007; Helseth et al., 2015; Juhan-Vague et al., 1991; Li et 
al., 2015; Saely et al., 2008). However, there are no data on PAI-1 4G/5G polymorphism and 
its role in NSAID-related GI complications. Our sample size was fairly large which confers on 
it a reasonable effect size that should detect any association between this SNP and NSAID 
ulcer status. However, we do not know the magnitude of effect. A limitation of our study is 
that other PAI-1 SNPs in linkage disequilibrium with the 4G/5G PAI-1 polymorphism such as 
the c.428G>T and c.429G>A (De Lange et al., 2013) were not genotyped and also we lacked 
samples (n=441) to genotype the entire cohort. 
In conclusion, we have examined the role of PAI-1 4G/5G polymorphism in the pathogenesis 
of NSAID-related GI complications and found that there was no association between this 
single guanosine insertion deletion (4G/5G) polymorphism and NSAID-related GI 
complications. This underscores the need for further evaluation of various other pathways 
that may be relevant in NSAID-related ulcers.  
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4.1 Introduction 
 
4.1.1 Previous EYA1 GWAS report 
 
A GWAS study on NSAID-related GI complications was conducted from July 2005 to June 
2011 to unravel a possible genetic basis for NSAID-related GI complications in a Caucasian 
population (Bourgeois, S et al, unpublished data 2016). The study cohorts were classified as 
either cases or control, and the phenotypic traits tested were age, gender, history of 
duodenal or gastric ulcer disease, use of PPI, H. pylori infection, concurrent drug use, and 
NSAID use.  
The report of the GWAS indicated that the “top hit” gene was located on the long arm of 
chromosome 8. A significant association (p=1.14x10-6, OR 2.01; CI 1.52-2.66) was identified 
between the EYA1 SNP rs12678747 and NSAID-related GI injuries (see figure 4.1).  
 
Figure 4.1: Manhattan plot of GWAS study on NSAID-related GI complications (Bourgeois, S 
et al., unpublished data 2016). The plot shows that there are “top hit” genes on 
chromosome 7 and 8, 10 and 17 all having signals with p<1x10-5. The gene on chromosome 8 
is the EYA1 SNP rs12678747 with a p value of (p=1.14x10-6; OR 2.01, CI 1.52-2.66). The 
broken lines indicate the notional threshold for significance. 
EYA1 SNP rs12678747, N=680 
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4.1.1.1 Aims and objectives 
 
The aim of the study was to ascertain an association between the EYA1 SNP rs12678747 and 
NSAID-related gastrointestinal complications and also to validate the report of the NSAID-
related ulcer GWAS study. Furthermore, the aim was also to characterise the polymorphic 
variation in the expression of EYA1 gene and protein expression in atypical gastrin secreting 
(AGS) cells and healthy human gastric epithelial cells.  
To date, there has not been any study or a previous report of an association between EYA1 
gene and GI complications in NSAIDs users. Additionally, there is also no EYA1 gene and 
protein expression data in gastric epithelial cells. The AGS cell is a validated in vitro model 
closely representing the human gastric mucosa in that it expresses both COX-1 and 2, with 
an increased expression of COX-2 upon stimulation (Hall et al., 2006).  This was therefore 
used as the cell model of choice for further characterisation in terms of EYA1 genotype, gene 
and protein expression. 
 
4.1.2 Structure of EYA protein 
As revealed by crystallographic work on pro-and eukaryotic haloacid dehydrogenase (HAD) 
phosphatases, all members of the HAD phosphatases superfamily share identical 
architecture of the active core, as shown in figure 4.2A. The modified Rossmann fold (figure 
4.2A) contains the catalytic residues which consist of three α/β sandwiches, comprised of 
repeating α and β subunits (Burroughs et al., 2006). 
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Figure 4.2: A: The Rossmann-like fold of HAD phosphatases formed by repeating β-α units 
(Seifried et al., 2012). β1-5: β subunits. B: A schematic view of the domain structure of Eya1-
4. Domain structures of Eya and its RDGN partners. P/S/T=proline-serine-threonine rich 
domain; EYA D2= EYA domain 2. 
 
  
As a member of the haloacid dehydrogenase (HAD) phosphatase superfamily, EYA proteins 
share a common active core with other HAD phosphatases, as revealed by crystallographic 
work on pro- and eukaryotic HAD phosphatases. However, unlike other protein tyrosine 
phosphatases (PTP), EYA does not utilise a cysteine residue in catalysis but rather, as a HAD 
phosphotransferase metalloenzyme, it employs an aspartate as a nucleophile and another 
conserved aspartate, two residues downstream as an acid catalyst (Rayapureddi et al., 
2003). This confers some specificity to this class of proteins which could potentially be 
explored in the design of inhibitors.  
β5
β1
 
β2
 
β4
 
β3
 
Asp27
 Asp25
 
Squiggle/flap loop 
P/S/T rich region 
 
EYA D2 P/S/T rich region EYA domain 
C N 
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The EYA proteins are composed of a highly conserved 271- amino acid C-terminal motif 
called the EYA domain (ED), which functions in EYA’s interaction with other proteins (sine 
oculis in drosophila and six1 in vertebrates), and contains the phosphatase catalytic domain. 
By contrast, the N-terminal of EYA is highly divergent between EYA family members, and its 
proline-serine-threonine (PST) rich transactivation domain is indispensable for their function 
as coactivators of transcription. Embedded in the PST domain is a second moderately 
conserved domain called the EYA domain 2 (ED2) (Landgraf et al., 2010; Silver et al., 2003).  
These are schematically presented in figure 4.2B and the different protein isoforms of EYA1 
are presented in table 4.1.         
 
4.1.3 The Role of EYA in health and disease 
EYA phosphatases play crucial role in a wide range of human diseases, from congenital birth 
defects, neurologic and cardiovascular disorders, to cancer (table 4.1). A role for EYA1 in 
ulcerogenesis has not previously been described. 
 
4.1.3.1 Putative role of EYA1 in NSAID-induced gastrointestinal complications 
EYA1 dephosphorylates Tyrosine-142 on histone following DNA damage or breaks and this 
dephosphorylation is an important step required in the recruitment of the DNA repair 
complex MRN (figure 4.4). The MRN complex in humans are a group of complex proteins 
consisting of MRE11, RAD50 and NBS1, which bind to double strand DNA breaks (DSB) to 
initiate DNA repair process (Cook et al., 2009). The mechanism by which NSAID causes 
damage to gastric epithelial cells and the relationship to EYA1 is unclear, but requires further 
investigation. 
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Table 4.1: Human EYA gene involvement in health and disease, modified from (Xu, 2013) and  
http://www.ncbi.nlm.nih.gov/gene/?term=eya2 
 
Unlike the Drosophila melanogaster which has one EYA gene, humans have four paralogs, designated as EYA 1-4. The name comes from their 
crucial function as components of a family of transcription factors called the ‘retinal determination gene network’ (RDGN). These genes play 
crucial roles in the development of various organs, are associated with some diseases and are also potential markers for various cancers. 
 
 
 
Gene Location  Target organs/tissues Associated human disease Cancers 
EYA1 Chromosome 8 Ear, branchial arches, and craniofacial, sensory 
neurons, thymus, and parathyroid, kidney, 
ribs, skeleton, muscle 
Branchial-oto-renal(BOR)  
syndrome, branchi-otic (BO) 
syndrome, cardiofacial 
syndrome (Seifried et al., 2013) 
Acute leukemia   
Under expressed in gastric cancers 
(Nikpour et al., 2014) 
 
EYA2 Chromosome 20 Muscle defects enhanced in EYA1/2 mutants - Ovarian cancer, dermoid tumors, 
colorectal cancer 
 
EYA3 Chromosome 1 Decreased body size, respiratory, muscle and 
heart function 
- Breast cancer cell line 
EYA4 Chromosome 6 Ear, Heart Late-onset deafness (DFNA10), 
cardiomyopathy, 
holoprosencephaly (HPE) 
(Seifried et al., 2013) 
Malignant peripheral nerve sheath 
tumours (Miller et al., 2010), 
sporadic and colitic neoplasia, Barrett’s 
oesophagus and oesophageal 
adenocarcinoma 
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Figure 4.3: The retinal determination gene network (RDGN) regulatory network, modified 
from (Jemc & Rebay, 2007; Rebay et al., 2005). All members of the RDGN play crucial role in 
the drosophilia eye development, which is initiated by the “toy” gene leading to activation of 
the SO/SIX/EYA complex and the downstream effect of drosophila eye development. The red 
arrows indicate the initiation steps in the transcriptional hierarchy of the key regulators of 
the drosophila eye. The black and double arrows indicate feedback steps.  
 
 
4.1.3.2 Role in cardiovascular disorder 
EYA1 mutations have been reported in patients with cardio-facial syndrome- a unique 
association of asymmetric crying face with congenital cardiac defects (Shimasaki et al., 
2004). Dilated cardiomyopathy as a result of a deletion mutation of EYA4 with associated 
heart failure and sensorineural loss has been reported. Biochemical analysis has 
demonstrated that following this deletion mutation, EYA4’s role as a transcriptional co-
activator may be impaired (Schönberger et al., 2005). 
 
Chapter 4 
 
123 
 
Deletion mutations of EYA4 gene is linked to dilated cardiomyopathy type 1J with associated 
heart failure. This is thought to result from failure of the shortened arm of EYA4, produced 
by the deletion mutation, to bind EYA4 and SIX proteins. In a study of the role of EYA4 in 
Zebra fish cardiac function, depleting EYA4 in Zebra fish caused significant reduction in mean 
ventricular areas at end-systole and end-diastole, with contractile features suggestive of 
severely compromised ventricular function, associated regional wall motion abnormalities 
and attendant non-uniform ventricular contraction and retrograde blood flow (Schönberger 
et al., 2005).   
 
4.1.3.3 Role in Cancers 
There is increasing evidence of over expression of EYAs and their role in many adult cancers 
which positively correlates with increased tumour size and metastasis. EYA2 has been 
implicated in breast and ovarian cancers while EYA4 is involved in malignant peripheral 
nerve sheath tumours (Farabaugh et al., 2012; Miller et al., 2010; Pandey et al., 2010; Zhang 
et al., 2005).  
More recently, EYA1 has been reported to be under expressed in gastric carcinoma and this 
novel finding is being exploited for its use as a prognostic marker for this cancer (Nikpour et 
al., 2014). This finding sharply contrasts from reports of over expression of other EYA 
paralogs in various other cancers (Jemc & Rebay, 2007). The phosphatase activity of EYA1 
has been reported as an essential driving force for breast cancer proliferation via interaction 
with, and maintaining the levels of Cyclin D1 and also important in the induction of cell 
contact-independent growth of breast cancer cells (Wu et al., 2013). The underlying 
mechanism of EYA’s role in cancer is that tyrosine phosphatase promotes cancer cell 
invasiveness and motility.  
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In ovarian and breast cancers, EYA2 is upregulated at the protein and RNA levels, partly as a 
result of genomic over amplification and this, in association with Six1 co-expression is a poor 
prognostic factor. EYA2 is a necessary cofactor for many of the metastasis promoting 
functions of Six1, and hence targeting Six1-Eya synergism may repress breast cancer 
progression (Farabaugh et al., 2012; Seifried et al., 2013).  Expression of EYA4 has been 
found to be approximately 100 fold higher in peripheral nerve sheath tumours than in 
normal nerve sheaths and inhibition of this expression using short hairpin RNA (shRNA) 
reduced cell adhesion and migration, and caused cell necrosis but had no effect on cell 
proliferation and apoptotic cell death (Miller et al., 2010). 
 
4.1.3.4 Role in branchio-oto-renal syndrome 
Mutations in the EYA gene cause a wide range of congenital disorders, due to their 
involvement in the formation of many organs and tissues (Seifried et al., 2013). Congenital 
anomalies which arise as a result of mutations in the EYA1 gene, detectable in 40% of 
affected individuals, include Branchio-oto-renal syndrome (BOR1) and Branchio-otic 
syndrome (BOS1) (Seifried et al., 2013). The former is an autosomal dominant disorder 
characterized by hearing loss (in >90% of affected individuals), ear malformations, fistulae 
and cysts in the neck and renal abnormalities or total renal agenesis, while the later (BOS) 
has all features of BOR except renal involvement. Renal defects manifest in only about 6% of 
BOR patients as against the 93% that present with hearing loss.  
Commonly occurring renal defects in BOR patients are malformation of the collecting 
system, polycystic, hypoplastic or complete renal agenesis (Chen et al., 1995; Heimler & 
Lieber, 1986) and these have also been observed in EYA1 heterozygous animals (Xu et al., 
1999).  
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The impairment of the function of the hair cells of the organ of Corti in the cochlea are 
known to generally cause sensorineural deafness, hence the phenotypic characteristics of 
individuals affected by dilated cardiomyopathy 1J (CMD1J) and deafness, autosomal 
dominant non-syndromic sensorineural deafness 10 (DFNA10) suggests that EYA4 is crucial 
post developmentally for a normal functioning organ of Corti (Seifried et al., 2013). 
 
4.1.4 The Biology of EYA1 gene 
EYA proteins belong to a novel family of proteins identified in many animals ranging from 
birds, frogs, and fish to higher vertebrates (Hoshiyama et al., 2007). Unlike Drosophila 
melanogaster which has only one EYA gene, humans have four paralogs, designated as EYA 
1-4. The name comes from their crucial function as components of a family of transcription 
factors called the ‘retinal determination gene network’ (RDGN) (figure 4.3), derived from 
their role in drosophila eye development (Jemc & Rebay, 2007; Rebay et al., 2005). EYA has 
been reported to be present in some higher plants like rice and Arabidopsis (Takeda et al., 
1999). In contrast to SO/SIX genes, EYA genes do not encode transcription factors but rather 
encodes proteins that interacts with DNA binding proteins such as So/six and other DNA-
binding proteins (Xu, 2013). 
 
4.1.4.1 EYA1 phosphorylase and transcription activity 
EYA, as a member of a conserved network of transcription factors, named collectively as the 
‘retinal determination gene network’ has been well characterized as transcriptional 
coactivators that function in consonance with So/Six proteins. This is crucial in many 
developmental contexts and also attributable to some disease, due in part to absent or 
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impaired EYA function (Jemc & Rebay, 2007). Analyses of the structure and function of both 
EYA and Gal4 DNA binding domain (Gal4DBD)-EYA fusion proteins has shown that the 
internal P/S/T rich region (figure 4.2B) is needed for transactivation. While ED2 is required 
for optimal activity in vitro and in vivo, it is not essential for transactivation. Six and Dach are 
known to be cofactors of EYA necessary for activation of transcription in cell based reporter 
gene assays and this is believed to explain the increase in ectopic eye formation when these 
cofactors are co-expressed with Eya in Drosophila (Silver et al., 2003). 
 
Alone, this family of proteins produces a low level of transcription, but transfection of Six/So 
and EYA produces tremendous activation of a number of reporter constructs. When Dach is 
added, an even greater transcriptional output is achieved (Ikeda et al., 2002; Silver et al., 
2003).  Following the identification of other binding partners for the Six family proteins, it is 
now thought that the Eya-Six-Dach complexes could have role as transcriptional activators 
and repressors. This opinion followed the finding that Six proteins act as transcriptional 
repressors on interaction with the Groucho (Gro) family corepressors (Silver et al., 2003).    
 
EYA are also members of the phosphatase subgroup of the HAD superfamily, which 
constitutes about one-fifth of all human phosphatase catalytic subunits. HAD phosphatases 
differ from others in that while the tyrosine specific phosphatases use serine or cysteine 
nucleophiles for phosphoryl transfer, HAD phosphatases use aspartate residue in the active 
site for nucleophilic attack. Phosphatase activity is optimal at a pH of approximately 5.5 and 
Mg2+, Ni2+, Co2+, and Zn2+ are essential cofactors for optimal enzyme activity. The 
phosphatase activity of the HAD phosphatases is a two-step phosphoaspartyl transferase 
mechanism; the first being the attack of the aspartate nucleophile on the phosphoryl group 
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of the intermediate leading to the formation of a phosphoaspartyl enzyme intermediate and 
the displacement of the substrate leaving group. The second step is nucleophilic attack, by a 
water molecule, on the phosphoaspartyl intermediate and the release of free phosphate 
with regeneration of the catalytic aspartate (Seifried et al., 2013).  
In vivo studies suggest that Eya phosphatase activity is important for the normal 
development of the eye in Drosophila. In BOR mutants, it’s been observed that phosphatase 
activity is lost, and this strongly suggest that phosphatase activity is important for 
transcription factor activity of EYA and this may be contributory to the disease. Also in Eya 
HAD mutants, the ability to reverse Dach-Six-mediated repression is lost in Eya (Silver et al., 
2003).               
 
4.1.4.2 EYA phosphatase activity and histone dephosphorylation 
Following genotoxic stress, EYA1 and 3 can dephosphorylate Tyrosine-142 of histone (H2AX), 
and this is a decisive phosphorylation mark that discriminates between apoptotic or 
survival/DNA repair response of cells (figure 4.4). H2AX is an established substrate of EYA 
phosphatase, as wild type EYA has been observed to remove the phosphotyrosine mark of 
EYA, while the phosphatase-inactive mutant EYA has little or no effect (Cook et al., 2009).  
 
The novel finding that EYA proteins are functional phosphatases, containing an embedded 
HAD phosphatase signature sequence was a major landmark in developmental biology 
because it indeed demonstrated for the first time, a transcription factor with an intrinsic 
phosphatase activity (Li et al., 2003; Rayapureddi et al., 2003; Tootle et al., 2003).  
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Though EYA’s phosphatase activity has earlier been noted to be very important in the 
transcriptional activation of some Six-dependent reporter genes, emerging evidence 
indicates that in Drosophila, down-regulating EYA phosphatase activity does not generally 
attenuate transcriptional output (Jemc & Rebay, 2007; Li et al., 2003). Despite these 
phosphatase activities of the EYAs, the establishment of a physiological target is yet to be 
fully elucidated (Seifried et al., 2013).  From the fore going, bearing in mind the results of the 
GWAS, we propose biological plausibility for EYA1 in NSAID-exposed mucosal epithelial cells 
that includes modulation of cell death/survival decisions which can lead to ulcerogenesis.  
 
Figure 4.4: Proposed model for EYA1 dephosphorylation of serine-139 phosphorylated 
histone following DNA damage adapted from Cook et al., 2009. H2AX= histone; MRN 
complex=DNA ancillary repair factors. 
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4.2 Methods 
4.2.1 Characterization of the association between EYA1 SNP rs12678747 and GI 
complications in NSAID users 
4.2.1.1 Patients recruitment and sample collection 
Patient cohort, recruitment and sample collection is as described in sections 2.2.1 and 2.2.2. 
 
4.2.1.2 Allelic discrimination for EYA1 SNP rs12678747 
Following genomic DNA extraction as described in section 2.2.4, genotyping of the EYA1 SNP, 
rs12678747 was performed using TaqMan® SNP Genotyping assays according to 
manufacturer’s instructions.  Fluorescence and allelic discrimination were determined using 
the SDS software (version 2.2; Applied Biosystems, USA). The forward primer sequence of 
this assay is 5’CAGAGTATTAATAAGAACCACCTGGTCAA3’, while the reverse primer sequence 
is 5’TGATGAGTTGTCTGTAATATACTACAGGAAGT3’. Details of the thermocycling conditions 
are as described in section 2.2.4. 
 
4.2.1.3 Statistical analysis  
Non-Caucasian patients and patients with missing genotype data were excluded from the 
analysis. Genotype frequencies were tested for Hardy-Weinberg equilibrium (HWE) in the 
control group only and in the sample as a whole, with a p value <0.01 assumed to indicate 
deviation from HWE.  
In order to test for association between EYA1 SNP rs12674747 and PUD (ulcer vs. no ulcer), 
two logistic regression models were fitted. The first (the ‘baseline model’) included 
covariates to represent aspirin use, proton pump inhibitors (PPI) use and gender. The second 
(the ‘genetic model’) was the same model, but with the addition of a covariate to represent 
EYA1 SNP rs12674747. An additive mode of inheritance was assumed, with wild-type 
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homozygotes coded 0, variant heterozygotes coded 1 and variant homozygotes coded 2. The 
two models were compared using a likelihood ratio test to determine the association 
between rs12674747 and ulcer status. An odds ratio with 95% confidence intervals was 
computed for rs12674747. Further analyses were carried out using gastric ulcer and duodenal 
ulcer cases separately. The logistic regression analysis was repeated for the additional 
outcome measure of gastrointestinal bleeding. Tests were conducted to assess the 
association between rs12674747 and upper gastrointestinal bleeding (UGIB vs. no UGIB), and 
between rs12674747 and bleeding ulcers (bleeding ulcer vs. non-bleeding ulcer). Again, 
covariates were included to represent aspirin use, PPI use and gender. For all analyses, 
sensitivity analyses were conducted including only cases without any evidence of H. pylori as 
cases. 
 
4.2.2 Characterization of EYA1 gene expression in the peripheral blood mononuclear cells       
(PBMC) of healthy volunteers.    
 
4.2.2.1 Recruitment and demographics of healthy volunteers  
Following ethical approval, 30 healthy volunteers were recruited after informed consent was 
obtained from each participant. Inclusion criteria were absence of any medical condition and 
willingness to participate in the study. Approximately 15mls of whole blood was collected 
from each participant into 2 PAXgene tubes (Preanalytix QIAGEN, Germany) for RNA 
extraction and one EDTA tube for DNA analysis.   
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4.2.2.2 Blood RNA extraction from peripheral blood mononuclear cells (PBMCs) 
Using PAXgene RNA extraction kit (Preanalytix QIAGEN, Germany), total RNA was extracted 
from PBMCs as described in the manufacturer’s protocol. The RNA yield and quality was 
determined using NanoDrop spectrophotometer according to manufacturer’s protocol. 
Samples with A260/280nM ratio higher than 1.8 were included in these experiments. These 
were stored at -800C for later use. 
 
4.2.2.3 EYA1 gene expression and allelic discrimination assay.  
cDNA was synthesized from 100ng-500ng of RNA samples using high capacity reverse 
transcription kit as per manufacturer’s instructions (Applied Biosystems, USA). RNA samples 
were thawed on ice and 20µl reaction containing 2µl of 10x RT buffer; 0.8 µl of 10x RT 
random primers; 2 µl of 25x (100nM) dNTP mix; 1 µl of Multiscribe Reverse Transcriptase; 1 
µl of RNase inhibitor; 3.2 µl of nuclease-free water and 10 µl of RNA samples.  
Reverse transcription was performed using the Veriti® Thermal cycler (Applied Biosystems, 
USA) programmed as follows: 25oC for 10 minutes, 37oC for 120 minutes and 85oC for 5 
minutes and then cooled rapidly to 4oC. cDNA was either stored at 4oC for short term use or 
at -20oC for later use. 
The Taqman® gene expression assay (Applied Biosystems, USA) is a technology that utilizes 
oligonucleotide probes and primers that are sequence specific. To prepare a 20 µl reaction, 
the 20x Taqman gene expression assay for EYA1 and beta actin genes were thawed on ice. 
The components of the reaction are 1 µl of 20x Taqman gene expression assay, 10 µl of gene 
expression master mix; 7 µl of RNase free water and 2 µl of cDNA, and these were added to 
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each well in a 398-well plates in triplicates and for quality controls, no template controls 
(NTC) were added. The endogenous control gene for this experiment is beta actin. The 
Applied Biosystems HT 7900 fast real-time PCR System (Applied Biosystems, USA) was used 
for the thermal cycling under the following conditions: 10 minutes at 95o C followed by 45 
cycles of the denaturing step at 95oC for 15 seconds and an annealing step for 1 minute at 
60oC. To determine the EYA1 genotype of individual participants, genomic DNA was 
genotyped using the Taqman assay as described in section 4.2.1.2  
 
4.2.3 Determination of EYA1 gene expression in healthy gastric epithelial biopsy samples 
by qPCR  
 
4.2.3.1 Patient recruitment and demographics 
cDNA from corpus tissue biopsy and genomic DNA from100 sex and age-matched healthy 
control patients was kindly received from Professor Varro, University of Liverpool. 
Endoscopy and gastric epithelial biopsy sampling had previously excluded any pathology. 
 
4.2.3.2 Real-time Polymerase chain reaction and allelic discrimination 
The DNA samples were quantified using NanoDrop Spectrophotometry as per 
manufacturers’ instruction and then normalized to a final concentration of 20ng/µl.  The 
gene expression assay is as described in section 4.3.4.2. However, this experiment was 
performed in duplicate because the amount of sample was very limited. Allelic 
discrimination was then performed as described in section 4.2.4. 
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4.2.3.3 Gene Expression data analysis  
Using the SDS software, version 2.2 (Applied Biosystems, USA), gene expression was 
quantified by the number of cycles at which the amplification curve crosses the threshold 
value; this is the point where the fluorescence signal surpasses the background signal.  The 
comparative CT method was used to determine the difference between the mean target CT 
value for the EYA1 gene and the mean control CT value for beta actin in AGS cells and human 
embryonic kidney (HEK) cells.  
Using the Livak and Schmittgen method, the level of expression of EYA1 was determined 
(Livak & Schmittgen, 2001):  
∆CT = CT (gene of interest) – CT (reference gene) 
The expression for each sample was then calculated using 2-∆CT. The fold change was then 
determined using the formula: 2-∆CT (EYA1 gene)/ 2
-∆C
T (Beta actin gene).  One-way ANOVA 
was done to compare the mean relative expression of EYA1 in different cells using Graphpad 
Prism, version 5. 
 
4.2.4 Characterization of EYA1 gene expression in AGS cells 
4.2.4.1 AGS immortalized cell culture 
Atypical gastrin secreting cells (AGS) were the generous gift of Prof Andrea Varro. AGS cells 
were seeded in Dulbecco's Modified Eagle's medium (DMEM) (supplied by Life Technologies) 
supplemented with 1% antibiotic/antimycotic, 1% penicillin/streptomycin and 10% fetal 
bovine serum (FBS) and cultured in a T75 flask in monolayer at 37o centigrade in a 
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humidified atmosphere of 95% O2 and 5% CO2. At 90% confluence, cells were passaged or 
cell pellets used in protein lysates. To determine the cell count, 10µl of AGS re-suspended in 
DMEM was placed in the counting chamber and cell viability determined by the Trypan blue 
exclusion test of cell viability using the CountessTM automated cell counter, following 
manufacturers’ instruction (Invitrogen). Only cells that have viability ≥92% were passaged.  
 
4.2.4.2 Extraction of total RNA from AGS cells  
Total RNA was extracted from AGS cells when they achieved 100% confluence. Tryptinized 
AGS cells were re-suspended in PBS, transferred into a 2ml cryovial and 1.8mls of RNA 
stabilization solution, RNAlater®(Applied Biosystems) added to the cells and left in room 
temperature for 15 minutes, and then preserved at -80o C. RNA extraction from AGS cells 
suspended in RNAlater® was performed using the RNeasy® mini kit following the product’s 
protocol (QIAGEN).      
 
4.2.5 Characterization of EYA1 protein expression by Western blot 
4.2.5.1 Preparation of protein lysates from AGS cells 
RIPA buffer was supplemented with 1% protease inhibitor cocktail (both obtained from 
Sigma Aldrich, Poole, UK). Protein lysates of AGS cells were prepared by washing a 100% 
confluent flask of cultured cells twice with ice-cold PBS (Invitrogen, UK) and effluents were 
discarded. 1ml of PBS was then added to the flask and the monolayer of AGS cells were 
detached off the bottom of the flask as much as possible using a cell scraper. The PBS 
containing the detached cells was than pippeted into a 1.5ml eppendorf tube and spun for 2 
Chapter 4 
 
135 
 
minutes. The supernatant was discarded and 300µl of RIPA buffer was added to the pellet of 
cells and mixed and placed briefly in a Sonicator (for 10 secs) to break up the cells. The 
sonicated cells were spun at 13,000rpm for 20 minutes at 4o centigrade and the protein 
supernatant transferred into a new eppendorf tube and stored frozen at -80oC. 
 
4.2.5.2 Protein lysate quantification  
AGS protein lysates were diluted with PBS 1:1, 1:10 and 1:100 and 10µl of sample was placed 
in each well in duplicates. The standard was prepared by dissolving 2mg of human serum 
albumin in 1ml of water and 10µl of standard concentrations of 0, 100, 200, 500, 1000, 1200, 
1600 and 2000µg/ml was added in duplicate to a 96-well plate. Bradford reagent was diluted 
in water in a ratio of 1:5 and 250µl of the reagent was added to all wells containing samples 
and standard protein. The absorbance of the assay was determined in a plate reader at a 
wavelength of 595nM. The average absorbance was calculated and then a standard plot was 
used to determine sample concentration.  
 
4.2.5.4 Western blot assay 
The chemical and reagents required for this assay were: Running Buffer 1X (Invitrogen MOPS 
stock solution 20X); Transfer Buffer 1X (NuPAGE stock solution 20X); 10X Tris Buffered Saline 
(TBS) stock (80g NaCl, 2g KCl, and 30.3g Trizma Base, all dry reagents were obtained from 
Sigma Aldrich, dissolved in 800ml dH2O, the pH adjusted to 7.4 with pure HCL and topped up 
to a final volume of 1L. 1X TBS/T was prepared by adding 100ml of 10X TBS + 1ml Tween 20 
and topped up to 1L;  and SDS stripping buffer (20ml 10% SDS, 12.5mL 1M Tris HCl pH 6.8, 
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700l -mercaptoethanol) added to 66.8ml of distilled water. The anti-EYA1 (product 
number ab85009) and anti-beta actin polyclonal primary antibodies (product number 
ab8227), and the goat anti-rabbit IgG horse raddish protein (secondary antibody, product 
numbers ab97051) were all obtained from abcam. 
As per the Bradford Assay, 5, 10 and 20µg of AGS protein sample was added to 5µl of sample 
buffer (300µl of reducing agent and 700µl of sample buffer). This was heated to 85oC for 5 
minutes and cooled rapidly on ice for 5-10 minutes and electrophoresed using precast gels 
(Invitrogen, UK) in x1 running buffer in the presence of antioxidant. Protein was then 
transferred from gel to nitrocellulose membrane (Invitrogen, UK) using the gel sandwich in 
x1 transfer buffer.  
Non-specific binding was blocked overnight by adding 25mls of 5% non-fat milk powder 
(made by adding 5g of milk powder in 50ml of TBS/T) to each membrane in the cold room on 
a mixer. The membrane was incubated in the appropriate primary/secondary antibody for 1 
hour at room temperature. The membrane was washed using TBS/T after incubation with 
the each antibody. 1ml of Chemiluminescence reagent was added to the membrane for 1 
minute and exposed to Kodak film for 1 minute in a developer plate.  
 
4.2.5.4 Protein densitometry data analysis 
The films were scanned using the Quantity one 1-D analysis software (Biorad). The scanner 
was allowed to equilibrate for 5-10 minutes and following manufacturers’ instruction, all 
films developed from the western blot experiment were scanned and the images saved. The 
density of the blot was determined using ImageJ software. 
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4.3 Results 
4.3.1 Patients demographic data and data analysis 
The demographic characteristics and patient distribution in the case and control cohorts is as 
presented in the flow diagram (figure 2.2) and table 2.2. About 1200 of the recruited 1300 
patients were genotyped. The reasons for exclusion were due to withdrawal from the study 
for various reasons such as unknown NSAID status (n=25), non-white ethnicity (n=31), 
unknown ulcer status (n=6), and withdrawal (n=41). Of the 1197 that participated in this 
study, 66.8% had endoscopic confirmation of PUD while 33.2% had no ulcers on endoscopy. 
In the case cohort, UGIB was present in 23.0% and 14.4% of NSAID users and non-users 
respectively. A detailed clinical and socio-demographic characteristic of patients with and 
without ulcers is presented in figure 2.2 and table 2.2. A univariate analysis of non-genetic 
covariates was performed and the results are presented in table 2.3, chapter 2.        
 
4.3.2. Association between EYA1 polymorphism and GI ulceration 
The EYA1 SNP rs12678747 was tested for association with case-control outcome status. The 
association was tested using logistic regression with covariates representing NSAID use 
(whether none; non-aspirin NSAIDs; aspirin or both aspirin and non-aspirin NSAIDs), PPI use 
and gender. EYA1 SNP, rs12678747 was in Hardy-Weinberg equilibrium (p<0.05). The allelic 
and genotype frequencies of EYA1 SNP is as presented in Table 4.3; however, there are no 
available data on the genotype frequencies of this SNP in Caucasian population, making 
comparison impossible. The variant allele frequency from our data is 0.37, a value that is 
significantly different (p<0.05) than figures from databases which report the global minor 
allele frequency (GMAF) for this SNP as 0.4405 (NCBI).  EYA1 SNPs rs13260349 and 
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rs2380716 variant allele frequencies among Han Chinese non-syndromic orofacial clefts 
patients have been reported as 0.9 and 0.069 respectively (Zeng et al., 2013), which are also 
significantly (p<0.05) different from our data.  
An analysis including only patients who used NSAIDs and developed ulcer as cases (n=466), 
and those with endoscopic diagnosis of PUD without NSAID use as control (N=334) was 
done; association was tested by way of logistic regression using likelihood ratio test (LRT) to 
compare models with and without covariate representing EYA1. The test of association was 
statistically significant for both models with covariate and without covariates (p=0.0007 
without covariates and p=0.0003 with covariates; odds ratio 1.52, 95% CI; 1.21, 1.91). The 
pseudo R2 value for the model including age, PPI use and gender was 16.9%. These are 
summarised in tables 4.2 and 4.4. 
Assuming an additive model, a repeat analysis in which the cases (n=800) were expanded to 
include ulcer patients with and without NSAIDs use. There was no association between SNP 
and binary ulcer status (p=0.970, odds ratio 1.00; 95% confidence interval (CI) 0.82 to 1.23). 
The pseudo R2 for model including NSAID use, H. pylori status, PPI use, gender and EYA1 was 
24.7%. A sensitivity analysis was done, including only cases without any evidence of H. pylori 
as cases (n=361); there was no association between SNP and binary ulcer status (p=0.961).   
Further tests of association were undertaken for the EYA1 SNP and upper GI bleeding status 
with patients who have upper GI bleeding as case (n=155) and no upper GI bleeding as 
control (n=1042). Applying the genetic model described above showed that there was no 
association between EYA1 and upper GI bleeding status (p=0.514) while sensitivity analysis 
showed a p=0.9. Still, assuming an additive mode of inheritance and applying the genetic 
model described above, association of SNP and ulcer and bleeding status was tested by 
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logistic regression with patients who had ulcer and GI bleed as cases (n=155) and ulcer with 
no bleed as control (n=645). The test of association did not show statistical significant 
(p=0.297). Table 4.2 presents a summary of covariates tested against EYA1 and the 
association/outcome measures. 
Table 4.2: NSAID covariates tested against EYA1 single nucleotide polymorphism   
Covariates tested against 
EYA1 SNP rs12678747 
             n           Test of association 
 
Cases Control   p Odds ratio 
NSAIDs ulcer vs No ulcer 466 334 0.0003 1.52; 95% CI 1.21, 1.91 
 
H. pylori +NSAIDs ulcer  230 397 0.0004 1.63; 95% CI 1.24, 2.13 
 
NSAIDs ulcer vs no ulcer in 
H. pylori positive patients^ 
230 56 0.0001 2.79; 95% CI 1.57, 4.95 
 
 
                                          GU 
$Ulcer location            
                                             
                                          DU 
407 397 0.787  
 
313 
 
397 
   
0.192 
 
$Binary ulcer status 800 397 0.970 1.00; 95%CI 0.82, 1.23 
 
$Upper GI bleed status 155 1042 0.514  
 
$Ulcer and GI bleed status* 155 645 0.297  
*Ulcer and bleed=case, ulcer no bleed=control; ^H. pylori positive patients only in both case and 
controls. GU=gastric ulcer; DU=duodenal ulcer. $covariates include NSAID use, PPI use and gender. 
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                Table 4.3: Genotype and allelic frequencies for EYA1 SNP rs12678747 for NSAID users and non-users 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
The genotype and allelic frequencies correlates with reported frequencies for the European population and there was no significant difference 
(p˃0.05) between these frequencies in the case and control groups. UGIB= upper gastrointestinal bleeding; AA=homozygote wild type; AT= 
heterozygote variant; TT= homozygote variant; *the UGIB status of 2 patients was missing. 
                                                                  Genotype frequency                                                                                                          Allele frequency 
 
Status 
 
n   NSAIDs Users (n=588)  Non-users (n=609) NSAIDs Users (n=588) Non-users (n=609) 
  AA 
 
AT TT AA AT TT A T A T 
  Ulcer 800 0.38 
 
0.50 0.12 0.57 0.37 0.06 0.63 0.37 0.76 0.24 
  No ulcer 397 0.56 
 
0.32 0.12 0.51 0.41 0.08 0.72 0.28 0.72 0.26 
  *UGIB 155 0.43 
 
0.45 0.12 0.63 0.31 0.06 0.66 0.34 0.79 0.21 
 *No UGIB 1042 0.42 
 
0.47 0.11 0.54 0.39 0.07 0.66 0.34 0.74 
  
0.26 
Ulcer with UGIB 
 
155 0.43 
 
0.45 0.12 0.63 0.31 0.08 0.66 0.34 0.79 0.21 
Ulcer  no UGIB   
    
645 0.38 
 
0.52 0.10 0.57 0.38 0.05 0.64 0.36 0.76 0.24 
Status 
 
n   Aspirin Users (n=426)  Non-aspirin users (n=771) Aspirin-users (n=426) Non users (n=771) 
  AA 
 
AT TT AA AT TT A T A T 
Ulcer 800 0.35 
 
0.52 0.13 0.54 0.40 0.06 0.61 0.39 0.74 0.26 
No ulcer 397 0.58 
 
0.32 0.10 0.51 0.39 0.10 0.74 0.26 0.71 0.29 
*UGI bleed 155 0.42 
 
0.46 0.12 0.56 0.37 0.07 0.65 0.35 0.75 0.25 
*No UGIB 1042 0.40 0.48 0.12 0.52 0.40 0.08 0.64 0.32 0.72 0.28 
Ulcer with UGIB 
 
155 0.42 0.45 0.13 0.55 0.37 0.08 0.64 0.36 0.74 0.26 
Ulcer without UGIB 645 0.33 
 
0.54 0.13 0.54 0.40 0.06 0.60 0.40 0.74 0.26 
Chapter 4 
                                                                                                                                                                       140 
4.3.3 Association between EYA1 polymorphism and location of ulcer 
The site of the ulcer was distributed as follows in this cohort: gastric ulcer 407 (50.9%), 
duodenal ulcers 313 (39.1%), both gastric and duodenal ulcers (7.8%), and pyloric ulcers 
(2.0%). Test of association between SNP and site of ulcer was performed as described in 
section 4.3.2 but including only gastric ulcers as cases in the first analysis and then repeating 
the analysis with only duodenal ulcers as cases, and in both cases, no ulcers as control 
(n=397). Those with both gastric and duodenal ulcers were excluded from the analysis.  
There was no association between EYA1 SNP and gastric or duodenal ulcers with p=0.267 
and p=0.157 respectively. Furthermore, gastric and duodenal ulcer sensitivity analysis which 
included only cases without any evidence of H. pyIori infection as cases (n=211 for gastric 
ulcers and n=123 for duodenal ulcers) reported p>0.05 for both. These are presented in 
table 4.2. 
 
4.3.4 Influence of H. Pylori infection 
To explore the association between EYA1 and ulcer status in the presence of H. pylori 
infection further, SNP was tested for association with case (NSAIDs ulcer and H. pylori 
infection, n=230) and controls (no ulcers, n=397) as described in section 4.3.2. Analysis 
repeated with and without covariates shows a significant association between EYA1 and 
NSAIDs ulcer in the presence of H. pylori infection p=0.0007 and p=0.0004 respectively. The 
odds ratio for the second model (with covariates) was 1.63 (95% CI 1.24, 2.13). Including 
only H. pylori positive patients in both cases (n=230) and controls (n=56), using the same 
model resulted in p<0.0001 without covariates and p=0.0001 (odds ratio 2.79, 95% CI 1.57, 
4.95) with covariates (table 4.2).  
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4.3.5 Association between EYA1 polymorphism and GI complications in aspirin users 
Analysis was done by excluding patients treated with non-aspirin NSAIDs, including only 
aspirin-treated patients. SNP was tested for association by logistic regression, with 
covariates to represent aspirin use, PPI use and gender as described in section 4.3.2. There 
was no significant association between EYA1 SNP and binary ulcer status as shown in table 
4.4 which presents all covariates tested and the outcome measures. 
Table 4.4: Aspirin covariates tested against EYA1 single nucleotide polymorphism   
Covariates tested against 
EYA1 SNP rs12678747 
             n               Test of association 
 
Cases Control     p Odds ratio 
$Binary ulcer status 800 397   0.568 1.06; 95% CI 0.87, 1.29 
 
$Upper GI bleed status 155 1042   0.630  
 
$Ulcer and GI bleed status* 155 645   0.341  
 
*Ulcer and bleed=case, ulcer no bleed=control; ^H. pylori positive patients only in both case and 
controls. GU=gastric ulcer; DU=duodenal ulcer. $covariates include NSAID use, PPI use and gender. 
 
4.3.6 Influence of concurrent use of steroids 
The distribution of steroid users and non-users did not differ significantly between groups 
for the NSAIDs (p=0.44) and aspirin (p=0.1) cohorts. Hence, concurrent use of steroid was 
not a significant predictor of ulcer status when tested in the regression models. This data is 
presented in table 4.5 which also shows the percentage of steroid users in each subgroup. 
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Table 4.5: Concurrent use of steroids and NSAIDs according to ulcer status 
Subgroups Steroid users *n/N (%) 
 
Ulcer and NSAID use 19/471 (4.0%) 
 
Ulcer and no NSAID use 12/333 (3.6%) 
 
No ulcer and NSAID use 7/123 (5.7%) 
 
No ulcer and no NSAID use 7/279(2.5%) 
 
Ulcer and aspirin use 8/329 (2.4%) 
 
Ulcer and no aspirin use 23/475 (4.8%) 
 
No ulcer and aspirin use 6/95 (6.3%) 
 
No ulcer and no aspirin use 8/307 (2.6%) 
 
*n= number of steroid users; N=number in subgroup 
 
4.3.7 EYA1 gene expression and correlation with genotype 
4.3.7.1 Patient characteristics and demographics 
100 cDNA and genomic DNA samples were provided by Professor Andrea Varro (University 
of Liverpool) for the determination of the role of EYA1 polymorphism in its expression in the 
healthy gastric epithelium. 53.5% were males while 47% were females and the age range of 
participants was 19-88 years. The mean age for the males was 61.1±15.4 and 55.9±16.9 for 
the females. 34 samples were excluded as the gene expression data was incomplete due to 
insufficient sample. The allelic discrimination data matched with each patient’s gene 
expression data are as presented in figure 4.5. The results show that the mean EYA1 gene 
expression in the patients carrying the variant allele was not different from carriers of the 
wild type allele (p=0.3218). This data is in agreement with earlier work on EYA1 
(rs12678747) RNA sequencing (Carr et. al., -unpublished data) of 10 cases and 10 controls 
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(figure 4.6), which reported no statistically significant difference in the mean EYA1 counts 
per million mapped areas between the wild and variant allele carriers in the control cohort 
(n=10); however, there was statistically significant difference (p=0.025) in the mean EYA1 
counts per million mapped areas in the ulcer case cohort between the wild-type (AA) and 
variant (AT/TT) EYA1 rs12678747 alleles (Carr et. al; unpublished data). 
 
Figure 4.5: Mean relative gene expression of the wild type (AA) EYA1 (rs12678747) and the 
variant (AT/TT) type. There was no statistically significant difference (p>0.05) between the 
mean relative gene expression in the wild type (AA) cohort and the variant type (AT/TT) 
cohort of patients with healthy gastric epithelial biopsy, this result agrees with the RNA 
sequencing data presented in figure 4.6. 
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Figure 4.6:  EYA1 RNA sequencing data of gastric epithelial cells of 10 cases and controls 
grouped according to EYA1 rs12678747 genotype. Based on EYA1 genotype, there is a 
statistically significant difference in the EYA1 counts per million mapped reads of the wild 
type genotype (AA) and  the variant genotype (AT/TT) among the case cohort (n=10) but no 
statistically significant difference was observed in the controls (n=10). 
 
4.3.7.2 Relative expression of EYA1 in AGS cells 
In search for a model to study NSAID-related gastric injury, we used the AGS cell line. AGS 
cells are known to behave similar to target cells and are therefore representative in terms of 
response to the anti-inflammatory and adverse effects of the NSAIDs (Hall et al., 2006). The 
abundance of endogenous basal expression of EYA1 in AGS cells was determined as well as 
in HEK cells and healthy human gastric biopsy tissue. As shown in table 4.6, EYA1 is 
expressed in AGS cells, HEK cells and healthy gastric biopsy samples with a relative 
expression of 4.86X10-6, 6.7X10-4 and 1.0X10-3 respectively, relative to the 
standard/endogenous control, β-actin. Similar to the reports of lower EYA1 gene expression 
in gastric cancer cells compared to the surrounding healthy epithelium (Nikpour et al., 
EYA1 expression by rs12678747Genotype
Control Antrum Case Antrum Case Ulcer
AA AT/TT AA AT/TT AA AT/TT
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2014), we found a statistically significant (p<0.05) lower relative expression of EYA1 in AGS 
cells compared to the gastric epithelium of healthy volunteers.  
Table 4.6: Comparative analysis of EYA1 relative gene expression for different cell types 
 
       Mean CT 
Average 
∆ T 
Relative 
expression 
(2^-∆ T) 
 
 
 
^P value Tissue type EYA1 β-Actin 
AGS 36.94 19.29 17.65 4.86X10-6            
HEK 36.88 26.33 10.55 6.7X10-4 *P<0.05 
Healthy HGB 38.22 26.63 11.59 1.0X10-3 *P<0.05 
*AGS EYA1 relative expression is significantly lower than the EYA1 relative expression in 
human embryonic kidney cells (HEK) cells and healthy human gastric biopsy sample (HGB). 
This is in agreement with the reports of lower EYA1 relative gene expression in human 
gastric cancer cells compared to adjacent normal epithelium (Nikpour et al., 2014). CT= cycle 
time. 
 
4.3.8 Characterization of EYA1 protein expression in AGS cells by Western blot 
The concentrations of the unknown samples were determined using the Bradford protein 
concentration assay, with standard concentrations of human serum albumin as standard. A 
curve of the concentration (y axis) and the optical densities (x axis) of the standard samples 
was constructed and the protein concentrations of the AGS cell lysates samples were 
calculated.  
To further determine the level of expression of EYA1 protein in AGS cells, western blot was 
performed; this showed significant expression of the 65kDA EYA1 protein. There was 
significantly (p<0.05) lower relative expression of the EYA1 protein (4.86X10-6) compared to 
the endogenous β-actin (relative expression= 0.007289) (table 4.7 and figure 4.7). 
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Figure 4.7: EYA1 protein expression. Figure A is the blot of EYA1 protein from 5, 10 and 20µg 
of AGS cell lysates, while figure. B shows the blot for the endogenous β-actin protein 
expression in AGS cells. 
     
Table 4.7: AGS EYA1 and β-actin protein densitometry data 
 
EYA1 protein density  analysis      β-actin protein density analysis 
 
        Density(CNT/MM2)           Density(CNT/MM2) Relative 
expression 
(EY 1 β-actin) Exp 1  Exp 2 
Mean 
density±SE Exp 1 Exp 2  
Mean 
density±SE 
5µg 
sample 43851 36329 40091±5319 52096 56102 54099±2832 
0.74 
10µg  
sample 46316 39813 43065±4599 57239 57137 57188±72 
0.75 
20µg 
sample 53778 47879 50829±4171 68003 68201 68102±141 
0.75 
Relative EYA1 protein expression in AGS cells shows a relatively high expression of the 
protein despite a significantly low EYA1 gene expression in AGS cells. EXP= experiment; SE= 
standard error. 
 
4.4 Discussion 
Genome-wide association studies which involve scanning of the whole genome and 
associating common genetic variants, SNPs and phenotypic characteristics/complex diseases 
of interest have now become feasible. A survey of the genome of a large cohort usually in a 
prospective study that provides detailed and meticulously collected information on the 
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phenotypes/clinical characteristics has the power to elucidate common genetic variants that 
are associated with complex diseases (Kottgen et al., 2008).  This has been used to explore 
the genetic basis of various complex diseases like hypertension, diabetes, Crohn’s and 
coeliac diseases as in the Wellcome Trust Case Control Consortium (2007).  Despite some 
notable successes, linkage and candidate gene studies have often failed to deliver definitive 
results (2007). There has not been any previous GWAS on the toxicity of NSAID on the upper 
GI. 
Our data shows that a case-control analysis including only patients with evidence of use of 
NSAIDs as cases (n=466), reveals a significant association between binary ulcer status and 
EYA1 SNP (p<0.005, OR 1.52, 95% CI 1.21, 1.91). Bonferroni testing to correct for multiple 
testing did not change this association.  
This is a very significant and novel finding because this association from our data validates 
the report of GWAS on NSAID-related GI complication in which EYA1 is reported as the “top 
hit” gene in this study. Furthermore, expanding the case cohort (n=800) to include ulcer 
patients without NSAID use resulted in lack of association (p=0.970). This finding further 
implies that the EYA1 SNP rs12678747 is associated with NSAID-related ulcer.  
Whether this association is purely due to a treatment-gene interaction or it is in support of a 
plausible role of EYA1 polymorphism in NSAID-related ulcers needs to be further elucidated. 
A statistically significant association (p=0.0004; odds ratio 1.63 95% CI 1.24, 2.13) was also 
noted when H. pylori positive patients with NSAID ulcers were tested as cases (n=230) 
against non-PUD patients as controls (n=397). The role of H. pylori infection in the 
pathogenesis of PUD has been well characterized. This association between EYA1 SNP and 
this highly successful bacterial pathogen known to cause PUD on its own or in synergism 
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with NSAID use has not been previously reported. Moreover, this data may suggest a 
possible synergistic relationship between EYA1 SNP and H. pylori in ulcerogenesis. H. pylori 
infection is associated with a state of chronic gastric inflammation leading to PUD and 
mucosal associated lymphoma or adenocarcinoma (Montecucco & Rappuoli, 2001; Peek Jr 
& Blaser, 2002).  
Infection with wild type H. pylori has been reported to induce changes in the expression of a 
variety of host genes and proteins particularly proteins such as serine/threonine and 
tyrosine kinases (of which EYA1 is a member), transcription factors, cell cycle-related 
factors, actin cytoskeletal signalling molecules and these are potential determinants of H. 
pylori virulence (Backert et al., 2005). Whether H. pylori infection of gastric epithelial cells 
interferes with the expression of EYA1 in these cells needs to be explored further. 
EYA1 belongs to the tyrosine kinases which as reported, are among the proteins whose 
expression in AGS cells are altered following infection with wild type H. pylori. If this 
alteration in protein expression leads to a down regulation of these kinases (Backert et al., 
2005; Backert & Selbach, 2005), of which EYA1 is a member, the resulting attenuation of 
EYA1 activity could lead to a reduced ability of these epithelial cells to survive DNA damage, 
ultimately progressing to denudation of the mucosal surface and culminating in ulceration.  
The above could explain the significant association we observed between H. pylori positive 
NSAID-induced ulcers and EYA1. The persistent association noticed when H. pylori positive 
patients as cases (n=230) were tested against H. pylori positive non PUD patients as control 
(n=56) may suggest that this interaction may be a true association of NSAIDs/H. pylori 
infection and EYA1 SNP in the pathogenesis of ulcers and not merely a confounding variable.  
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There are, however, no previous reports on EYA1 SNP and NSAID-related GI ulcer and 
bleeding. We are the first to report the MAF (0.36) of this SNP in a Caucasian population, 
and this is significantly (p<0.05) different from the global MAF reported as 0.44 (NCBI).  Our 
data also shows that concurrent use of steroid is not a significant predictor of ulcer status.  
Reports on the use of steroids as a risk factor in NSAID-related ulcers have been fraught 
with controversy (Valkhoff et al., 2012). While most studies implicate steroids as risk factors 
for NSAID-related ulcer, others report no association. Our data supports previous reports 
that there is no association between the use of steroid and NSAID-related ulcers (de Abajo & 
García Rodríguez, 2001).  However our numbers are limited and since this was not our 
primary hypothesis, our findings should be treated with caution. Indeed, it has been 
reported that steroids in high doses produce gastric lesions in experimental animals and 
man via the inhibition of prostaglandin biosynthesis at the level of arachidonic acid 
elaboration from membrane phospholipids (Jama et al., 1975; Lancaster & Robert, 1978).  
The major phenotypic consequence of loss of EYA1 activity is accelerated apoptotic cell 
death in tissues and subsequent agenesis of target tissues (Xu et al., 1999). Whether this 
effect is seen in developed organs needs to be investigated. EYA1 has been established as a 
protein tyrosine phosphatase, which acts to effect a damage-signal-dependent 
dephosphorylation of an histone (H2AX) carboxy-terminal tyrosine phosphate (Y142), 
promoting efficient DNA repair rather that apoptosis in response to genotoxic stress in 
mammalian cells (Cook et al., 2009).  
Increased apoptotic response following evidence of increased serine 139 phosphorylation 
has been observed in the renal tubular cells of developing kidneys (Cook et al., 2009). 
Phosphorylation of H2AX by ATM/ATR phosphatidylinositol-3-OH kinase (PI (3) K-family 
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kinases at the nuclear level is now known to be an extraordinarily important component of 
apoptosis caused by a perturbation of the JNK/SAPK pathway (Lu et al., 2006). Furthermore, 
EYA1 is recruited to H2AX foci that mark DNA double strand damage and while wild type 
EYA1 efficiently removed this phosphotyrosine mark on H2AX, the phosphatase inactive 
mutant EYA1 proteins had little or no effect (Cook et al., 2009). 
Similar to reports from other studies, we noted the higher prevalence of NSAID-related 
gastric ulcers (51.6%) compared to duodenal ulcers (38.5%) (Voutilainen et al., 2001). 
However, this contrasts from a study on the incidence of PUD in a Western population that 
reported a higher incidence of duodenal ulcers than gastric ulcers (Groenen et al., 2009). 
This may reflect the changing aetiologies in the pathogenesis of peptic ulceration (Musumba 
et al., 2013). 
We have observed that despite a lower relative expression of EYA1 gene in AGS and gastric 
epithelial biopsy cells, the protein expression was much higher, almost equivalent (0.75) to 
that of the endogenous control, β-actin. EYA1 proteins are transcriptional co-activators and 
this unexpected higher expression may suggest a role for this protein in the gastric 
epithelium.  
Our study has several strengths; firstly, it is the first to report an association between the 
EYA1 SNP rs12678747 and NSAID-related peptic ulceration. Hitherto, most of the data 
available on EYA genetic variation has focused on the brachio-oto-renal syndrome, non-
syndromic orofacial cleft palate; congenital cardiomyopathy and potential roles in cancer 
pathogenesis. Our data has a large sample size (about 1200) improving the effect size 
greatly, hence enabling us to see the association reported here. The study design that 
involved use of endoscopy to diagnose PUD, UGIB, and ascertain presence or absence of H. 
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pylori increased the validity of our data.  Our study cohort was exposed to a wide variety of 
NSAIDs including aspirin and this enabled us to examine any difference in the association 
between these NSAIDs and the EYA1 SNP. We further expanded our control cohort to 
include two groups of patients - one with ulcer but no NSAID use and the second with no 
ulcer but use of NSAIDs confirmed. This approach would enable associations that are due to 
gene-by-treatment interaction rather than being a prognostic marker of NSAID-related ulcer 
to be unmasked (Musumba et al., 2013).   
We are also the first to report the expression of EYA1 protein in the AGS and human gastric 
epithelial cells; prior to this, the only data available was a recent publication reporting a 
lower EYA1 gene expression in gastric cancer cells compared to neighbouring epithelium 
(Nikpour et al., 2014). There has not been any previous work on the relative expression of 
EYA1 gene based on the rs12678747 genotype.  
The limitations of this study are that we evaluated only one SNP, rs12678747. Looking at 
other SNPs which are in close linkage disequilibrium with the EYA1 SNP analysed in this 
study may provide further information. Secondly, we still do not know the exact mechanism 
by which EYA1 predisposes to NSAID-related ulceration and this will need further study. 
Clearly, with our polymorphism which leads to milder effects on expression, we would not 
expect to see the congenital malformations that are observed in patients with severe loss of 
function mutations (Heimler & Lieber, 1986). Third, the non-significant difference in the 
mean gene expression between the wild type and the variant rs12678747 genotypes may be 
due to a low sample size; a repeat of this analysis with a higher sample size may be required 
to bring to a conclusion the exact relationship between EYA1 gene expression and EYA1 
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genotype. However, it is also possible that the effect of the variant on expression may only 
be manifest in the presence of disease rather than in normal tissue. 
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Chapter 5 
A functional analysis of the role of EYA1 in aspirin-induced         
gastric epithelial cell death 
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5.1 Introduction 
5.1.1 Aspirin-induced cell death in AGS- what is known? 
Aspirin and other NSAIDs have been demonstrated to induce both the intrinsic and extrinsic 
pathways of apoptosis; mitochondrial release of cytochrome c and the activation of 
caspase-9 are observed with the intrinsic pathway, while the activation of caspase-8 induces 
the extrinsic pathway (Gu et al., 2005; Redlak et al., 2005; Zimmermann et al., 2000). 
Various modes/pathways of aspirin-related gastric epithelial cell death have been 
suggested.  Table 5.1 presents a summary of available reports on aspirin-induced cell death 
in AGS cells. 
 
5.1.2 Models for the study of cell death in gastric epithelium 
Prior to the report by Hall and his colleagues, there existed no validated in vitro model for 
the assessment of the gastrointestinal toxicity of COX-2 inhibitors or NSAIDs, and hence 
models using human cell lines or human platelets and monocytes were the standard (Hall et 
al., 2006). Various systems that have been used to study the inhibitory activities of NSAIDs 
and natural compounds against COX-1 and COX-2 have been classified as follows: 1) systems 
that use animal enzymes, animal cells and cell lines; 2) models using human cells or human 
platelets and monocytes; and 3) newer and evolving models that behave similar to the 
target cells and are therefore representative of them in terms of response to the anti-
inflammatory and adverse effects of the NSAIDs (Pairet & Van Ryn, 1998). For instance, 
while COX-2, mRNA and protein are both constitutively expressed and inducible at specific 
locations in both animals and man (Halter et al., 2001; O'Neill & Ford-Hutchinson, 1993), 
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COX-1 is constitutively expressed in most tissue and may be responsible for the synthesis of 
PG in normal gastric mucosa which is essential for the maintenance of mucosal homeostasis.  
Therefore an appropriate in vitro model for assessing the gastrointestinal adverse effects of 
COX inhibitors should constitutively express both COX-1 and COX-2 in appropriately relative 
amounts and should express COX-2 in response to physiological stressors. AGS cells fulfil 
these criteria as they constitutively express both COX-1 and COX-2, with COX-1 expression 
approximately 4 times greater than COX-2 expression. Also hydrogen peroxide treatment of 
AGS resulted in a 27-fold increase in PG synthesis (Hall et al., 2006).  
Using this model, it was feasible to rank compounds for potential for GI adverse effects as 
follows: rofecoxib <acetaminophen <nimesulide < celecoxib <salicylic acid < ibuprofen < 
aspirin < naproxen <indomethacin, from lowest to highest. This rank estimate of GI toxicity 
provided by using either A23187-mediated arachidonic acid release or addition of 100µM of 
arachidonic acid is associated with clinical rankings of NSAIDs gastropathy, with a lower 
therapeutic index observed in AGS models more accurately reflecting the clinical scenarios 
than older models utilizing enzymes or non-target cells (Hall et al., 2006).  
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   Table 5.1: Studies on the mechanisms of aspirin-induced gastric epithelial cell death 
Author Title Aspirin 
conc. 
Treatment 
duration 
High through-put screening method  
(Leung et al., 2009) Aspirin-induced mucosal cell death in 
Human gastric cells: Role of caspase-
independent mechanism 
40mM 2-4 hrs Acridine orange-ethidium bromide(EtBr) assay 
(Redlak et al., 2005) Role of mitochondria in aspirin-induced 
apoptosis in human gastric epithelial cells 
40mM 1-4 hrs Cell death ELISA kit 
(Power et al., 2004) Aspirin-induced mucosal cell death in 
Human Gastric cells: Evidence supporting 
an apoptotic mechanism 
3-50mM 24 hrs Terminal deoxynucleotidyl transferase (TdT)-
mediated deoxyuridine triphosphate (dUTP) nick-
end labelling (TUNEL) assay 
(Redlak et al., 2008) Prevention of deoxycholate-induced 
gastric apoptosis by aspirin: Roles of NF-
kB and PKC signalling 
40mM  1 hr Acridine orange-ethidium bromide (EtBr) assay 
(Redlak et al., 2007) Aspirin-Induced Apoptosis in Human 
Gastric Cancer Epithelial Cells: 
Relationship with Protein Kinase C 
Signaling 
40mM 1-4hrs Cell death ELISA Kit 
(Gu et al., 2005) Activation of the caspase-8/Bid and Bax 
pathways in aspirin-induced apoptosis in 
gastric cancer 
1-4mM 1-3 days MTT, acridine orange staining 
(Zhou et al., 2001) Non-steroidal anti-inflammatory drugs 
induce apoptosis in gastric cancer cells 
through up-regulation of bax and bak 
1mM 0, 12, 24, 
36, 48, 60 
MTT, acridine orange staining 
(Zhu et al., 1999) Non-steroidal anti-inflammatory drug-
induced apoptosis in gastric cancer cells is 
blocked by protein kinase C activation 
through inhibition of c-myc 
0.1-10mM 1-3 days Measurement of DNA content of cells by PI staining 
and FACS analysis to detect the preG1  peak; 2) 
Agarose gel electrophoresis of genomic DNA to 
detect fragment; 3) AO staining to detect the typical 
morphological changes under fluorescence 
microscopy 
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5.1.3 Benzbromarone and benzarone as EYA inhibitors 
Benzbromarone (BBR), a benzofuran derivative, is a potent uricosuric agent that increases 
the excretion of uric acid through the kidneys. It lowers serum urate and increases urate 
excretion in normal, hyperuricemic and gouty patients. In short and long term studies, 
benzbromarone reduces serum uric acid level by one-third to one-half, maintaining its 
efficacy for up to 8 years (Heel et al., 1977). 
Benzbromarone and its metabolite benzarone are potent inhibitors of the EYA tyrosine 
phosphatase with selectivity for EYA over a representative of typical protein tyrosine 
phosphatase (PTP), PTP1B. Both are active in cellular assays where they have been observed 
to inhibit the EYA-promoted motility of mammary epithelial cells and endothelial cells. They 
are also known to attenuate angiogenesis observed in in vitro, in vivo and ex vivo assays 
(Tadjuidje et al., 2012). Benzbromarone also inhibited the EYA catalytic domain (ED) with 
similar potency. Other structurally related compounds were also tested for their potential 
EYA inhibitory action and it was found that those compounds which retain their basic 
scaffold of phenol and a benzofuran linked by carbonyl group had IC50 values similar to that 
of benzbromarone. The phenol moiety seems to be required for EYA binding and docking 
studies have revealed that the OH group forms H-bond with Tyr329 of EYA3. The 3, 5-
dihalogenation of BBR gave rise to a compound with the highest binding affinity, while the 
product from the dehalogenation of benzarone had an affinity half of the parent compound, 
BBR towards EYA 3. Similar effects were observed with related compounds such as 
dimethylbenzarone a compound without halogen substituent but has 1-C alkyl side chain at 
position 2; and the mono-iodinated and di-iodinated derivatives of benzarone, respectively 
(Pandey et al., 2013; Tadjuidje et al., 2012). Also, removal of the two bromine atoms or 
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increasing the length of the aliphatic chain on the benzofuran did not significantly affect the 
inhibitory effects of these compounds. The compounds that lacked the benzofuran or the 
phenol group had the least inhibitory effect suggesting that both moieties are required for 
potent EYA inhibition (Tadjuidje et al., 2012). A synthetic hydroxylated BBR metabolite, 6-
OHBBR had similar in vitro EYA3 inhibitory activity to that of benzarone and an IC50 more 
than twice that of BBR. On the contrary, the 5OH-BBR and the 1’OH-BBR were reported to 
be less effective in the inhibition of EYA3 (Pandey et al., 2013).             
 
5.1.4 Plausible role of EYA1 in apoptosis  
DNA damage occurs in living cells as a result of interaction with different ‘genotoxins’, and 
following this, the decision to either commence DNA damage repair or apoptotic process is 
crucial. It has been reported that γ-H2AX is involved in the adjudication of the balance 
between these two outcomes, and phosphorylation of tyrosine 142 modulates the induction 
of functional apoptotic or repair complexes (Cook et al., 2009). 
 A vital function of H2AX S139 phosphorylation is to provide a docking site for DNA repair 
factors (such as mediator of DNA damage checkpoint protein 1, MDC1) near or at DNA 
double- strand breaks (Rogakou et al., 1999). A group has demonstrated that MDC1 binds 
directly to phosphorylated S139 of H2AX at the sites of double strand breaks; however, 
following Y142 phosphorylation, binding of repair factors to phosphorylated serine 139 
mediated by MDC1 is inhibited while recruitment of pro-apoptotic factors especially JNK1 is 
activated (Stucki et al., 2005). 
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JNK1 is a stress-response kinase, which when activated by DNA damage, initiates a pro-
apoptotic cascade of events: it translocates into the nucleus and phosphorylates substrates 
such as H2AX S139, an event believed to be critical for DNA degradation mediated by 
caspase activated DNA (CAD) in the apoptotic cells (Lu et al, 2006). In confirmation of the 
above, Cook and his colleagues demonstrated a robust interaction between transfected wild 
type H2AX and endogenous JNK1 in 293T cells in response to high dose radiation, an 
interaction noted to be markedly reduced in the case of the H2AX Y142F variant/mutant 
(Cook et al., 2009).  Loss of EYA3 is reported to result in complete loss of MDC1-H2AX 
interaction. Thus following EYA3 knock down using siRNA, and testing for MDC1-H2AX 
interaction by co-immunoprecipitation, there was complete loss of this interaction (Cook et 
al, 2009).    
There is evidence to suggest that in response to DNA damage, EYA is recruited to H2AX foci 
that mark double-strand breaks (figure 4.4), as chromatin immunoprecipitation analysis 
after 4-hydroxytamoxifen (4-OHT) induction of I-Ppol in 293T cells revealed that γH2AX and 
EYA3 were present, suggesting a direct role for EYA in the cellular response to genotoxic 
stress.  
Three groups have independently identified EYA as a potential substrate for the DNA 
damage response kinases ATM/ATR, as inhibition of ATM/ATR function blocked the 
interaction between EYA1 or EYA3 and H2AX in response to ionizing radiation, noting that 
H2AX is an EYA tyrosine phosphatase substrate. This is supported by the fact that EYA has 
the ability to directly dephosphorylate H2AX phosphorylated on Y142 (Lavin & Kozlov, 2007; 
Matsuoka et al., 2007; Stokes et al., 2007).    
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Because EYA1 is involved in the cell’s decision to either proceed to apoptosis or DNA repair, 
loss of function involving this gene may modulate this decision-making process. The aim of 
this chapter was to investigate the mechanisms at play in aspirin-related gastric cell death 
and validate the possible role of the EYA1 protein in aspirin-induced apoptosis in gastric 
epithelial cells (AGS) by functionally ascertaining the effects of EYA chemical inhibition in 
this process. 
 
5.2 Methods 
5.2.1 Experimental techniques 
 
5.2.1.1 Cell seeding and dosing 
AGS cell line was cultured as described in section 4.2.4.1. At 90% confluence, cells were 
tryptinized and cell count done as described in the same section.  5,000; 7,500; 10,000; 
15,000; 20,000 and 30,000 cells in 50µl of complete media per each well in a 96-well plate 
were seeded in triplicate, and incubated for 6 hours to recover from handling. These were 
then grown for 12 hours and MTT assay performed to determine optimal cell density 
(15,000cells/well) for all future experiments.  
For all aspirin treatments, unless otherwise stated, 0, 0.2, 1, 2, 10, 20, 50, and 100mM of 
aspirin was dissolved in 0.7% DMSO and cells were treated for 30 minutes, 3 hours and 12 
hours duration. Likewise, benzbromarone doses of 0, 0.4, 1, 4, 10, 40, 100, 200, 300, 350, 
and 400µM suspended in 0.1% DMSO were used in the treatment of AGS cells for similar 
durations as the aspirin treatment. 
Chapter 5 
 
164 
 
5.2.1.2 MTT assay 
The compound (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT), is 
readily taken up and reduced, in part by the action of dehydrogenase enzymes in 
metabolically active cells, to generate reducing equivalents such as NADH and NAPDH. The 
resulting intracellular precipitate, formazan salts can be solubilized and quantified by 
spectrophotometry (Berridge et al., 2005). 
To determine the viability of AGS cells at each cell density, or following drug dosing, the 
MTT assay was performed. The reagents required in this experiment were 5M tetrazolyl 
blue tetrazolinium (MTT) solution, HBSS, 50% v/v dimethylformamide and 20% w/v sodium 
dodecyl sulphate. 5 M MTT solution was prepared by dissolving 5mg of tetrazolyl blue 
tetrazolinium in 1ml of HBSS; all chemicals and reagents were obtained from Sigma Aldrich.  
Lysis buffer was prepared by adding 30mls of distilled water to 50mls of 50% v/v 
Dimethylformamide. 20g of 20% w/v sodium dodecyl sulphate (SDS) was added to the 
above solution and the bottle was given a gentle shake to dissolve. 20mls of distilled water 
was then added to the solution and to ensure that the SDS is completely dissolved, the 
solution was warmed in a water bath at 370C for 1 hour.  
The media was removed carefully by aspiration, and 20µl of freshly prepared MTT solution 
added to each well containing AGS cells, adding also to empty wells, as negative controls 
and incubated for 3 hours, before 100 µl of lysis buffer was added to each well and the plate 
covered and incubated overnight. The plate was then shaken for 15 minutes and the 
absorbance read on a Beckman Coulter DTS 880 plate reader at 595nm using Apex software, 
version 1.0.0.14. 
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5.2.1.3 Caspase Glo assay 
Caspase 3 and 7 are members of the cysteine aspartic acid-specific protease (caspase) family 
of effector proteins that play key roles in apoptosis in mammalian cells. The activity of these 
proteases can be measured by a homogenous luminescent assay, the caspase-Glo® 3/7 
assay. This assay, optimized for caspase activity, luciferase activity and cell lysis contains the 
tetrapeptide sequence DEVD that provides the luminogenic caspase 3/7 substrate. Cleavage 
of the substrate produces a “glow type” luminescent signal, following the consumption of 
aminoluciferin by luciferase, which is proportional to the amount of caspase activity 
detected on a plate reader (Promega Corporation). To perform this assay, cells were treated 
as described in section 5.2.1.1. At the end of the treatment period, equal volume of caspase 
glo 3/7 assay was added to each well and the luminescence determined using Beckman 
Coulter DTS 880 plate reader after 30 minutes.  
For all caspase glo 3/7 experiments, 2 sets of the experiments were set up, with one set 
treated with 20µM of Zvad and the other set not treated with Zvad. Three independent 
experiments were performed. 
 
5.2.2 Characterization of the viability of AGS cells in different acid pH range 
In a bid to mimic the internal milieu of the stomach (pH 1.5-3.5), we tried to ascertain the 
effect of growing the AGS cells under low pH as is found in the stomach. The pH of complete 
media was measured using a pH meter under sterile conditions and this was determined to 
be 8.3. The pH of the culture media was then reduced to 3.0, 4, 4.5, 5, 5.5, 6, 6.5 and 7 by 
titrating different volumes of concentrated hydrochloric acid in 10ml of complete media. 
The pH was then confirmed again using the pH meter.  
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15,000 cells in 50µl of media at different pH range were seeded per well in triplicate and 
cultured for 3 and 12 hours. At the end of the treatment time, MTT assay was performed as 
in section 5.2.1.2, and the absorbance determined in the plate reader. This experiment was 
performed in three replicates. 
 
5.2.3 Characterisation of aspirin-induced AGS cell death mechanisms 
To determine the dose of aspirin required for this experiment, we calculated the 
concentration of aspirin in the gastric juice for a typical low dose aspirin user (75-300mg). 
The volume of gastric juice in the stomach at each point in time is between 20-100mls 
(Steingoetter et al., 2015). Hence we used this range as the volume of gastric juice in order 
to determine the concentration of aspirin. The calculations are as follows: 
Volume of gastric juice in the stomach = 20-100mls 
Concentration=
𝑛𝑜.𝑜𝑓 𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑠𝑜𝑙𝑢𝑡𝑒(𝑛)
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑖𝑛 𝐿𝑖𝑡𝑟𝑒𝑠  = 
𝑛
𝑣
 
Molecular weight of Aspirin = 180 g/mol (C9H8O4 )   
75mg of Aspirin =0.075 g 
No. of moles in 0.075g of aspirin = 
𝑤𝑒𝑖𝑔ℎ𝑡
𝑀𝑜𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 =  
0.075
180
 = 4.166 x10−4 M = 0.416 mM 
For 20mls gastric juice, C = 
0.416
0.02𝑙  
 = 21mM/L 
For 100mls gastric juice, C = 
0.416
0.1
  = 4.2 mM/L 
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For 300mg of aspirin: 
Number of moles= 
𝑤𝑒𝑖𝑔ℎ𝑡
𝑀𝑜𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 = 
0.3
180
 =1.66 x 10-3 = 1.66mM 
Hence, for 20mls (0.02l) of gastric juice, aspirin concentration = 
1.66
0.02
 = 83mM/L 
Assuming gastric juice volume of 100mls (0.1L), the concentration of aspirin= 
1.6
0.1
 = 16.7mM/L 
All serial dilutions of drugs were confirmed using Molarity graph pad. This informed the 
choice of aspirin concentration between 0.2mM-100mM in testing its effects on cell 
viability. Prior to the viability assay, we determined the pH of complete media-containing 
aspirin at each aspirin concentration used in the experiments (see table 5.2). 
 
Table 5.2: Aspirin concentrations used in the viability assays and their respective pH  
Aspirin concentrations (mM) in media pH of media at each aspirin concentration 
0 8.30 
0.2 8.20 
1 8.20 
2 8.08 
10 7.79 
20 7.37 
50 6.40 
100 3.98 
 
Cell seeding and dosing are as described in section 5.2.1.1. A positive control (1µM 
Staurosporin) and 2 negative controls using 0.7% DMSO and cells in media (no drug) 
respectively, were also added to each experiment. MTT assay was then done as described in 
section 5.2.1.2.  
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To further elucidate the exact mechanism of cell death at play in this assay, caspase glo 3/7 
assay was setup as described in section 5.2.1.3; however, another experiment was setup in 
which prior to treatment with aspirin, the AGS cells were pre-treated with 20µM of the 
caspase inhibitor, Zvad for 1 hour. Aspirin concentrations and duration of treatment are as 
described in section 5.2.1.1.  
 
5.2.4 Characterisation of benzbromarone toxicity in AGS cells 
Cell seeding and dosing are as described in section 5.2.1.1.  Staurosporine (1µM) was used 
as a positive control. These drugs were dissolved in DMSO and added to complete media at 
a final DMSO concentration of 0.1%.  Two negative controls that include cells in complete 
media only and cells in 0.1% DMSO without benzbromarone were also added. These were 
left to incubate for 30 minutes, 3 hours and 12 hours.  
At the end of the treatment period, MTT assay was performed as described in section 
5.2.1.1 to determine viability of the AGS at the these concentrations and treatment 
duration. Furthermore, to perform caspase glo 3/7 assay, benzbromarone was serially 
diluted to make x2 concentrations of the concentrations stated in section 5.2.1.2 and 50µl 
of the benzbromarone-containing media was added to AGS cells in 50 µl of media to give a 
final volume of 100 µl and a final concentration of 1, 4, 10, 40, 100, 200, 300, 350, and 
400µM benzbromarone. Controls were added as above.  
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5.2.5 Assessment of benzbromarone modulation of aspirin-induced cell death. 
To determine the effect of pre-treatment of AGS cells with benzbromarone prior to aspirin 
exposure, AGS cells were treated with 1, 2.5 and 5µM respectively of benzbromarone for 3 
hours. Aspirin concentrations, treatment duration and controls in section 5.2.1.1 were used 
for this experiment and 3 independent experiments were performed. MTT assay was then 
performed at the end of each treatment period as described in section 5.2.1.2.    
For the caspase glo 3/7 assay, aspirin concentrations, treatment duration and controls are 
as described in section 5.2.1.1. A second control was setup on the same plate but here, prior 
to treatment with aspirin, AGS was then exposed to Zvad for 1 hour after treatment with 
benzbromarone. Caspase Glo 3/7 assay was then performed as described in section 5.2.4 
and luminescence taken on a plate reader. 
 
5.2.6 Validating the aspirin-related cell death with PARP-cleavage using Western Blot 
100,000 cells were seeded into each well in a 6-well plate in 1.5mls of complete media and 
left to grow. At 70% confluence, the cells were then treated with 10, 20 and 50mM 
concentrations of aspirin, adding 1µM staurosporine as positive control, in fresh media, for 
12 hours. The negative control, 0.7% DMSO without aspirin was added. Cells that did not 
detach were scraped and centrifuged to form pellets. The pellets were then frozen at -80o C 
if to be used at a later date and protein lysates prepared from the pellets as described in 
section 4.2.5.1. Bradford and Western blot assays were then performed as described in 
section 4.2.5.2 and 4.2.5.3 respectively. 
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The primary and secondary antibodies were cleaved PARP (Asp214) rabbit mouse antibody 
(product number 5625) and anti-rabbit IgG, HRP-linked Antibody (product number 7074), 
respectively, while GAPDH was used as loading control and all were obtained from Cell 
Signalling Technology (CST), USA. The primary antibody detects endogenous levels of the 
large fragment (89kDa) of human PARP-1 protein produced by caspase cleavage, and does 
not recognise full length PARP-1 or other PARP isoforms (Cell Signalling Technology). 
5.2.7 Statistical analysis 
The MTT absorbance data was presented as a percentage of the negative control (0mM) 
and the mean ± SE for 3 replicate experiments was calculated. A one-way analysis of 
variance (1-way ANOVA) or the 2-way ANOVA (applying the Bonferroni post-tests analysis to 
compare means where applicable) was computed using the Prism Graphpad Software. 
Further test of significance of means was carried out using the Tukey’s multiple comparison 
tests.  
The data on the caspase activity were presented as the luminescence (RLU), and as above, 
the mean ± SE of 3 replicate experiments was calculated. Also the Tukey’s multiple 
comparison tests was applied to determine if there are any difference in the observed 
means of the control and among the treatment group. All data were rounded off to one 
decimal place. 
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Results 
5.3.1 Optimal cell density 
We performed a pilot assay to determine the optimal density of AGS cells required for the 
viability experiments by seeding different numbers of AGS cells in triplicate in 96-well plates 
and incubated them for 12 hours. The mean absorbance for each cell density was 
determined and the cell density plotted against the absorbance.  
The cell density with the highest absorbance (15,000cells/well) was taken to be the 
optimum cell density for further experiments. Cell viability declined at higher cell densities 
(figure 5.1). 
 
 
Figure 5.1: Optimal cell density for 96-well plate via MTT assay. There is steady increase in 
absorbance until 15,000cells/well after which the absorbance begins to drop at 20,000 
cells/well (*Optimum cell density).    
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5.3.2 Effect of pH on the viability of AGS cells cultured in different acid pH ranges 
The physiologic pH of the stomach has been determined to be in the range of 1.5-3.5 (Ivey, 
1986).  To mimic the pH of the stomach in the media in which the AGS cells were cultured, 
we determined the volume of concentrated/sterile hydrochloric acid required to bring the 
pH of complete media to lower pH values. The MTT assay was used to assess viability 
following a-12 hour incubation at different pH values as shown in figure 5.2.  
We observed a significant (p<0.05) decrease in viability of AGS cells from pH 6.5 and lower, 
with about 50% reduction in viability at pH 3.0. As a result of the finding of significant cell 
death with lower pH values, and bearing in mind that the aspirin solution is acidic (table 
5.1), we decided to perform the viability assays at the pH (8.3) of complete media.  
                 
Figure 5.2: Decline in viability of AGS with decrease in pH of media. There was significant 
(p˂0.05, * indicates significant difference) decline in AGS cells viability as pH of the media 
falls, with a hallmark decline in viability of 50% at pH 3.0. We observed no significant 
(p>0.05) difference in viability at pH 7.0 and 8.3.  
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5.3.3 Aspirin-induced AGS cell death  
Following 30 minutes of incubation of AGS cell with aspirin, we noted a dose-dependent 
decline in the viability of AGS cells as determined by the MTT assay. The decrease in the cell 
viability was statistically significant (p<0.05) at aspirin concentrations above 2mM; at 
100mM, the viability of AGS exposed to aspirin dropped to about 6%. We also observed that 
for the 30 minute incubation, 1µM of the standard apoptosis inducer, staurosporine, caused 
a reduction in the viability of AGS cell comparable to the effect of 10mM and 20mM aspirin 
concentration (p>0.05), while observing a more marked effect at 50 and 100mM aspirin 
concentration.  
Table 5.3 presents the cell viability data and the statistical analysis, while figure 5.3 is a 
graphical representation of the aspirin-related dose dependent decrease in AGS cell 
viability.  
Contrary to the observed significant decline in cell viability starting at 2mM for the 30 
minute incubation period, following the treatment of AGS cells with aspirin for 3 hours, we 
noted a significant (p<0.05) reduction in cell viability from 1mM aspirin concentration in a 
dose dependent manner.  We also observed a time-dependent decline in the viability of AGS 
cells treated with 1µM staurosporine, when comparing the 30 minutes or 3 hours’ time 
points with the 12 hours’ time point.  
However, aspirin-treated AGS cells did not show significant (p>0.05) time dependent decline 
in cell viability, but rather a concentration-dependent effect (table 5.3). The finding of dose 
dependent decline in AGS cell viability supports previous reports of an increased percentage 
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of apoptotic cells when AGS cells were treated with increasing concentration of aspirin up to 
50mM for 24 hours (Power et al., 2004). 
 
Table 5.3: Comparing the effect of duration of aspirin exposure (time) on viability of AGS 
cells  
 
 
There was no significant difference in the time-dependent effect of aspirin on the viability of 
AGS cells treated with aspirin. Tukey’s comparison test was done, comparing 30 minutes 
and 3 hours; 30 minutes and 12 hours and 3 hours vs 12 hours. There was no significant 
difference between all aspirin doses and time duration while for staurosporine, there was 
significant difference (p<0.05) between (shown as *** in the table) 30 minutes and 12 hours 
incubation period, respectively. SE= standard error; Hrs=hours; min=minutes. 
       Aspirin treatment for 30 minutes, 3 and 12 hours 
Concentration 
Viability (%) of treated cells 
3O min ± SE 3 Hrs ± SE 12Hrs ± SE 
0mM 100±0 100.0±0.0 100.0±0.0 
0.2mM 94.1±4.5 95.2±0.8 96.3±2.6 
1mM 92.1±3.0 90.7±3.6 91.2±5.9 
2mM 86.7±5.5 86.3±4.2 88.9±3.6 
10mM 74.9±4.3 71.6±1.5 68.6±0.7 
20mM 72.3±3.1 58.8±4.4 60.2±1.7 
50mM 54.4±2.7 35.4±3.1 24.8±4.0 
100mM 6.0±.4 5.1±1.3 5.6±0.2 
Staurosporine (1µM) 79.3±3.2*** 60.5±0.7 29.8±2.5*** 
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Figure 5.3: Shows the bar chart representing the dose-dependent decrease in the viability of 
cells treated with aspirin for 12 hours. STP = staurosporine (1µM), used as positive control 
and 0µM concentration is the negative control. There is no significant effect of longer 
duration of treatment except for the staurosporine treated-cells that shows a significant 
(p<0.05) difference between the 30 minutes and the 12 hour time points. The effect of 
aspirin on the viability of AGS cells is concentration dependent but not time dependent, 
even at the maximum concentration of 100mM. *indicates statistically significant reduction 
in cell viability (while +indicates no significant difference) at these doses compared to the 
negative control (0µM). Black solid= 30mintes; grey solid bar= 3 hours; oblique bar= 12 
hours. 
 
To further characterize the cell death pathway for aspirin-induced cell death, we 
determined caspase 3 and 7 activities of aspirin-treated cells after 30 minutes, 3 hours and 
12 hours. For all treatment durations, we observed a dose-dependent decrease in the 
caspase activity of AGS cells. For the 30 minute incubation, the highest caspase activity for 
aspirin treated cells was observed at 0.2mM aspirin concentration.  
There was also a significant (p ˂0.05) decrease in the caspase activity of cells that were pre-
treated with ZVAD prior to aspirin treatment compared to cells that were not pre-treated 
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with aspirin. At the 12 hour time point, the positive controls (staurosporine-treated cells) 
had a remarkable increase in caspase activity, in excess of 40000 RLU. Similar to  the earlier 
observed time-dependent decrease in the viability of staurosporine treated cells, we 
observed a time-dependent increase in the activities of caspase 3 and 7 confirming that 
staurosporine-induced cell death is time-dependent (Boulares et al., 1999).  Additionally, 
aspirin-related cell death is not wholly caspase dependent. These data are presented in 
figure 5.4.  
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Figure 5.4: Summary data of caspase activity for all incubation periods. The longer the duration of aspirin treatment, the higher the caspase 3 
and 7 activities in the groups that was not pre-treated with the caspase inhibitor, Zvad, while there was significant decrease (p<0.05) in the 
caspase activity of the controls pre-treated with Zvad compared to non-Zvad-treated cells. STP= Staurosporine, as positive control. Bars from 
left to right are aspirin only for 12 hours (*), aspirin and Zvad for 12 hours (*), aspirin only 3 hours (>), aspirin with Zvad for 3 hours (>), aspirin 
only 30 minutes (#) and aspirin with Zvad 30 minutes(#) assays.  
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5.3.4 Effect of caspase inhibition on the viability of AGS cells treated with aspirin 
To further explore mechanisms underlying the aspirin-related cell death in AGS cells, we 
pre-treated AGS cells with the universal caspase inhibitor, ZVAD and compared the cell 
viability with ZVAD-untreated cells after 12 hours aspirin incubation.  
Contrary to the expected prevention of apoptosis following caspase inhibition, the results 
did not show any significant (p˃0.05) difference in caspase activity between both groups 
(figure 5.5). This suggests that caspase inhibition was unable to “rescue” the aspirin treated 
cells from apoptosis. This finding is corroborated by the report that inhibition of caspase 
was unable to inhibit cell death in AGS cells treated with 40mM of aspirin for 4 hours (Leung 
et al., 2009).  
 
Figure 5.5: There was no significant (p˃0.05) difference between the mean viability of AGS 
cells pre-treated with ZVAD compared to those that were not pre-treated with ZVAD prior 
to treatment with aspirin. Solid bar= aspirin only treatment for 12 hours; dotted bar= cells 
pre-treated with Zvad before aspirin exposure. 
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5.3.5 Characterisation of benzbromarone cell toxicity in AGS cells 
 
To determine the dose range of benzbromarone that would be appropriate for the pre-
treatment of AGS cells before treatment with aspirin without causing significant toxicity to 
the cells, we performed a MTT viability assay by incubating the cells with different 
concentrations of benzbromarone for 30 minutes, 3 and 12 hours.  
The results show a dose-dependent decrease in the viability of AGS cells from 0.4µM of 
benzbromarone; cell death became statistically significant (p<0.05; 95% CI 1.9-29.0) at 
higher concentrations (>4uM) (figure 5.6). Also the reduction in viability caused by 1 µM of 
staurosporine, a standard inducer of apoptosis (Boulares et al., 1999), was comparable 
(p>0.05; 95% CI -8.1-19.0) to the effect of 10 µM benzbromarone in the 30 minute 
incubation period.  
The viability data are presented in table 5.4 and graphically presented in figure 5.6. The 3 
and 12 hour incubation time experiments also showed similar trends in concentration-
dependent decrease in the viability of the AGS cells. Moreover, there was a statistically 
significant (p<0.05) time-dependent decrease in the viability of the cells from 200µM-
400µM when comparing 30minutes and 3 hours with the 12 hours’ time point ( table 5.4 
and figure 5.6).  
We further observed an increased ability of staurosporine to cause significant (p˂0.05) 
decrease in cell viability at 12 hours compared to 30 minutes and 3 hours.  This is suggested 
by the significant decrease (p<0.05) in cell viability associated with exposure to 
staurosporine (a reduction in cell viability from 71.4% and 66.6%) at 30 minutes and 3 hours 
respectively to 25.5% at the 12hour time point.  
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 Table 5.4: Effect of the duration of benzbromarone exposure on viability of AGS cells  
     Benzbromarone treatment for all time duration 
Concentration 
            Viability(%) of treated cells  
30mins ± SE 3Hrs ± SE 12Hrs ± SE 
0µM 100.0±0.0 100.0±0.0 100.0±0 
0.4µM 89.4±6.6 99.4±0.5 96.9±0.5 
1µM 90.4±7.0 98.9±3.0 97.1±1.1 
4µM 84.5±4.6 75.4±1.9 74.9±2.3 
10µM 76.8±10.2 70.7±6.2 68.9±2.7 
40µM 56.0±1.9 62.7±6.2 57.2±10.5 
100µM 57.1±1.9 57.8±2.7 51.2±5.0 
200µM 54.3±2.8 50.4±2.4 26.8±6.5** 
300µM 53.9±1.7 49.7±0.5 24.2±4.4** 
350µM 56.8±3.5 46.2±4.7 22.7±2.8** 
400µM 55.1±2.0 44.2±5.3 22.4±3.3** 
STP (1µM) 71.4±1.6 66.6±3.1 25.5±3.5** 
Decrease in the viability of cells with increasing benzbromarone concentration. From 200µM 
concentrations and higher, there was significant reduction (p<0.05) in viability at 12 hours 
treatment (**) compared to 30 minutes and 3 hours. Also, at 12hours, there was a 
significant decrease (p<0.05) in viability of AGS cell treated with 1µM of the positive control 
staurosporine. STP = staurosporine, used as positive control and 0µM concentration is the 
negative control which contains 0.1% of DMSO.
Chapter 5 
 
181 
 
           
          
Figure 5.6: Time-dependent decrease in the viability of cells treated with benzbromarone 
for all treatment durations. STP = staurosporine (1µM), used as positive control and 0µM 
concentration is the negative control which contains 0.1% of DMSO. From 200µM 
concentrations and higher, there was a significant reduction (p<0.05) in viability at 12 hours 
compared to 30 minutes and 3 hours. Also, at 12hours there was a significant decrease 
(p<0.05) in viability of AGS cell treated with 1µM of the positive control staurosporine. 
*indicates statistically significant reduction in cell viability (while +indicates no significant 
difference) at these doses compared to the negative control (0µM); solid bar= 
benzbromarone for 30 minutes, oblique line bar= benzbromarone 3 hours, dotted bar= 
benzbromarone 12 hours. 
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concentration of benzbromarone, there was a statistically significant difference (p<0.05) in 
the caspase 3/7 activities of the cells pre-treated with ZVAD compared with those not pre-
treated. These data are presented in figure 5.7.   
 
 
Figure 5.7: Graphical presentation of caspase activity in AGS cells treated with 
Benzbromarone with/without pre-treatment with ZVAD. There was a dose-dependent 
increase in caspase activity in the cells that were treated with benzbromarone, while there 
was significant difference (p<0.05) in the caspase activity of cells pre-treated with ZVAD and 
those not pre-treated. STP= Staurosporine as negative control; solid bar=benzbromarone 
without Zvad and oblique bar= benzbromarone with Zvad were all 12 hours assays. 
 
5.3.6 Modulating effect of EYA1 inhibitor, benzbromarone on aspirin-related AGS death.  
To determine the role of EYA1 inhibition on AGS cell death related to aspirin exposure, we 
pre-treated AGS cells with 1, 2.5 and 5 µM of benzbromarone for 3 hours prior to dosing the 
cells with aspirin for 12 hours. At all test doses, there was no significant (p>0.05) difference 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
C
as
p
as
e
 a
ct
iv
it
y 
(R
LU
) 
Concentration (µM) 
Chapter 5 
 
183 
 
in the viability of cells pre-treated with benzbromarone and the control. These are 
presented in in figures 5.8-5.10. 
 
Figure 5.8: Pre-treating the cells with 1µM benzbromarone for 3 hours prior to aspirin 
exposure for 12 hours did not cause a significant decrease in the viability of aspirin-treated 
AGS cells. Solid bar= aspirin only 12 hours assay; dotted bar= benzbromarone only 12 hours 
assay; STP= staurosporine as negative control. 
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Figure 5.9: Pre-treating the cells with 2.5µM benzbromarone for 3 hours prior to aspirin exposure for 3 and 12 hours respectively, did not 
reveal any significant (p>0.05) effect in the ability of benzbromarone to modulate aspirin-related toxicity in AGS cells. Bars from left to right are 
aspirin only for 12 hours, aspirin and 2.5µM benzbromarone for 12 hours, aspirin only 3 hours, aspirin with 2.5µM benzbromarone for 3 hours. 
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Figure 5.10: Pre-treating the cells with 5µM benzbromarone for 3 hours prior to aspirin exposure for 3 and 12 hours did not cause a significant 
decrease in the viability of aspirin-treated AGS cells, STP= staurosporine as positive control; bars from left to right are aspirin only for 12 hours, 
aspirin and 5µM benzbromarone for 12 hours, aspirin only 3 hours, aspirin with 5µM benzbromarone for 3 hours. 
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We then further explored the effect of EYA1 inhibition by benzbromarone on the caspase 
activity of AGS cells pre-treated with benzbromarone for 3 hours prior to aspirin exposure 
for 12 hours. The results of the experiments showed a decrease in caspase activity with 
increasing doses of aspirin but pre-treatment with benzbromarone did not alter this trend.  
However, this difference in caspase activity between ZVAD-treated cells and the untreated 
cells was lost at 50 and 100mM during the 12 hours treatment (Figure 5.11).  
 
 
Figure 5.11: Dose dependent-decrease in caspase activity with increasing dose of aspirin in 
AGS cells pre-treated with 5µM of Benzbromarone, to inhibit EYA1. Staurosporine treatment 
for 12 hours is associated with significant increase in caspase activity compared with the 
cells that were pre-treated with caspase inhibitor, ZVAD. The significant difference in the 
caspase activity between ZVAD-treated cells and the untreated cells is lost at 50 and 100mM 
during the 12 hours treatment. Solid bar= aspirin+5µM benzbromarone, no Zvad, 12 hours 
assay; narrow horizontal bars= aspirin+5µM benzbromarone with Zvad 12 hours assay. 
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5.3.7 Validating the cell death pathway of aspirin-related cell death in AGS by PARP-
cleavage using western blotting and cell morphology. 
The finding of reduced viability of AGS cells and the aspirin-related reduction in caspase 
activity suggests that the cell death may not be caspase dependent. Hence, to investigate 
the cell death pathways involved, we decided to probe for proteins which are markers of 
apoptosis. One such protein is poly (ADP) ribosyl polymerase (PARP), an 89kDa protein 
cleaved from the intact protein between ASP214 and GLY215 residue by caspase 3 following 
activation of apoptosis. This revealed that PARP cleavage in aspirin-induced apoptosis is 
dose-dependent: we did not detect cleaved PARP at 0mM and 50mM, but this was detected 
at 10mM and 20mM, the positive control, and the 1µM staurosporine (figure 5.12).  
This supports and also explains our earlier finding of higher caspase activity at lower doses 
of aspirin, than at 50mM and 100mM aspirin concentrations, suggesting that there is a role 
for caspase enzymes in aspirin-related cell death at lower doses but at higher doses, other 
modes of cell death that are non-caspase dependent come into play.  
Cell morphology is shown in figure 5.13 A-E: this shows features of necrosis at 50mM (figure 
5.13 D) and 100mM (figure 5.13 E) aspirin concentrations compared to lower aspirin 
concentration and the negative control (0mM). This is consistent with reports of various cell 
death mechanisms being involved in aspirin related-GI injury (Dikshit et al., 2006; Leung et 
al., 2009; Power et al., 2004). 
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Figure 5.12: Western blots showing the 89kDa cleaved PARP in the AGS cells treated with 
staurosporine and aspirin at 10 and 20 mM but not at 0 and 50mM. The intact PARP 
(116kDa) was not detected. The lower blot shows the loading control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) detected for all concentrations of aspirin. 
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Figure 5.13: Micrographs of AGS cells (x20) exposed to (a) 0mM; (b) 10mM; (b) 20mM; (d) 
50mM; and (e) 100mM aspirin. a) Viable cells with an intact plasma membrane and normal 
morphologic features; b and c) there are cells showing apoptotic morphology, with intact 
cell membrane and few necrotic cells (arrows); d and e) increasing presence of cells with 
evidence of cell swelling, loss of plasma membrane integrity and cellular disintegration, 
markers of necrosis. 
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5.4 Discussion 
We have examined the mechanism of cell death of AGS cells treated with aspirin and 
observed that the viability of AGS cells reduces in a dose-dependent manner irrespective of 
the duration of treatment with aspirin. The likely explanation for this is that passage of 
aspirin into the cells in an acidic pH is enhanced; therefore, aspirin achieves a high 
intracellular concentration rapidly, enough to cause increased membrane permeability and 
damage by luminal hydrogen ions (Schoen & Vender, 1989) even within 30 minutes of 
exposure.  
Similar to earlier reports that 2 tablets of aspirin dissolved in 100mls of water has a pH as 
low as 2.5 (Ivey, 1986), we note that 100mM of aspirin in complete culture media has a pH 
of 3.98, which brings the pH of the culture media to a level similar to the physiologic pH in 
the stomach, i.e. 2.5 (Schoen & Vender, 1989). Aspirin , as a weak acid has a pKa of 3.5 and 
exists in the non-ionized state in the acid environment of the stomach, but readily diffuses 
into the mucosal cells and in the intracellular pH of 7, is able to dissociate rapidly, leading to 
‘ion trapping’ in the relatively more water soluble ionized form (Schoen & Vender, 1989).  
The lack of the adaptive cytoprotection (Boku et al., 2001) as occurs in the in vitro cell model 
makes the cells more prone to direct injury from exposure to aspirin compared to the intact 
gastric epithelium. The roles of adaptive cytoprotection in preventing gastric epithelial 
damage have been discussed in chapter 1. 
Various modes of aspirin-related apoptotic cell death have been reported (Gu et al., 2005; 
Power et al., 2004; Redlak et al., 2005) with some studies suggesting a non-caspase 
dependent mechanism (Leung et al., 2009). Similar to the report of a non-caspase 
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dependent mechanism underlying aspirin-related cell death; we have observed a reduction 
in caspase 3 and 7 activities in the AGS cells treated with aspirin in a dose-dependent 
manner, in a fashion that correlates with the increasing proportion of morphologically 
necrotic cells with increasing aspirin concentration.  We found higher caspase activity in the 
negative control as well as at a lower aspirin concentration than in the highest aspirin 
concentration (100mM) used in our experiments suggesting that there are other 
mechanisms of cell death at play.  
A possible explanation is that aspirin has been observed to cause inhibition of caspase 
activation; pre-treatment of AGS cells with aspirin completely prevented caspase 3, 6 and 9 
activation following treatment with deoxycholate, an inducer of apoptosis in gastric 
epithelium (Redlak et al., 2008). Further to this, benzbromarone caused a dose dependent 
increase in caspase activity, which was lost when benzbromarone was co-incubated with 
aspirin.  
The significant difference in caspase activity of the ZVAD treated cells and the non ZVAD 
pre-treated cells that were exposed to aspirin suggests that there is still some level of 
caspase 3 and 7 activity, and this caspase inhibition by aspirin cannot be said to be complete 
in our model. This finding is in agreement with reports that caspases are activated in 
virtually all forms of programmed cell death, and the process of caspase activation is not the 
sole determinant of life and death decisions in programmed cell death (Belmokhtar et al., 
2001).  
Furthermore, inhibition of caspase activity with zVAD did not show any difference in the 
viability of AGS cells treated with aspirin for 12 hours in both the zVAD pre-treated cells and 
the non-pre-treated cells. This implies that caspase inhibition may not always ‘rescue’ AGS 
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cells exposed to DNA double strand breaking stimuli, such as aspirin toxicity, from cell 
death. This observation corroborates reports that caspase inhibition does not necessarily 
prevent cell death, neither does its activation necessarily cause cell death (Perfettini & 
Kroemer, 2003); rather , caspase inhibition only shifts cells to a non-caspase dependent  
self-destructive mode of cell death via the mitochondrial pathway (Leung et al., 2009).  
Various postulates behind the inability of caspase inhibition to confer complete protection 
against cellular injury include an unidentified inhibitor, such as zVAD, though able to block 
most caspases, may not be able to effectively neutralize all caspases (Lavrik et al., 2005). 
Secondly, there may be an inherent difficulty in obtaining high enough fractional inhibition 
to confer complete protection (Leung et al., 2009). The above findings suggest that besides 
caspase activation, there could be other biological processes involved that would explain 
aspirin-related gastric cell death that is wholly or partly caspase independent and is unable 
to be prevented by caspase inhibition (Budihardjo et al., 1999; Leung et al., 2009).  
Moreover, mitochondrial toxicity following ion trapping leading to increased mitochondrial 
membrane permeability, which cannot be prevented by caspase inhibition, leads to release 
of mitochondrial proteins which are drivers of cell death pathways (Leung et al., 2009). 
Caspases are known to initiate the intracellular events that lead to apoptosis and one such 
event is the demolition of nuclear DNA via histone associated fragmentation (Nuñez et al., 
1998; Oberhammer et al., 1993).  
The apoptosis inducer staurosporine was relatively ineffective in causing reduction in cell 
viability at 30mins and 3 hours compared to 12 hours. At 30 minutes, 10µM of 
benzbromarone was equivalent to 1 µM of staurosporine in terms of its propensity to cause 
reduction in cell viability. To further buttress the above findings, the caspase 3 and 7 
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activities at 30 minutes and 3 hours were significantly (p˂0.05) lower than at 12 hours. This 
corroborates the finding of a significant reduction in cell viability associated with treatment 
with staurosporine at longer time intervals than at shorter time intervals (Boulares et al., 
1999). Hence unlike the aspirin-induced decline in AGS cell viability which is concentration-
dependent, we note a significant time-dependent effect of staurosporine. Staurosporine 
toxicity has been reported to be time-dependent based on the type of cell line tested. It was 
observed to show a delay of up to 12 hours in causing cell death in one subline of mouse 
lymphocytic cell line, whereas significant cell death was noted after 3 hours in another 
mouse lymphocytic subline, and this has been attributed to the intactness of the caspase 
activation pathway (Belmokhtar et al., 2001). 
Benzbromarone has been reported to cause inhibition of EYA in various experimental 
models. While exploring the plausible role of EYA1 in apoptosis induced by the treatment of 
AGS cells with aspirin, we pre-treated AGS cells with the EYA chemical inhibitor 
benzbromarone, with the expectation that the inhibition of EYA1 would cause an increased 
cell death. Though we observed some decline in the cell viability of AGS cells pre-treated 
with 1 µM of benzbromarone at aspirin concentrations of 1-20mM during a 30 minutes 
treatment, this reduction in cell viability was not statistically significant (p˃0.05). As we did 
not confirm inhibition of EYA by benzbromarone (Tadjuidje et al., 2012) in vitro, it becomes 
hard to tell whether this finding is truly the effect of EYA inhibition or due to the toxicity of 
the inhibitor. Of course, we also do not know whether benzbromarone has off-target 
effects. 
To further explore the exact cell death mechanism involved in the observed aspirin-induced 
cell death, we probed the cleavage of PARP. AGS cells were treated with 10, 20 and 50mM 
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of aspirin, and 1µM staurosporine, including a negative control for 12 hours. The cell lysate 
was probed for PARP cleavage. Cleaved PARP on western blot was noted for 1µM 
staurosporine, 10 and 20mM aspirin but there was no PARP cleavage at 0mM and 50mM 
aspirin. 
PARP, in the presence of NAD, catalyses the poly(ADP-ribosyl)ation of a number of nuclear 
proteins and its activation depends on binding to the ends of DNA strand breaks, with a 
possible depletion of cellular NAD and ATP (Berger, 1985; Berger & Petzold, 1985). Typically, 
in response to cell death, PARP is cleaved primarily by caspase 3 into two components; the 
85kDa and the 24kDa subunits that contains the active site and the DNA binding domain of 
the enzyme, respectively, during drug-induced apoptosis in a variety of cells (Kaufmann et 
al., 1993; Nicholson et al., 1995; Tewari et al., 1995). This cleavage occurring between 
Asp214 and Gly215, is thought to prevent the depletion of intracellular ATP and NAD, 
thereby rescuing the cell from cell death (Berger, 1985). This caspase 3 cleavage of PARP is 
very well conserved in the PARP protein even in very distant species, underpinning the 
essential role of PARP cleavage in apoptosis (Rhun et al., 1998; Tewari et al., 1995). 
The inability to demonstrate PARP cleavage, the very low caspase activity at 50mM aspirin 
concentration, the mixed morphotypes at 20mM (Northington et al., 2007) and the 
morphologic changes similar to that occurring during necrosis (figure 5.15, c and d) suggests 
that necrosis, rather than apoptosis is the cell death mechanism at play at higher aspirin 
concentrations. This is rather a local toxic effect associated with increased intracellular 
aspirin concentration and ion trapping leading to cell necrosis (Scheiman, 1996).  
Our study has demonstrated that physiologic concentrations of aspirin cause apoptosis in a 
dose-dependent manner and at the high end dose similar to that used in the management 
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of mild musculoskeletal disorders; necrosis rather than apoptosis comes into play. 
Moreover, there are various other processes involved in the aspirin related cell death with 
PARP activation being one such mechanism. 
The strengths of our study are that we have utilised validated screening methods in 
identifying the effect of aspirin on AGS cells and then went further to examine the exact cell 
death mechanism involved using specific cell death pathway assays. Secondly, we have used 
a validated in vitro gastric cell model in performing our experiments, as this will make 
translation of data from this study to clinical setting more acceptable (Hall et al., 2006).  
The limitation of the MTT assay is that similar to ATP based assays, a number of other 
factors can inhibit mitochondrial reductases, and hence the conversion of tetrazolium salts 
is not a conclusive evidence of cell proliferation. It is also very susceptible to metabolic 
interference and may lead to false positive results; hence, bona fide markers of cell death 
must be used. This was however improved on by the use of further cell death validation 
assays to confirm our findings. The second limitation of our study, as earlier noted, was that 
we did not confirm benzbromarone inhibition of EYA (Tadjuidje et al., 2012).  Thirdly, an EYA 
knockout experiment was not performed; this would have produced stronger evidence of 
loss of EYA function than chemical inhibition alone.  
In conclusion, we have been able to demonstrate that there are multiple mechanisms at 
play in the cell death pathway associated with use of aspirin. One such mechanism is PARP 
cleavage, but there is still a role for caspase-dependent apoptosis depending on the 
concentration of aspirin used.  Moreover, at very high concentrations there is a switch from 
an apoptotic cell death to necrosis. 
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Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used 
medications with an annual prescription of over 30 million for aspirin alone in England 
(National Health Service information centre, 2007).  Also availability of these medications 
over the counter makes them more easily accessible than most other medications. NSAIDs 
are commonly used in the elderly in whom concomitant use of other drugs could increase 
the gastrointestinal toxicity of NSAIDs.  
Gastrointestinal complications, related to NSAID use have been estimated to cause 3500 
hospital admissions and 400 deaths per annum in the UK in those aged over 60 years, while 
over 60% of deaths from ADRs involving 1225 patients were attributable to NSAIDs 
(Langman, 2001; Pirmohamed et al., 2004). As revealed in our analysis, most of the patients 
with NSAID-related ulcers are in the older age group (>65years) who also have other co-
morbidities and take concomitant medications that could significantly increase their risk of 
NSAID-related gastrointestinal complications. We know that age, co-morbidity and 
concomitant medications increase the risk of NSAID-related GI complication (Deighton et al., 
2009; Valkhoff et al., 2012).  
We did not show an association between the UGT1A6 SNP rs1105879 and development of 
NSAID-related ulceration (p=0.052, odds ratio 1.21, 95% CI 1.00, 1.47), although this just 
missed statistical significance. This observation of a trend toward an association could be 
the result of the confounding effect of H. pylori infection, because following sensitivity 
analysis excluding cases with evidence of H. pylori infection negated any signal of 
association. Furthermore, excluding non-aspirin NSAID users from the analysis did not 
change the finding of a lack of association between UGT1A6 SNP rs1105879 and NSAID-
induced GI complications.  Our finding is contrary to our expectation because a loss-of-
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function polymorphism in UGT1A6, an important enzyme in the phase II metabolism of 
aspirin would be expected to lead to high plasma concentration of salicylic acid and 
ultimately to increased aspirin-related GI toxicity (Carlini et al., 2005; García-Martín, 2008).  
Previous studies aimed at establishing an association between UGT1A6 SNP and NSAID-
induced GI complications have reported no association (Shiotani et al., 2008; Shiotani et al., 
2009; Van Oijen et al., 2005a; Van Oijen et al., 2009b).  
Because of the trend toward association we observed in our study, and the small sample 
sizes of the 2 other previous studies in this area, we conducted a meta-analysis including our 
data and the 2 previous studies that passed our inclusion criteria; again there was no 
association (P=0.31, OR= 1.11, 0.91, 0.36) between this loss-of-function polymorphism and 
aspirin/NSAID-induced gastrointestinal complications. It appears safe to conclude that in 
terms of polymorphisms of aspirin/NSAIDs metabolizing enzymes, polymorphisms of 
UGT1A6 are either not relevant genetic risk factors for the development of aspirin/NSAID-
related GI complications or the effect size is very small which would require much larger 
sample sizes to uncover.   
By contrast, polymorphisms in CYP2C, a cytochrome P450 enzyme involved in the 
metabolism of the acetylsalicylic acid and other NSAIDs led to a statistically significant 
association between this polymorphism and NSAID-related GI complications (Carbonell et 
al., 2010; Figueiras et al., 2016). Polymorphic expression of UGT1A6 gene in the human 
gastric epithelium has been reported (Strassburg et al., 1998) and this could explain the 
isolated finding of an association between this SNP and duodenal ulcers (p=0.002) and a lack 
of association between gastric ulcers (p=0.302) and UGT1A6 SNP. However, a sensitivity 
analysis excluding H.pylori infected cases resulted in the loss of this association between 
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duodenal ulcers and UGT1A6 rs1105879 SNP. A limitation of this work is the small sample 
size. Also, because of a dearth of publications on this subject, we added studies conducted 
in non-Caucasian populations in our meta-analysis and this could introduce some variability 
in our study cohorts. 
We have examined the role of a functional promoter polymorphism (rs1799889) of 
Plasminogen activator inhibitor gene (PAI-1) in NSAIDs-related gastrointestinal toxicity. 
There are reports of increased fibrinolytic activity in patients with bleeding peptic ulcers, 
which is partially decreased by increased plasma PAI-1 levels and by acid suppression 
(Vreeburg et al., 2001).  
PAI-1 is believed to play a role in the protection of the gastric mucosa; there is increased 
expression of the plasminogen activator and increased fibrinolytic activity of tPA from 
biopsy specimens of peptic ulcer lesions with associated significantly elevated PAI-1 levels in 
the plasma of gastric ulcer patients with active ulcers compared to patients with inactive 
ulcers  (Kurose et al., 1990). Also,  it has been reported that in the presence of irritants of 
the gastric mucosa such as aspirin/NSAIDs and H. pylori infection, there is increased 
expression of PAI-1 mRNA, PAI-1, uPA and uPAR with associated inhibition of gastric 
epithelial proliferation (Kenny et al., 2008; Kenny et al., 2013a). 
Therefore, one would speculate that polymorphisms of PAI-1 rs1799889 SNP could be 
associated with an increased risk of NSAID-induced GI complications. Contrary to this, we 
could not find any association between PAI-1 5G/4G polymorphism and NSAID-related GI 
complications, despite a significantly higher frequency of the variant 4G allele, the 
occurrence of which did not differ between the case and control groups. Previous reports 
have associated the variant 4G/4G allele with higher plasma PAI-1 levels (Festa et al., 2003; 
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Lijnen & Collen, 1995a), and this higher plasma PAI-1 levels we speculated could 
compensate for the reduced activity of PAI-1, a phenomenon that could explain the lack of 
association between this SNP and NSAID-induced GI complications. NSAIDs and PPI cause 
increased PAI-1 expression in humans (Kenny et al., 2013a; Nørsett et al., 2011); as these 
medications were used by our cohorts it could have confounding effect on the interaction 
between this SNP and the ulcer status and may likely explain the observed lack of 
association. 
This speculation is validated by the observation that introducing the non-use of NSAIDs as 
an interaction term in our analysis showed some association (p=0.099), though not 
statistically significant. Furthermore, available evidence supports an interference of H. pylori 
with the activity of PAI-1 and this is thought to modulate the role of PAI-1 in gastric mucosal 
protection (Kenny et al., 2008). Finally, the entire cohort was not genotyped because of lack 
of DNA samples and this could also be a possible reason for the observed lack of association.  
Following the identification of EYA1 as the “top hit” in the NSAIDs GWAS study, we 
examined the role of a functional polymorphism of EYA1 in the pathogenesis of NSAID-
related GI complications. We reported a significant association between binary ulcer status 
and EYA1 SNP in a case-control analysis of patients with evidence of NSAID use. This finding 
is novel and very significant in that it has validated the report of the GWAS on NSAID-related 
GI complications. However, when the case cohort was expanded to include patients without 
evidence of use of NSAIDs, the significant association we detected earlier was negated. We 
speculate that the loss of association was likely due to a confounding effect of the inclusion 
of patients without any evidence of NSAID use in the case.  
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To further explore the functional consequence of this SNP association, we utilised an in vitro 
model using an immortalised gastric adenocarcinoma cell line (AGS). Here, we initially 
sought to determine whether aspirin exposure was associated with increased AGS cell 
death, and found that exposure of AGS cells to aspirin was associated with significant cell 
death (p<0.05) at concentrations <2mM. Also to model a loss of function EYA1 
polymorphism, we pre-treated AGS cells with an EYA1 chemical inhibitor prior to treatment 
with various concentrations of aspirin, this data was not statistically significant (see section 
5.3.6).  
Furthermore, we also examined the difference, if any, in EYA1 gene expression based on 
genotype in healthy human gastric biopsy samples. The mean EYA1 gene expression among 
carriers of the wild type allele (AA) was not different from those carrying the variant allele 
(AT/TT).  This data contrasts with the findings of EYA1 RNA sequencing data and the 
rs12678747 genotype in gut biopsy tissue from ulcer and antrum tissue in NSAIDs ulcer 
patients (Carr et. al., 2011-unpublished data). This may suggest that the SNP shows 
functional effects in relation to diseased tissues rather than normal tissue.  We of course do 
not know whether the SNP is truly the causal variant, or whether it is in linkage 
disequilibrium with another functional variant. 
We also noted a significant association between NSAIDs ulcers in the presence of H. pylori 
infection, and EYA1 SNP with/without covariates. H. pylori is associated with changes in the 
expression of the serine/threonine tyrosine kinases and transcription factors (Backert et al., 
2005; Backert & Selbach, 2005) and this could possibly explain the effects we have seen in 
the presence of H. pylori infection.  It would be worthwhile to examine the exact modulating 
role of this infection on the expression of EYA1 gene. This is important because 54.4% and 
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14.9% of the cases and controls respectively were positive for H. pylori infection.  We have 
earlier highlighted the interaction of H. pylori with NSAID use, serine/threonine tyrosine 
kinases and transcription factors, including the modulating role of this infection on the 
effect of PAI-1 on gastric epithelial protection and proliferation. These multi-level 
interactions of H.pylori with both genetic and non-genetic factors in our study would have 
significant confounding effect on our data.   
Another intriguing finding from our data was that in the gene expression assay, we observed 
that the expression of the endogenous control gene, β-actin, was significantly higher 
(p<0.05) than the expression of the EYA1 in AGS cells; however, at the protein level we 
noted that the expression of EYA1 and β-actin was almost equivalent (0.75). Thus, despite a 
low expression of the gene, the protein expression is significantly up-regulated but the 
mechanisms of this are unclear. Different mechanistic hypotheses of aspirin-related GI 
injury have been presented and current evidence suggest that the systemic effect of aspirin 
may be more dominant in the pathogenesis of NSAID-induced GI complications (Sostres et 
al., 2010); however we note that the topical/direct effect of aspirin may be more significant 
in the development of aspirin-related GI complications than is currently known.  
Firstly, we reported that polymorphism of aspirin metabolizing enzyme, UGT1A6 is not 
relevant to the development of these complications. Secondly, from our data, 100mM of 
aspirin in complete media has a pH of 3.98, and AGS cells cultured in complete media 
(normal pH 8.3) in which the pH has been adjusted to 4 using HCL, had a reduction in the 
viability of the cells by over 40%, even without aspirin exposure. This finding supports our 
observation that 300mg of aspirin (commonly given for acute coronary syndrome), in the 
physiologic state, achieves an intra-gastric concentration of about 83mM (based on our 
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estimates), and If extrapolated from our cell models, this could cause about 30-40% 
reduction in the viability of the cells. Therefore, we speculate that the direct effect of aspirin 
on gastric epithelial cells viability may be more significant and more relevant than is 
currently thought.   
Previous studies have reported various mechanisms of aspirin-induced cell death (Leung et 
al., 2009; Power et al., 2004; Redlak et al., 2005; Redlak et al., 2007; Redlak et al., 2008); this 
is consistent with our finding that there were multiple modes of aspirin-induced cell death 
ongoing concurrently in the cell model depending on the concentration of aspirin used in 
treating the cells. Specifically, contrary to previous observations of a caspase 9 dependent 
cell death mechanism (Power et al., 2004; Redlak et al., 2005), we found a significant dose 
dependent decrease in the caspase 3 and 7 activity of the cells despite a significant fall in 
the viability of the cells compared to the controls, suggesting that there is a role for non-
caspase dependent mechanisms in the cell death. Furthermore, caspase inhibition with the 
universal caspase inhibitor ZVAD did not “rescue” the AGS cells from aspirin-related 
decrease in cell viability, supporting our speculation that aspirin-related cell death may not 
be wholly caspase dependent.  
To further validate the cell-death mechanism involved in this assay, we probed for PARP, a 
marker for apoptosis and found that the 89kDa protein was cleaved in the aspirin-treated 
cells in a dose-dependent manner, with PARP cleavage occurring in the positive control 
(1µM staurosporine), 10 and 20mM aspirin but not at 0 and 50mM of aspirin. This suggests 
that at lower doses of aspirin, apoptotic cell death occurs while at high doses of aspirin, 
non-apoptotic cell death occurs. This is necrotic cell death as revealed by morphologic 
features in AGS cells treated with high doses of aspirin (see figure 5.13). These confirmed 
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our earlier speculation that there is multiple cell-death mechanisms involved in aspirin-
related AGS cell death.  Furthermore, our data also confirms that though apoptosis may be 
occurring, the exact apoptotic mechanism may be non-caspase 3/7 dependent.   
We have looked at the study from clinical, molecular and functional points of view. Our 
study has reported several novel findings and validated some previous reports. For instance, 
we have been able to validate the NSAIDs GWAS report in which EYA1 was the candidate 
gene implicated in the NSAID-related gastrointestinal toxicity. Our pharmacogenomic study 
was conducted using a larger sample size; sensitive study design and data analysis structure 
that should detect any association between these polymorphisms and NSAID-related GI 
complications. For instance our work on the role of polymorphism in UGT1A6 and NSAID-
related gastrointestinal complications used a sample size 4-7 folds larger than the sample 
size of similar studies published previously.   
In conclusion, as is the case with most complex diseases, the pharmacogenetics of NSAID-
related gastrointestinal complications is difficult to elucidate fully because not only are the 
phenotypes complex but there are multiple factors involved including environmental, life 
style, co-morbid diseases and other patient-specific factors.  Further work is needed in this 
area so that we fully understand the mechanisms and develop predictive and preventive 
strategies to prevent NSAID-induced gastric ulceration.  This is important as current 
preventative strategies, for example use of proton pump inhibitors is not fully successful, 
and these drugs are associated with serious adverse reactions.  It is likely that aspirin and 
other NSAIDs will be much more widely used in the future because of the increasing age of 
our population, as well as the expanding indications of aspirin-NSAID, for example in cancer 
chemoprevention.                            
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